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Abstract 
This thesis investigates the genetic and molecular aspects of the skeletal muscle channelopathies, in 
particular periodic paralysis. A genetic study was conducted to identify causative mutations in a 
cohort of patients who did not have a genetic diagnosis following routine diagnostic screening. 
Through screening of the coding regions of SCN4A 9 mutations were identified, 6 of which were 
novel. Additionally, exome sequencing in a PMC family identified 10 variants in 7 genes, although 
only three genes of interest: RYR-1, AGRN and COL6A3. However, further work is needed to confirm 
the variants found. Two SCN4A mutations identified in this thesis were studied in vitro using two-
electrode voltage clamp and patch clamp in Xenopus laevis oocytes and HEK-293 cells, respectively. 
D1420G is associated with a Hypo PP phenotype and is located within the S3 segment of DIV. No 
Hypo PP mutation has been associated with this region of the channel. D1420G was found to 
produce a gating pore current which is activated by negative voltages. This is the first Hypo PP 
mutation outside of the S4 voltage sensor to produce a gating pore current and support the notion 
that D1420G is a pathogenic mutation. R222Q was identified in a patient showing a myotonic 
phenotype. R222Q affects the S4 R2 gating charge of DI. A known Hypokalemic Periodic Paralysis 
mutation, R222W, affects the same residue. Both R222 mutations were compared in order to 
determine how two mutations affecting the same residue can cause different phenotypes. R222Q 
was found to cause a 16 mV hyperpolarizing shift in the voltage dependence of channel activation, 
which is consistent with a myotonic phenotype, whilst R222W had no effect. Both mutations were 
found to produce a gating pore current. This is the first time a myotonia related mutation has been 
found to cause a gating pore current. 
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1 Chapter 1: Introduction 
1.1 Skeletal Muscle 
Skeletal muscle forms a part of the locomotor system which is responsible for all voluntary 
movement, maintains posture and stabilises joints(Franzini-Armstrong & Jorgensen, 1994; 
Huijing, 1998; Lieber & Friden, 2000). It is a precise and effective machine composed of a 
number of interlinking and intricate networks which are vital for contractile activity.  
An individual muscle is composed of muscle fibre bundles. Muscle fibres are long, 
cylindrical and multinucleated cells. Each muscle fibre contains numerous tubular 
structures called myofibrils(McComas, 1996). Myofibrils contain filaments which run the 
length of the muscle fibre and are vital for the contractile ability of the muscle(H.E. Huxley, 
1963; HUXLEY & HANSON, 1954).  
The cell membrane that surrounds each muscle fibre is known as the sarcolemma. It 
contains an orchestra of ion channels and pumps which maintain the negative resting 
membrane potential and generate action potentials. Invaginations of the sarcolemma, 
which run between the myofibrils, form a membrane network known as the T-tubule. The 
function of the T-tubule is to allow the quick distribution of action potentials from the 
surface to the centre of the cell(Frankenhaeuser & Huxley, 1964; Franzini-Armstrong, 1999; 
A. Huxley & Stampfli, 1951; Huxley 1969). It is found in close contact with the sarcoplasmic 
reticulum which is the organelle responsible for storage and release of Ca2+. Arrival of an 
action potential induces the release of Ca2+ from the sarcoplasmic reticulum, triggering 
muscle contraction(Franzini-Armstrong, 1999; H.E. Huxley & Brown, 1967). 
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Pathogenic mutations of the genes encoding the individual components that make up the 
skeletal muscle network results in disruption to normal contractile activity and 
consequently a wide range of disorders such as the muscular dystrophies, congenital 
myopathies and the skeletal muscle channelopathies(Cannon 2006; Jurkat-Rott et al.,2002). 
1.2 Electrical properties of skeletal muscle 
Most cells maintain a negative resting membrane potential(A. Huxley & Stämpfli, 1951). In 
excitable cells the membrane potential changes in response to different stimuli. Changes to 
the membrane potential occur when ion channels open, allowing the permeation of the 
ions across the otherwise impermeable plasma membrane(KIMIZUKA & KOKETSU, 1963). 
Excitable cells use electricity to relay signals. The main unit of electrical signals is known as 
the action potential. The action potential is rapidly propagated along the membrane of 
axons or muscles and is regenerative and self propagating(Frankenhaeuser & Huxley, 1964; 
Guy & Seetharamulu, 1986). An action potential is controlled by the opening and closing of 
ion channels, specifically voltage gated Na+ and K+ channels, although in muscle Cl- channels 
also play an important role in shaping the action potential(Barnett & Larkman, 2007; 
Eisenberg & Gage, 1969; Hodgkin & Katz, 1949; Institutet, 1964; Karin Jurkat-Rott, Fauler, & 
Lehmann-Horn, 2006). The electric signal is transduced into a cellular or mechanical 
response e.g. muscle contraction. 
In muscle, action potentials are initiated at the neuromuscular junction when a stimulus 
from the motor neuron depolarises the sarcolemma above the threshold for activation of 
voltage gated sodium channels. Activation of voltage gated  sodium channels results in the 
rapid inflow of Na+ into the cell, which results in the depolarisation of the membrane 
potential, to a peak potential of ~+30 mV. Depolarisation of the membrane potential results 
in activation of voltage gated potassium channels, increasing membrane permeability to K+, 
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allowing for efflux of K+ from the cell down the electrochemical gradient, which helps to 
repolarise the cell(Guy & Seetharamulu, 1986). 
Skeletal muscle has an unusually high Cl- conductance compared to other cells – accounting 
for up to 85% of all membrane conductance at rest (Bryant & Morales-Aguilera, 1971; 
Palade & Barchi, 1977). A large Cl- conductance plays an important role in stabilising the 
membrane potential and in the repolarisation of the membrane potential after an action 
potential, enabling muscle activity to be maintained during repeated stimulation. Following 
an action potential, K+ builds up within the T-tubules. Repeated action potentials can cause 
a increase in the T-tubule K+ concentration, which is large enough to shift the equilibrium 
potential of K+ (Keq), leading to depolarisation of the skeletal muscle membrane potential. 
This promotes more action potentials and further depolarisation. The presence of a high Cl- 
conductance within the skeletal muscle negates the depolarising effect of K+ build up within 
the T-tubules (Aromataris & Rychkov, 2006). 
The action potential propagates along the sarcolemma to the T-tubules, where the 
excitation-contraction coupling machinery is found. Arrival of the action potential activates 
the voltage gated calcium channel. Conformational changes within the channel upon 
activation lead to activation of the ryanodine receptor within the sarcoplasmic 
reticulum(Bannister, 2007; Block, Imagawa, Campbell, & Franzini-Armstrong, 1988; 
Franzini-armstrong & Jorgensen, 1994; Franzini-Armstrong, 1999). Activation of the 
ryanodine receptor results in release of Ca2+ from the sarcoplasmic reticulum into the 
cytoplasm(Frankenhaeuser & Huxley, 1964; A. Huxley & Stämpfli, 1951; H E Huxley, 1969). 
The sudden increase in Ca2+ within the cytoplasm triggers activation of the contractile 
apparatus leading to muscle contraction. Relaxation of the muscle occurs through removal 
of the cytoplasmic Ca2+ via Ca2+ pumps(Berchtold, Brinkmeier, & Müntener, 2000; Karin 
Jurkat-Rott et al., 2006). 
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Figure 1-1 Diagrammatic representation of muscle action potential initiation (diagrammatic concept adapted from Cannon 2006 review) 
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1.3 Ion Channels 
1.3.1 What are Ion channels? 
The hydrophobic plasma membrane acts as an electrostatic barrier for the movement of 
small inorganic ions such as Na+, K+, Ca2+ and Cl-. A variety of different ion-transporting 
proteins (ion channels and ion pumps) have evolved to allow the movement of specific ions 
across the plasma membrane. This highly controlled movement of ions into and out of a cell 
is important for numerous biological processes such as regulation of cell volume or pH, 
muscle contraction, conduction of nerve impulses, control of heartbeat, sensory reception 
and ciliary clearing of pathogens (Hille,2001). 
Ion pumps move ions across the plasma membrane against the concentration gradient and 
require energy to do so. Within the extracellular space there is a high concentration of Na+ 
and Cl- ions while inside the cell a high K+ concentration is found. Cytoplasmic Ca2+ is kept at 
very low concentrations (nanomolar range) by sequestration into intracellular storage 
organelles (Barnett & Larkman, 2007). 
Ion channels form an aqueous pore within the plasma membrane that provides a pathway 
for the passive movement of ions along the electrochemical gradient, at a rate that is often 
close to that of free diffusion. The flow of ions through channels transports ions from one 
compartment to another, e.g. across the epithelial cells in the kidneys and generates an 
electrical current that is used to relay electrical signals. The activity of ion channels is 
controlled by specific biological signals, allowing for the tightly controlled movement of ions 
in response to an appropriate stimulus. 
1.3.2 Classification & function of ion channels 
Ion channels can be classified by a number of functional or structural characteristics, for 
example: the mode of gating (e.g. voltage-, mechano-  or ligand gated channels), the type 
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of ion they are permeable to (e.g. sodium or potassium ions), the number of pores (e.g. 
two-pore channels), where the channel is expressed (e.g. P (purkinje)-type calcium 
channels), rectification (inward- or delayed rectifier K+ channels) and conductance (large 
and small conductance K+ channels).  
Voltage gated ion channels are a particular class of ion channels found in excitable cells 
such as neurons and muscle cells. Their activity is controlled by changes in the membrane 
potential. Channels are activated by a change in membrane potential, above a threshold, 
which causes a conformational change within the channel and subsequent opening of the 
channel, allowing ions to flow into or out of the cell (Kew & Davies, 2009). For the purpose 
of this work further focus will be placed on the voltage gated cation channels and more 
specifically voltage gated sodium channels. 
1.3.2.1 Potassium channels 
Potassium channels make up a large family of ion channels that are widely expressed 
throughout almost all organisms and have one basic function: to allow K+ ion movement 
across the cell membrane. The voltage gated potassium channels mediate the movement of 
K+ out of the cell following depolarisation of the membrane potential. They play a crucial 
role in the repolarisation of the membrane during an action potential. The inwardly 
rectifying K+ (Kir) channels allow for the movement of K+ ions into the cell and are involved 
in setting and resetting the resting membrane potential (Hibino et al.,2010). 
Members of the potassium channel family show a diverse range of roles in excitable and 
non excitable cells, from cell growth and survival in prokaryotes to cellular signalling in 
eukaryotes. The cellular processes in which these channels play a role varies with the 
localisation of the channel, for example, in the heart they help to regulate the heartbeat;  in 
the pancreas they enable insulin release from beta-cells; and in renal epithelium they 
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enable cellular recycling of K+ to regulate the electrolyte balance(Miller,2000; Shieh et 
al.,2000).  
Potassium channels are categorised based upon the primary structure of the channel. There 
are two main types of potassium channel: Voltage gated potassium Channels (Kv) or 
Inwardly rectifying potassium channels (Kir). The Kir family of potassium channel is 
subdivided into 4 groups: Classical Kir channels (Kir2.x, constitutively active), G protein 
gated Kir Channels (Kir3.x), ATP-sensitive potassium channels (Kir6.x) and potassium 
transport channels (Kir1.x,Kir4.x, Kir5.x and Kir7.x). 
1.3.2.2 Sodium channels 
Voltage gated sodium channels are highly selective to sodium ions, and are found in 
numerous organisms in which they are highly conserved. They play a key role in the 
generation and propagation of action potentials in excitable cells. The role of sodium 
channels within the initiation of an action potential means they are critical for the 
transmission of information between excitable cells allowing for co-ordination of processes 
and networks.   
To date nine sodium channels have been characterized which are expressed in a variety of 
tissues. Four sodium channels (NaV1.1, 1.2, 1.3 and 1.6) are primarily expressed within the 
central nervous system, three channels within the peripheral nervous system (NaV1.7, 1.8 
and 1.9), one in skeletal muscle (NaV1.4) and one in cardiac muscle (NaV1.5).These sodium 
channels show different biophysical and pharmacological properties, cellular functions and 
tissue localisation. For example, NaV1.4 is expressed in skeletal muscles, is tetrodotoxin 
sensitive, and is important for muscle contraction, whilst NaV1.8 is expressed within 
peripheral sensory nerves, is tetrodotoxin insensitive, and is important for nociception 
(Catterall et al.,2012; Marban et al.,1998). 
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1.3.2.3 Calcium channels 
Voltage gated calcium channels are the hallmarks of excitable cells. They mediate the influx 
of calcium in response to membrane depolarisation allowing Ca2+ to act as a secondary 
messenger to electrical signalling. The activity of these channels is vital for the transduction 
of membrane potential changes into a variety of physiological events such as muscle 
contraction, endocrine and synaptic secretion, and gene expression. Signal transduction in 
various cell types involves different voltage gate calcium channels which show differential 
tissue expression as well as variations in physiological and pharamacological properties. For 
example, Cav1.1 is highly expressed in skeletal muscle T-tubules, is dihydropyridine 
sensitive, and acts as the voltage sensor for the coupling of muscle depolarisation to the 
release of Ca2+ from the sarcoplasmic reticulum (SR). 
Ten calcium channel genes have been identified which encode channels with different 
localisation, pharmacological and physiological properties. These channels can be grouped 
into three families on their molecular properties (see Dolphin 2006 for review): (1) the high-
voltage activated (HVA) dihydropyridine-sensitive (L-type, CaV1.x) channels; (2) the HVA 
dihydroyridine-insensitive (P/Q, N & R type, CaV2.x) channels and (3) the low–voltage 
activated (T-type, CaV3.x) channels (Birnbaumer et al., 1994; Ertel et al., 2000; Perez-Reyes, 
1998)(Dolphin, 2006). 
1.3.2.4 Chloride channels 
As with other ion channels, chloride channels are ubiquitously expressed and are found in 
all living organisms. Chloride channels allow the passive diffusion of Cl- ions across the 
plasma membrane along the electrochemical gradient. Whilst they are permeable to many 
anions, Cl- is the permeating ion within these channels as Cl- is the most abundant ion 
within cells (Maduke et al.,2000). They play a vital role in a variety of different biological 
processes from maintaining skeletal muscle excitability, cell volume regulation or ion 
homeostasis.  
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Three different families of chloride channel have been identified thus far: CLC, CFTR and 
ligand gated Cl- channels. Of these the CLC channels are the most characterised and well 
known. There are 9 CLC family members, which show different localisation and functions 
(Jentsch et al.,2002; Mindell et al.,2001). Members of this subfamily show 50-80% sequence 
identity (Jentsch et al., 2002; Maduke et al.,1999). Interestingly some members have been 
since been shown to act as Cl-/H+ exchangers but still share similar molecular architecture 
with other members of the family (Accardi & Miller,2004). 
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1.3.3 Structural Features of cation channels 
Due to a common evolutionary relationship, the voltage gate cation channels share number 
of structural features, including the structure of the central pore and voltage sensing 
domain (VSD).  
The inwardly rectifying potassium channels form the simplest structural motif of the 
voltage gated cation channels (Figure 1-1). Kir subunits are composed of only two 
transmembrane segments, M1 and M2, which together with a re-entrant P-loop form the 
pore domain (Hibino et al.,2010). The voltage gated potassium channels are large proteins 
where the structure of these channels can be subdivided into two functional sub-domains: 
the pore domain (S5-S6) and the voltage sensing domain (VSD; S1-S4).  The S5 and S6 
segments are analogous the M1 and M2 helices of the Kir channels. Voltage gated 
potassium channels (KV) are composed of tetramers of α subunits (Ho et al.,1993; Yang et 
al.,1995a).  
The α subunit of the voltage gated sodium (Nav) and calcium (Cav) channels do not form 
tetramers but are large multi domain proteins. Each Nav or Cav α subunit is composed of 
four homologous domains (I-IV). Each domain is equivalent to a single subunit of a voltage 
gated potassium channel (Doyle et al.,1998; George at al. 1992; Hille & Schwarz,1978; Noda 
et al. 1984; Takahashi et al.,1987; Trimmer et al., 1989; Yang et al.,1995b) 
. 
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Figure 1-2 Schematic representation of potassium channels. 
Topology of the a single α subunit for A) voltage gated potassium channels or B) inward 
rectifiers and C) four subunits forming a functional channel.  
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1.3.3.1 Pore domain of the voltage gated cation channels 
The ionic pore is the central component of voltage gated cation channels. It not only forms 
the permeation pathway but provides the gating mechanisms for opening and closing the 
channels as well as controlling the selectivity of the channel. Within cation channels the 
permeation pathway can be found at the interface of four individual subunits or domains 
along the axis of symmetry. The pore is formed by four re-entrant P loops (the loop region 
linking the S5 and S6 segments) together with the S5 and S6 segments (Chahine et al.,1998; 
Heinemann et al.,1992; Noda et al. 1989; Pérez-García et al.,1996). 
All the channels share a common pore architecture which is formed by a narrow selectivity 
filter, found towards the extracellular end of the channel; a large central cavity; and 
separate activation and inactivation gates, which can be found at the intracellular end of 
the channel (Doyle et al., 1998; Jan & Jan, 1997; Kuo et al., 2003; Long et al.,2005; 
Payandeh et al.,2011). The crystal structure of the tetrameric bacterial sodium channel 
from A. butzleri, NavAb, showed an extracellular funnel formed by the P2 helix which is not 
present in potassium channels (Payandeh et al., 2011). It is thought that the funnel may be 
specific to sodium and calcium channels. In sodium channels, there are four lateral 
openings from the membrane into the lumen of the pore (Payandeh et al., 2011). These 
fenestrations allow a connection between the pore cavity and the membrane lipids but are 
not present in potassium channels. 
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Figure 1-3 Schematic diagram of the α-subunit of voltage gated sodium and calcium channels 
The α-subunit of voltage gated sodium and calcium channels is composed of four homologous domains each containing 6 transmembrane helices. Each of 
the four domains contributes towards the formation of the central ionic pore.  
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1.3.3.1.1 Selectivity filter 
Ion selectivity is central to the proper functioning of the voltage gated cation channels. Ion 
selectivity is in the most part determined by the selectivity filter. The selectivity filter is 
found at the narrowest part of the pore and formed by the re-entrant P loops which line 
the pore. The amino acid residues within the P loops interact with the permeating ions to 
control the selectivity of the channel.  
Whilst the overall pore structure of sodium, potassium and calcium channels is similar, the 
structures of the selectivity filters differ and provide means for selecting for permeation of 
a distinct ion.  
In potassium channels the selectivity filter is formed by the conserved sequence: T-X-G-
(Y/F)-G (Choe, 2002; Heginbotham et al.,1994; Mackinnon, 1995). Oxygen atoms from the 
carbonyl backbone of the selectivity filter, stabilise the movement of K+ ions through the 
pore in a nearly fully dehydrated state (Doyle et al., 1998; Roux & MacKinnon, 1999; Zhou 
et al.,2001). 
In sodium channels, there are four residues which are critical for ion selectivity: aspartate-
glutamate-lysine-alanine (DEKA), one provided by each domain (Heinemann et al.,1992; 
Payandeh et al.,2011; Yang et al. 1993). Interaction with these residues allow Na+ ions to 
travel through the selectivity filter in a partially dehydrated state, in contrast to the 
mechanism for K+ channels (Payandeh et al., 2011).  
Despite the fact that Na+ and Ca2+ ions have an almost identical diameter (~2 Å) and that 
the extracellular Na+ concentration is 70 fold higher than Ca2+, calcium channels can 
prevent the permeation of Na+ ions. Calcium channel selectivity is determined by the 
presence of four glutamate residues (EEEE motif) within the selectivity filter. Substitution of 
just two of these residues has been shown to confer Na+ selectivity to calcium channels 
(Heinemann et al., 1992; Yang et al. 1993). The structural basis of selectivity of Ca2+, and 
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block of Na+, was recently determined by modifying the selectivity filter of the NavAb 
channel to that of a calcium channel (Tang et al., 2014).The crystal structure of this 
modified NavAb channel showed that calcium selectivity is determined by the amino acid 
side chains of the selectivity filter. Selectivity of calcium over sodium is due to the presence 
of two high affinity binding sites within the selectivity filter to which the more 
electropositive Ca2+ ion binds tightly preventing Na+ permeation  
1.3.3.1.2 Channel Gating 
Gating of the voltage gated cation channels involves two types of gate: activation and 
inactivation gates. They enable the controlled flow of ions into or out of the cells for the 
length of a given stimulus and prevent an excess of ionic movement.  
Gating of the cation channels involves structural rearrangements of the activation and 
inactivation gates (Baukrowitz & Yellen, 1995; Panyi & Deutsch, 2006). At rest, the 
activation gate is closed whilst the inactivation gate is open. Upon depolarisation the 
voltage sensor induces a conformational change which opens the activation gate within the 
pore, allowing the permeation of the specific cation (Catterall,2010). Following activation, 
many channels inactivate rapidly (through closure of the inactivation gate) to prevent 
further permeation of ions. Inactivation can be both time and voltage dependent and 
results in the transition of an open channel into an inactivated, non-conducting state. The 
conformation of this state is distinct from the closed, non-conducting state. After a given 
time period the channel recovers from inactivation (the activation gate closes and the 
inactivation gate opens) restoring the channel to the closed state from which it can be 
activated. 
Activation gate 
The activation gate is formed by the cytoplasmic convergence of the four S6 
transmembrane segments which line the pore (del Camino et al.,2000; del Camino & Yellen, 
2001; Liu et al.,1997). In the closed state, the S6 helices form a bundle that blocks the pore 
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and prevents the entrance of ions into the central cavity of the pore. The activation gate of 
voltage gated cation channels is coupled to the voltage sensor via the S4-S5 linker (Lu et 
al.,2002). Opening of the activation gate occurs following depolarisation of the membrane 
potential and involves rearrangement of the intracellular end of the S6 segment (del 
Camino et al., 2000; del Camino & Yellen, 2001; Hackos et al.,2002; Holmgren et al.,1998; 
Holmgren et al.,1997; Liu et al., 1997). For many channels, a glycine residue within the S6 
segment forms a hinge. This hinge enables the movement of the N-terminal part of the S6 
segment, to open or close the activation gate (Ader et al., 2009; Doyle et al., 1998; 
Holmgren et al.,1998; Jiang et al., 2002; Kelly & Gross, 2003; Liu et al., 1997; Perozo et 
al.,1998). 
Inactivation Gates 
Kv and Nav channels show two main types of inactivation: fast or slow, whilst for Cav 
channels inactivation is more complex. Fast inactivation of Kv channels involves the 
occlusion of the internal vestibule of the pore by cytoplasmic domains, in a ball and chain 
mechanism. Site directed mutagenesis of amino acids within the N-terminal domain of 
Shaker Kv channels were found to disrupt channel inactivation, indicating that the N-
terminus plays a role in channel inactivation (Hoshi et al.,1990). Application of a peptide 
containing the first 20 amino acids of the N terminus was able to restore inactivation to 
non-inactivating Kv channels (Zagotta et al.,1990). The gate region for the N-terminal “ball” 
lies within the hydrophobic central cavity and inner pore of the potassium channel (Zhou et 
al.,2001). 
Kv channel slow inactivation is sensitive to cation concentrations and involves the 
rearrangement of the outer vestibule and the selectivity filter (Yellen, 2002). The selectivity 
filter of potassium channels has been found to have two conformations: activated or 
inactivated. In low potassium concentrations the selectivity filter of KcsA channels was 
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found to undergo a conformational transition into the inactivated state (Cordero-Morales 
et al., 2006; Imai et al.,2010).  
Fast inactivation of Nav channels occurs via a “hinged lid” mechanism in which an 
inactivation gate blocks the intracellular side of the pore (analogous to ball-and-chain 
mechanism of Kv channels) whilst slow inactivation of sodium channels occurs via a global 
conformational change in channel structure, which is less characterised. Fast inactivation is 
mediated by the highly conserved loop between DIII and IV, which acts as the inactivation 
gate. A short hydrophobic cluster of three amino acids, Ile-Phe-Met (IFM motif), in the DIII-
DIV loop is a crucial part of the inactivation gate (Vassilev et al.,1988; Vassilev et al.,1989). 
Substitution of these three residues to glutamine removes inactivation completely (West et 
al., 1992). Small peptides containing the IFM motif are sufficient to restore inactivation in 
mutant non-inactivating channels, suggesting the gate has a docking site on the 
intracellular site of the pore (Eaholtz et al. 1994). The docking site of the gate is thought to 
include DIV S4-S5 intracellular loops (Lerche et al., 1997; McPhee et al. 1998), DIII S4-S5 
loops (Smith & Goldin,1997) and the intracellular side of DIV S6 (McPhee et al.,1995), 
mutations of residues in these areas result in impaired inactivation. 
Inactivation of Cav channels is important for the tight regulation of intracellular calcium 
levels which enables Ca2+ to act as a secondary messenger. Inactivation of calcium channels 
appears to be more complex than seen in potassium or sodium channels. Calcium channels 
undergo three different types of inactivation: calcium dependent inactivation and fast or 
slow voltage dependent inactivation.  
Calcium dependent inactivation provides a negative feedback loop to Ca2+ influx, as it is 
triggered by a high intracellular Ca2+ concentration. It has been shown to only occur in HVA 
channels and is mediated by calmodulin (CaM) which acts as a Ca2+ sensor. Binding of Ca2+ 
to CaM enables Ca-CaM to bind to an IQ-like motif on the C terminus of the channel and 
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induces rapid channel inactivation(Budde et al.,2002; Lee et al.,1999; Peterson et al.,1999; 
Zühlke et al.,1999). Channel chimera and site direct mutagenesis experiments were used to 
establish the regions of the Cav channel which are involved in the fast inactivation. The S6 
transmembrane segment, DI –DII, DII-III and DIII-IV linker regions and the C terminus have 
all been shown to play a role in channel fast inactivation (Berjukow et al., 2001; Soldatov et 
al.,2012; Soldatov et al.,1998; Stotz et al.,2001; Zhang et al.,1994). Inactivation is thought to 
occur via a “hinged lid” mechanism similar to that seen in sodium channels (An & Zamponi, 
2005; Kubalová, 2003; Stotz et al.,2000)  
Slow inactivation occurs following a prolonged duration of membrane depolarisation (~1 
minute). It is mediated by a group of hydrophobic amino acids located near the cytoplasmic 
ends of the S6 transmembrane segments (Shi & Soldatov, 2002).  
1.3.3.2 Voltage sensing domain  
The voltage sensing domain of voltage gated cation channels is formed from the S1-S4 
segments and enables these channels to activate in response to a change in voltage 
(MacKinnon, 1991). The S4 segment acts as the main “voltage sensor” of the channel. It 
contains a conserved sequence of positively charged residues at every third amino acid 
position (the first charged residue on at the N-terminal end of the S4 is denoted R1, the 
second R2 and so forth). These charged residues act as gating charges that are sensitive to 
changes in transmembrane voltage. Their movement in response to a change in voltage 
controls channel gating. Neutralisation of these positive charges disrupts the voltage 
dependence of channel gating, highlighting their important role in conferring voltage 
sensitivity (Aggarwal et al.,1996; Seoh et al,. 1996; Starace & Bezanilla, 2001).  
The localisation of the gating charges is unusual since it incurs a high energetic cost to place 
charged residues within the hydrophobic environment of the phospholipid membrane. The 
voltage sensor is located within the aqueous crevice of a channel structure called the gating 
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pore which is formed by the remaining segments of the voltage sensing domain, S1-S3 (Sato 
et al., 2001). Counter charges within the gating pore (from the S2 and S3 segments) help to 
stabilise the positive charges, reducing the energetic cost of placing charged residues in a 
hydrophobic environment (DeCaen et al.,2009; DeCaen et al.,2008; Papazian et al., 1995; 
Seoh et al., 1996; Tiwari-Woodruff et al.,2000). In support of this is the crystal structure of 
NavAb, which shows that there are two clusters of negatively charged residues with which 
the S4 segment interacts (Payandeh et al., 2011). These clusters are called the extracellular 
negative-charge cluster (ENC) and the intracellular negative-charge cluster (INC). Each 
cluster contains highly conserved residues that form electrostatic interactions or hydrogen 
bonds with the S4 gating charges forming a network of interactions that help to stabilise S4 
segment movement (Payandeh et al., 2011). Furthermore, the crystal structure has shown 
there is a large aqueous cleft that extends ~10 Å into the membrane region to a point called 
the hydrophobic constriction site (HCS). The HCS contains three highly conserved residues 
(Ile, Phe & Val) which act to seal the voltage sensing domain against aberrant ionic leakage 
during the movement of the S4 segment (Payandeh et al., 2011). 
Upon membrane depolarisation the S4 voltage sensor translocates outward through the 
gating pore, triggering a conformational change within the protein, which is transmitted 
through the S4-S5 linker resulting in opening of the main pore. Movement of the charged 
residues through the electric field of the membrane generates a transient gating current. 
The movement pattern of the voltage sensor has been supported by substituted cystine or 
histidine accessibility method (SCAM or SHAM) and toxin exposure experiments (DeCaen et 
al.,2008; Mantegazza & Cestèle, 2005; Pérez-García et al.,1996; Starace & Bezanilla, 2001). 
These experiments found that R2 and R3 are accessible to modification by cysteine specific 
reagents from the inside of the cell when the channel is in the resting state and become 
accessible from the outside after depolarisation (Catterall,2000; Gandhi et al.,2003; Larsson 
et al.,1996; Männikkö et al.,2002; Yang et al.,1996; Yang & Horn,1995). This supports the 
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idea that the voltage sensor moves in an outward motion during depolarisation. Similar 
experiments with the S3 segment have shown that the S3 doesn’t move during activation of 
the Nav1.4 (Nguyen, 2002) or the Drosophila Shaker potassium channel (Gandhi et al., 
2003). 
1.3.3.3 Chloride channels 
Voltage gated CLC chloride channels are the outliers of the voltage gated ion channels. They 
do not share the molecular architecture of the voltage gated cation channels. CLC channels 
are formed by two subunits. Each subunit is composed of 18 intramembrane α helical 
segments (A-R) and contributes a single pore to the dimer. The presence of two 
independently gate pores gives CLC channels a characteristic double barrelled structure.  
Chloride channels have two independent pores (one from each subunit). The formation of 
each pore from a single subunit is in vast contrast to other voltage gated ion channels in 
which the pore is formed along the axis of symmetry between the different subunits (or 
domains in the case of Cav and Nav channels). The pore lining residues come from different 
regions within the primary sequence of the channel (Ludewig, Pusch, & Jentsch, 1996, 
1997; Middleton, Pheasant, & Miller, 1996).  
There is no conserved charged sequence within CLC channels that corresponds to the 
voltage sensor as in the cation channels. In fact, the voltage dependence of CLC channel 
gating does not arise from the movement of charged residues within the protein as seen in 
channels with voltage sensing domains. Instead voltage sensitivity is derived from the 
movement of the permeating Cl- ion (Jentsch et al., 2002; Christopher Miller, 2003). 
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Figure 1-4 Schematic diagram of a single CLC monomeric subunit  
The individual subunits are composed of 19 helices, which are indicated by blocks labelled A-R.  
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1.3.4 Ion Channels & Disease 
Considering the important role ion channels play in biological processes it is no surprise 
that mutations in these proteins are known to cause human disease and disability. Diseases 
that develop due to a defect in ion channel function, either through genetic or acquired 
factors, are known as channelopathies. Disruption of ion channel function leads to a change 
in the electrical excitability of excitable cells or the cellular ion homeostatsis. 
Channelopathies affect a range of different areas within the body, causing a range of 
conditions including epilepsy, migraine, blindness, deafness, cardiac arrhythmia, diabetes, 
cystic fibrosis and more.  
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1.4 Skeletal Muscle Channelopathies: clinical features 
Mutations in the voltage gated ion channels expressed in skeletal muscle cause disruption 
to sarcolemma electrical excitability resulting in two main phenotypes; myotonia and 
episodic attacks of weakness, which are two ends of the spectrum of electrical disruption 
(See Vicart et al. 2005 for review). The two phenotypes can be broadly separated into the 
non-dystrophic myotonias and the periodic paralyses, although significant overlap of 
symptoms can occur between these groups. The non-dystrophic myotonias include 
myotonia congenita (MC), paramyotonia congenita (PMC) and sodium channel myotonia 
(SCM) where the principal symptom is muscle stiffness. The periodic paralyses are divided 
into hyperkalemic periodic paralysis (Hyper PP), hypokalemic periodic paralysis (Hypo PP) 
and Anderson-Tawil syndrome (ATS) all of which show episodes of flaccid muscle paralysis 
as the main symptom.  
Skeletal muscle channelopathies have provided naturally occurring models to study the 
role, function and structure of skeletal muscle ion channels.  
1.4.1 Non Dystrophic Myotonia 
The non-dystrophic myotonias are a group of rare disorders grouped by the common 
symptom of myotonia. This group of disorders includes myotonia congenita, paramyotonia 
congenita and sodium channel myotonia.  
Disruption to normal ion channel function results in enhanced muscle excitability that 
manifests as myotonia. In normal muscle fibres a single stimulus from the neuromuscular 
junction will result in a single action potential that initiates a single muscle contraction. 
However, in muscle affected by myotonia a voluntary contraction produces a sustained 
burst of action potentials that persist even after the initial stimulus has finished. This results 
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in delayed muscle relaxation following contraction which patients often describe as muscle 
stiffness. It has been shown to have a worldwide prevalence of approximately ~1 in 100,000 
although there are variations between countries (Emery, 1991; Horga et al., 2013). 
1.4.1.1 Myotonia Congenita 
Myotonia congenita presents with transient attacks of muscle stiffness from infancy up 
until as late as the fourth decade. Myotonia occurs on the first voluntary movement often 
following rest after exercise but shows improvement with repetition of movement. This is 
known as the warm up phenomenon. There are two forms of myotonia congenita which are 
distinguished by the form of inheritance: Thomsen’s disease (OMIM 160800), which is 
dominantly inherited; and the recessively inherited Becker’s disease (OMIM 255700). 
Thomsen’s disease usually presents in early childhood often before the age of three years 
with generalised myotonia that affects the legs, arms and hands, making falls a frequent 
occurrence and grasping objects difficult. Onset of Becker’s disease occurs slightly later 
between the ages of 8 and 12 years old with much the same symptoms as Thomsen’s 
disease although patients show much more severe myotonia that has a greater impact on 
their daily lives. 
Upon clinical examination patients can show muscle hypertrophy with normal muscle 
strength which can allow them to participate in sports that favour muscle strength over 
speed (Matthews et al., 2010; Wakeman et al.,2008). Percussion myotonia – where the 
muscle is pressed leaving an indent for several seconds - can also be noted in many 
patients. Electromyography (EMG) needle testing of resting muscle in patients with either 
form of myotonia congenita shows myotonic bursts in all muscles tested. Myotonia can be 
triggered by rest after exercise, hunger, stress or fatigue. A large amount of phenotypic 
variability is seen within myotonia congenita even amongst family members.  
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1.4.1.2 Paramyotonia Congenita  
Paramyotonia congenita (PMC, OMIM 168300) is an autosomal dominant disorder which 
shows onset during early childhood and is established by the first decade of life. For PMC 
the prominent symptom is muscle stiffness that unlike other forms of myotonia is made 
worse by repeated muscle activity (paramyotonia) and exposure to cold (Fournier et al., 
2006). Muscle stiffness is brought on during exercise rather than after exercise as with 
other forms of myotonia. Cold sensitivity in PMC can be dramatic and can make it difficult 
for patients to cope during cold weather. Myotonia mainly affects the upper limbs, face, 
tongue and hands with eyelid lag a notable common feature in patients (Miller et al.,2004). 
In addition, myotonia may be accompanied by weakness and in some cases full attacks of 
paralysis. As with the attacks of myotonia, weakness can also be exacerbated by cold and 
exercise (McClatchey et al.,1992; Wagner et al., 1997). Myotonia is often short lived, lasting 
seconds to minutes whereas weakness lasts much longer, on the scale of hours or days. 
Unlike myotonia congenita, PMC is less frequently associated with muscle hypertrophy 
although it is thought to be present in about 30% of patients (Matthews et al., 2008a). 
During EMG testing patients exhibit a gradual and persistent reduction in compound muscle 
action potential (CMAP) during a short exercise test which can be enhanced by both cooling 
and repetition. 
1.4.1.3 Sodium Channel Myotonia 
Sodium channel myotonia is clinically distinct from both myotonia congenita and PMC 
(Table 1-1). Initially it was described as three separate diseases: myotonia fluctuans, 
myotonia permanens and potassium aggravated myotonia. These disorders have been 
combined to form sodium channel myotonia, as they all have a similar phenotype and 
shared genotype (Matthews et al., 2010; Raja Rayan & Hanna, 2010). Patients show 
autosomal dominant inheritance with a purely myotonic phenotype that sometimes shows 
severe potassium sensitivity. Cold sensitivity is not always present but can be with varying 
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severity (Colding-Jørgensen et al.,2006; Heine et al.,1993; Orrell et al.,1998; Rossignol et al., 
2007). Weakness is never shown in these patients and if present will rule out SCM as a 
diagnosis. Myotonia is generalised throughout the body with transient attacks of muscle 
stiffness ranging in severity and length of time. In addition, some cases may show the 
warm-up phenomenon while others show paradoxical myotonia (Lee et al.,2009). Due to 
the pure myotonia phenotype, SCM can be difficult to distinguish clinically from dominant 
myotonia congenita. 
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Table 1-1 Clinical features of the non dystrophic myotonias 
 Myotonia Congenita Paramyotonia Congenita Sodium Channel Myotonia 
Gene CLCN1 SCN4A SCN4A 
Mode of Inheritance Dominant & Recessive Dominant Dominant 
Age of onset 1st decade 1st decade 1st decade 
Distribution of 
myotonia 
Recessive = lower limbs 
Dominant = upper limbs 
Face & upper limbs Face & upper limbs 
Sensitivity to Cold None Yes Variable 
Warm up  Yes No Sometimes 
Episodic weakness In recessive form Yes No 
Other Features Muscle hypertrophy Paradoxical myotonia Painful myotonia & K+ 
sensitivity 
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1.4.2 Periodic Paralysis 
The periodic paralyses encompass disorders characterised by transient attacks of weakness. 
This abnormal electrical excitability is limited only to skeletal muscle, except in the case of 
Andersen-Tawil Syndrome. There are four known forms of periodic paralysis: Hyperkalemic 
periodic paralysis (OMIM 170500), Hypokalemic periodic paralysis (OMIM 170400), 
Andersen-Tawil Syndrome (OMIM 170390) and Thyrotoxic periodic paralysis (TPP, OMIM 
188580). Hyper PP and Hypo PP can be distinguished by differences in the potassium levels 
during attacks of paralysis: (Hyper PP = high, Hypo PP = low, see Table 1-2).  
In between transient attacks patients retain normal muscle strength and reflexes, and in 
mild cases attacks can be circumvented through life style changes that avoid known triggers 
such as carbohydrate rich meals and stress for Hypo PP or high potassium and rest after 
exercise for Hyper PP. Regardless of the severity and frequency of attacks many patients 
can develop progressive proximal myopathy that can make daily life difficult. Mobility aids 
are needed in later life for ~50% of periodic paralysis patients (Meyer et al., 2008). 
1.4.2.1 Hyperkalemic Periodic Paralysis 
Hyper PP is an autosomal dominant disorder that presents with recurrent paralytic attacks 
usually in the first decade. Following the second decade attacks decrease in frequency over 
time. Attacks of weakness can occur at any time of the day and are relatively short in 
duration (10 minutes to 4 hours) and will normally be followed by periods of normal muscle 
activity (Jurkat-Rott & Lehman-Horn, 2007). A diagnosis can be made by noting attacks of 
weakness associated with elevated serum potassium (>6 mEq/L) although some patients 
may have normal levels. Paralysis can be precipitated by ingestion of potassium rich foods 
and rest after exercise but can be improved by intake of glucose. Hyper PP shows significant 
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overlap of symptoms with PMC, with 50-75% of patients are affected by myotonia (Miller et 
al.,2004; Plassart et al., 1994). On clinical examination myotonia is most notable in the 
tongue, as well as facial and hand muscles, and can be measured through EMG needle 
testing.  
1.4.2.2 Hypokalemic Periodic Paralysis 
Hypo PP is the most common form of periodic paralysis and is inherited in an autosomal 
dominant fashion but shows reduced penetrance in women (Miller et al.,2004). Onset of 
Hypo PP is later than seen in Hyper PP, beginning in the second decade. The main feature of 
Hypo PP is recurring attacks of weakness that are associated with low serum potassium 
levels (<3 mEq/L), that are of longer duration than Hyper PP, and can last for several hours 
or days. Myotonia is never present in Hypo PP. Thus, the presence of myotonia in a patient 
with periodic paralysis directs the diagnosis towards Hyper PP. In most cases of Hypo PP, 
the paralytic attacks take place in the early morning with the patient unable to move their 
limbs although facial muscles are spared. The frequency and severity of these transient 
attacks varies significantly between patients and variability in severity is even seen between 
family members (Bulman, 1997; Hong et al., 2010). Attacks are triggered by exercise, stress, 
some medications such as insulin, and carbohydrate rich meals. Hypo PP attacks can be 
ameliorated by ingestion of oral potassium.  
1.4.2.3 Andersen-Tawil Syndrome (ATS) 
Andersen-Tawil syndrome (ATS) is a distinct and rare variant of periodic paralysis that 
affects less than 10% of all periodic paralysis patients. It differs from the other periodic 
paralyses as it is a multisystem disorder that shows a triad of symptoms: periodic paralysis, 
cardiac abnormalities, and distinctive facial and skeletal characteristics (Haruna et al., 2007; 
Meola et al. 2009). Whilst the triad of symptoms is a defining feature of disease, the 
presence of all three features is variable, with lack of one often confusing diagnosis 
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(Modoni et al., 2011). Onset occurs during the first or second decade often with episodes of 
weakness before the development of cardiac features. Attacks of paralysis are triggered by 
the same precipitating factors as other forms of periodic paralysis and recovery normally 
takes 24 to 48 hours. As with other forms of periodic paralysis attacks of weakness can 
occur upon awakening in the morning.  
1.4.2.4 Thyrotoxic Periodic Paralysis (TPP) 
Thyrotoxic periodic paralysis (TPP) is the only sporadic form of periodic paralysis to be 
identified. This form of periodic paralysis is found in thyrotoxic individuals. Attacks of 
weakness can sometimes be associated with hypokalemia and can be indistinguishable 
from those seen in Hypo PP patients. A higher prevalence of disease is seen in Asian and 
Hispanic populations - 2% compared to 0.1% in non Hispanic Caucasians (Kelley et al.,1989; 
Okinaka et al., 1957; Ryan et al., 2010) 
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1.5 Genetic Causes of Skeletal Muscle Channelopathies 
1.5.1 Non-Dystrophic Myotonia 
1.5.1.1 Myotonia Congenita 
Myotonia congenita is caused by mutations in the gene CLCN1 which encodes the skeletal 
muscle chloride channel CLC-1 (George et al. 1993; Koch et al., 1992). Over 150 mutations 
have been found in CLCN1 to date associated with the dominant or recessive forms of 
myotonia congenita (Brugnoni et al., 1999; Mailänder et al.,1996; Meyer-Kleine et al.,1995; 
Plassart-Schiess et al., 1998; Sangiuolo et al., 1998; Zhang et al.,1996). CLCN1 is composed 
of 23 exons with mutations causing myotonia congenita spread widely across the gene. One 
potential mutation hotspot has been highlighted for dominant MC in exon 8 whilst no 
hotspot has been identified thus far for recessive mutations (Fialho et al., 2007; Matthews 
et al., 2010).  
Most causative mutations in dominant myotonia congenita have been found to be 
heterozygous missense mutations, although, two nonsense mutations: Arg894X and 
Glu193X, have been identified (George et al.,1994; Wu et al.,2002). Dominant mutations 
are localised to the subunit interface and result in the disruption of dimer interaction 
(Jurkat-Rott et al.,2005). In contrast, recessive mutations show more diversity in the type of 
mutation as indels, splice site alterations, truncations, missense or nonsense errors have 
been identified to date.  
Recessive myotonia congenita can be caused by homozygous or compound heterozygous 
mutations which can result in dimers where both subunits contain a mutation. The impact 
of a single recessive mutation is often not sufficient to cause disease which is highlighted by 
heterozygous carriers of CLCN1 recessive mutations who are often asymptomatic. The 
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inheritance of two recessive mutations (both subunits contain a mutation) results in a 
larger disruption of channel functioning which results in myotonia. 
Many cases of recessive MC have been reported to have only a single mutation despite full 
sequencing the coding region of the gene. In addition, ~25% of patients lack any mutations 
in CLCN1 following full screening of the gene (Meyer-Kleine et al., 1995; Zhang et al.,1996). 
Raja Rayan et al. 2012 showed that 6.7% of recessive MC patients have a partial or whole 
exon deletion in CLCN1. Tandem analysis of CLCN1 together with SCN4A identified 
mutations in 93% of cases in a cohort of NDM patients (Trip et al.,2008). This highlights the 
importance of investigating other genes in suspected myotonia congenita cases.  
Unusually, some mutations have been reported to cause both dominant and recessive 
forms of MC (such as R894X, G230E, T268M and R317Q), despite both forms showing 
different mechanisms of disease (Sun et al.,2001; Zhang et al.,1996). No clear explanation 
has been found for the presence of dual inheritance mutations although a number of 
hypotheses, such as different allelic expression, have been suggested. 
1.5.1.2 Paramyotonia congenita and Sodium Channel Myotonia 
Paramyotonia congenita and sodium channel myotonia are allelic disorders which are 
caused by mutations in the SCN4A gene, which encodes the voltage gated sodium channel, 
NaV1.4 (McClatchey et al. 1992; Ptacek et al., 1991, 1993).  
To date 35 pathogenic mutations within SCN4A have been identified in relation to PMC or 
SCM, with most causing a missense change. Mutations are widely distributed across the 
gene. The majority of PMC mutations are found within exons 22 and 24. The same is true 
for SCM although to a lesser extent (Matthews et al., 2008a; Trip et al.,2008). The most 
common PMC mutations have been identified as T1313M and R1448C (Jurkat-Rott et 
al.,2010; McClatchey et al.,1992; Ptacek et al., 1993; Ptácek et al., 1992; Yang et al.,1994) 
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whilst for SCM they are V1589M and G1306E (Lerche et al., 1993; Matthews et al., 2008b) 
Only one indel of SCN4A has been identified thus far. Kubota et al 2011 found a small indel 
c.3912+6_3912+10delinG within the intronic region between exon 21 and exon 22 causing 
aberrant splicing of the gene. The aberrantly spliced isoform encodes a functional channel 
with a 35 amino acid insertion that elongates the DII-DIV loop of NaV1.4, leading to a gain of 
function within the channel. 
About 20% of PMC and SCM cases have no identifiable mutation in SCN4A following full 
sequencing of the whole coding region. There is a possibility that this could be the result of 
unidentified intronic mutations such as the one identified by Kubota et al 2011; mutations 
in known genes such as CLCN1; mutations of promoter sites; or mutations within 
unidentified genes. 
1.5.2 Periodic Paralysis 
1.5.2.1 Hyperkalemic Periodic Paralysis 
Hyperkalemic periodic paralysis was the first skeletal muscle channelopathy for which a 
causative gene was identified. Through the linkage analysis of two Hyper PP families the loci 
which maps to chromosome 17q23-25 was highlighted (Ptácek et al., 1991; Rojas et 
al.,1991). This loci contains the gene SCN4A which encodes the α subunit of the voltage 
gated sodium channel NaV1.4 (Fontaine et al., 1990). 10 mutations have been identified to 
date in relation to Hyper PP. Causative mutations are, thus far, all missense mutations 
which are spread across the gene; although a large number of the mutations are located 
within exons 13 and 24. Hyper PP mutations are located in areas that play an important role 
in channel gating. Clusters of mutations are seen within S4-S5 loop and S6 DIV, which have 
been identified as potential docking sites for the inactivation gate. The most common 
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Hyper PP mutations are T704M and M1592V (exons 13 and 24, respectively), which account 
for 60 % and 30 % of Hyper PP cases respectively, (Vicart et al., 2005). 
A large amount of overlap is seen between Hyper PP and PMC in terms of phenotype and 
genetic causes. A number of SCN4A mutations, for example T704M, A1156T, M1360V and 
R1448C/H, which have been reported with overlapping phenotypes between PMC and 
Hyper PP (Brancati et al., 2003; Hayward et al.,1999; McClatchey et al.,1992; Vicart et al., 
2005; Wagner et al., 1997). 
 Following sequencing of the whole coding region of SCN4A, ~20% of Hyper PP cases have 
no identified causative mutation (Matthews et al., 2008a). This might be explained by the 
presence of intronic SCN4A mutations, such as the intronic indel identified in PMC (Kubota 
et al., 2011); or mutations in currently unidentified genes. 
1.5.2.2 Hypokalemic Periodic Paralysis 
Hypokalemic periodic paralysis has been associated with mutations in two different genes. 
Initially, genetic analysis linked hypokalemic periodic paralysis to missense mutations in the 
gene CACNA1S. This gene encodes the α1 subunit of skeletal muscle voltage gated calcium 
channel CaV1.1 (Elbaz et al. 1994; Jurkat-Rott et al.,1994). However, mutations in CACNA1S 
alone could not explain all cases of Hypo PP. Linkage in Hypo PP families with no CACNA1S 
mutation revealed mutations within SCN4A (referred to as Hypo PP2) (Bulman et al., 1999).  
The presence of two causative genes for Hypo PP can be in some part explained by the fact 
that these proteins have homologous structures. Mutations in both CACNA1S and SCN4A 
are not located to a particular exon, but map to the conserved S4 segment of the voltage 
sensing domain. Out of 21 Hypo PP mutations, 18 have been shown to cause neutralisation 
of the positively charged residues of the voltage sensor (Matthews et al., 2009). Three 
mutations have been found outside of the voltage sensor of either channel. V876E and 
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H916Q in the calcium channel and P1158S of the sodium channel were found in patients 
with a conventional Hypo PP phenotype. For V876E mutation regions of the gene 
corresponding to the voltage sensors were not ruled out.  
CACNA1S accounts for 70% of Hypo PP cases whilst just 10-20% of affected individuals have 
SCN4A mutations (Miller et al.,2004; Venance et al., 2006). In 10-20% of cases the genetic 
cause is unaccounted for which indicates the possibility of an unidentified causative gene.  
1.5.2.3  Andersen-Tawil Syndrome 
Andersen-Tawil Syndrome  is caused by mutations within the potassium channel gene, 
KCNJ2, which encodes the inwardly rectifying potassium channel Kir2.1 (Plaster et al., 
2001). ~70% of ATS cases can be accounted for by mutations in KCNJ2 (Smith et al.,2006; 
Weir et al.,2011). Over 60 mutations have been identified in KCNJ2, to date, in relation to 
ATS, most of which are loss of function mutations. However following sequencing of KCNJ2, 
30% of patients remain without a genetic diagnosis. Recently, a new gene has been 
associated with ATS – KCNJ5 which encodes the inwardly rectifying potassium channel 
Kir3.4. Mutations in KCNJ5 have been previously associated with LQT syndrome. Kokunai et 
al 2014 identified a KCNJ5 mutation in an ATS family which was found to mimic a KCNJ2 loss 
of function mutation. Currently, no genotype-phenotype correlation has been identified 
within ATS patients due to the high variability in symptoms (Kimura et al., 2012).  
1.5.2.4 Thyrotoxic Periodic Paralysis 
Thyrotoxic periodic paralysis has been associated with mutations in a newly indentified ion 
channel gene, KCNJ18 which encodes the inwardly rectifying potassium channel Kir2.6 
(Cheng et al., 2011; Ryan et al., 2010). However, the genetic cause of TPP is often 
unresolved as less than 50% of TPP cases are accounted for by mutations in KCNJ18. Thus 
far, seven mutations have been identified in KCNJ18 in association with TPP (Ryan et al., 
2010). Two further mutations within the gene have been identified in sporadic periodic 
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paralysis (SPP), a non familial form of periodic paralysis without hyperthyroidism (Cheng et 
al., 2011). The majority of mutations within KCNJ18 affect the C terminal region of the 
protein. A single nucleotide deletion has been identified leading to a frameshift and stop 
codon (c.428del C, p.Ile144fs). The KCNJ18 gene is transcriptionally regulated by the thyroid 
hormone (Ryan et al., 2010).   
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 Hypo PP Hyper PP ATS TPP 
Gene CACNA1S 
SCN4A 
SCN4A KCNJ2 KCNJ18 
Mode of 
Inheritance 
Dominant Dominant Dominant Dominant 
Age of onset 1st or 2nd decade 1st decade 1st or 2nd decade 1st or 2nd decade 
Attack of 
Muscle 
Paralysis? 
Yes Yes Yes Yes 
Length of 
Attacks 
Hours to days Minutes to hours Minutes to days Minutes to days 
Ictal K+ Levels Low High or normal Low, normal or high Low, normal or 
high 
Triggers Carbohydrate 
Rest after 
exercise 
Potassium 
Rest after exercise 
Rest after exercise Rest after 
exercise 
Permanent 
weakness 
Yes Yes Sometimes Sometimes 
Myotonia No Sometimes No No 
Other Features No No Dysmorphic Features 
& cardiac conduction 
defects 
Hyperthyroidism 
Table 1-2 Clinical features of periodic paralysis 
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1.6 Treatment for skeletal muscle channelopathies 
Patients with skeletal muscle channelopathies have symptoms which continue throughout 
adulthood, can worsen with age leading to permanent muscle weakness and can impact 
greatly on the quality of life. In addition, there is a range of severity experienced by patients 
resulting in a need for a variable approach to treatment depending on the patient.  
The current treatments for the skeletal muscle channelopathies are imperfect. For the main 
treatments of the skeletal muscle channelopathies, adverse side effects pose a problem 
especially due to involvement of cardiac muscle seen in ATS and following administration of 
anti-arrhythmic Mexiltine for treatment of myotonia. In addition, little is known about the 
mechanism of action or efficacy of the therapies used and too few randomised control trials 
have been conducted. Further research is needed in order to fully understand the 
mechanism by which the therapies work. The ideal treatment would involve targeting the 
specific protein dysfunction that results in the attacks of myotonia or paralysis in patients. 
This would hopefully lead to better efficacy in treatments with fewer side effects due to 
tissue specific molecular targets.  
1.6.1 Non-dystrophic myotonia 
In some mild cases treatment of myotonia can simply include avoidance of triggering 
factors; such as exposure to cold or demanding exercise, however this is not sufficient for 
those who are more severely affected.  
The current treatments available for NDM involve the use of off label drugs with sodium 
channel blocking activity, such as anti-epileptic and anti-arrhythmic drugs. A number of 
drugs used have been given anecdotal support for the use for treating myotonia such as 
quinine and phenytoin (Matthews et al., 2010; Raja Rayan & Hanna, 2010; Trivedi et 
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al.,2014a). The most common drug used to treat myotonia is mexiletine which is an anti-
arrhythmic drug that blocks sodium channels of both skeletal and cardiac muscle in a use 
dependent manner.  
Few controlled trials have been conducted looking at the efficacy of treatments for the 
Non-Dystrophic Myotonias. A 2006 Cochrane review found that there was insufficient data 
available in order to consider any treatment safe and effective for NDM (Trip et al.,2006). 
Difficulties arise in performing randomised trials for such a rare disorder which shows a vast 
amount of genetic and phenotypic variability. Until 2012 Mexiletine had only shown to be 
effective through an uncontrolled clinical trial (Kwiecińsk et al,. 1992). The first randomized 
controlled trial of Mexiletine for the treatment of myotonia was conducted by CINCH (the 
consortium for clinical investigation of neurologic channelopathies). This trial showed that 
Mexiletine significantly improved patient stiffness although some adverse cardiac events 
were reported (Statland et al., 2012; Trivedi et al., 2012).  
1.6.2 Periodic paralysis 
An important part of treatment of periodic paralysis is avoiding factors that can trigger an 
attack of weakness. In Hyper PP this involves avoiding potassium rich foods and fasting 
whilst for Hypo PP, patients are recommended to eat small regular meals to avoid 
carbohydrate loading.  
As with treatment of the non-dystrophic myotonias, most drugs used have been shown to 
work through case reports or anecdotal evidence. Onset of attacks of paralysis can be 
treated through the intake of oral potassium, in Hypo PP, or inhalation of salbutamol, in 
Hyper PP. For both forms of periodic paralysis, prophylactic treatment mainly occurs 
through the administration of the carbonic anhydrase inhibitors: acetazolamide or 
 
 
50 
 
dichlorphenamide. These drugs have been shown to have beneficial effects on attack 
frequency and muscle strength.  
Acetazolamide and dichlorphenamide have been shown to activate of calcium activated 
potassium channels – BK channels. Both drugs have been shown to prevent paralysis and 
weakness in potassium depleted rats by activating the BK channels and enabling the 
repolarisation of skeletal muscle fibres (Tricarico et al.,2006). Increased hyperpolarizing K+ 
current would counteract the abnormal depolarization of the muscle fibres and may 
account for some of the beneficial effects of these drugs.  However, it is still not fully 
understood how carbonic anhydrase inhibitors work to improve Hypo PP symptoms. It has 
been suggested that they may act to help deal with the acidic environment of the skeletal 
muscle which could be caused by the gating pore current (Matthews & Hanna, 2010). 
It has been reported that acetazolamide is unable to prevent or in fact worsens attacks of 
paralysis in some Hypo PP patients (Matthews et al.,2011). Furthermore acetazolamide has 
been shown to prevent myopathy in potassium depleted rats, although the ability to avert 
progressive myopathy of Hypo PP patients is unclear (Tricarico et al.,2008).  
Recent studies of the mouse models of hypo periodic paralysis (Hypo PP NaV1.4 R669H & 
CaV1.1 R528H) have shown bumetanide could be a potential new treatment for Hypo PP. 
Bumetanide acts upon the Na-K-2Cl transporter within skeletal muscle (van Mill et 
al.,1997). It was shown that bumetanide prevents development of weakness and restores 
force during an attack (Wu et al.,2013a; Wu et al.,2013b). Trials are now underway in order 
to establish the efficacy of bumetanide in the treatment of the human disease. Bumetanide 
may act to prevent muscle depolarization by altering the intracellular chloride 
concentration which is thought to predispose the skeletal muscle to paradoxical 
depolarization (Geukes Foppen et al.,2002; van Mil et al.,1997; Wu et al.,2013). 
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There have been very few randomised control trials that study the effectiveness of drugs 
for the treatment of periodic paralysis. A 2008 Cochrane report found one randomised 
control study of dichlorphenamide which was shown to be effective in the prevention of 
attacks of weakness in both hypo and hyperkalemic periodic paralysis. Two small studies 
provided evidence that acetazolamide could improvement of muscle strength. The report 
concluded that there was still insufficient evidence in order to provide guidelines for the 
treatment of periodic paralysis (Sansone et al.,2008). 
Treatment of ATS is complicated by the necessity of treating the triad of symptoms present. 
As with other forms of periodic paralysis, treatments are based on current anecdotal 
evidence rather than detailed controlled studies. It has been suggested that the carbonic 
anhydrase inhibitors may have a beneficial effect on the frequency of attacks for ATS 
patients, but the effect on the cardiac muscle is still unclear. Combining treatment with oral 
potassium has been shown to have a beneficial effect on cardiac muscle (Sansone & Tawil, 
2007). The standard treatment for the cardiac symptoms of ATS is through the use of beta-
adrenergic blockers such as propranolol or calcium channel blockers such as amlodipine 
and nifedipine (Sansone & Tawil, 2007). Treatment of the cardiac symptoms of ATS through 
the use of anti-arrhythmic drugs can result in the exacerbation attacks of paralysis in some 
cases.  
For TPP the main form of treatment is treatment of the thyrotoxocosis as there are no 
specific treatments for attacks of paralysis. Acetazolamide cannot be used in TPP patients 
because it is thought to worsen symptoms experienced in these patients (Tricarico & 
Camerino, 2011).   
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1.7 Pathomechanism of Skeletal Muscle Channelopathies 
1.7.1 Hyperkalemic Periodic Paralysis, Paramyotonia Congenita and 
Sodium Channel Myotonia 
The allelic diseases of Hyper PP, PMC and SCM show a spectrum of phenotypes from 
enhanced excitability (myotonia) to reduced excitability (periodic paralysis) with fluctuation 
and overlap between the two.  
The common mechanism behind these disorders is the presence of gain of function 
mutations which lead to an increase in the inflow of Na+ ions and subsequent increase in 
the depolarisation of the muscle membrane (Jurkat-Rott et al.,2010). This depolarisation 
activates more sodium channels leading to repetitive firing of action potentials; the 
hallmark of myotonia. Myotonic activity of the muscle leads to increased sodium inflow and 
depolarisation. If the depolarisation is large enough the sodium channels may enter an 
inactivated state. Inactivation of  sodium channels prevents cells from firing action 
potentials, resulting in flaccid, inactive muscle; the hallmark of periodic paralysis (Jurkat-
Rott et al.,2010). 
Sodium channels mutations often disrupt fast inactivation or increase channel activation 
(Cannon,2000). Whilst different mutations target the same gating mechanisms, the 
impairment varies depending on the disorder which results in the difference in phenotypes 
despite similar mutation defects. The extent of depolarisation is predicted to be smaller for 
mutations causing myotonia compared to Hyper PP mutations which is why the main 
symptom is myotonia with some transient weakness (Bendahhou et al.,1999; Cannon,2000; 
Rojas et al.,1999). 
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Most PMC and SCM mutations cause a reduced rate of channel fast inactivation but do not 
affect the extent of the inactivation. In addition, mutations also result in an enhanced rate 
of recovery from inactivation. These defects lead to an increase in the number of sodium 
channels available for activation following an action potential, increasing muscle excitability 
(Bouhours et al., 2004; Mitrovic et al., 1996; Plassart-schiess et al.,1998).  
Hyper PP mutations have been reported to disrupt both channel inactivation and/or 
activation. Some mutations, such as M1592V, cause a slower rate of channel inactivation 
and prevent complete fast inactivation (Bendahhou et al.,2002; Hayward et al.,1999; Rojas 
et al.,1999). Following a prolonged depolarisation, 1.5-5% of mutant channels remain open, 
whilst the majority of WT channels undergo full fast inactivation with only 0.1% of channels 
remaining open (Cannon et al.,1991). This extended opening of the sodium channel persists 
until the channel closes upon repolarisation. The persistent current depolarizes the 
membrane, causing inactivation of the sodium channels rendering the muscle inexcitable. 
For some Hyper PP mutations the voltage dependence of fast inactivation is shifted to 
depolarising direction, which results in increased Na+ currents, muscle depolarisation, 
inactivation of the sodium channels and muscle inexcitability (Cannon,2002). 
Other Hyper PP mutations, such as T704M and I693T, cause a hyperpolarising shift of the 
voltage dependence of channel activation (Bendahhou et al.,2002, Bendahhou et al.,1999; 
Brancati et al., 2003; Yoshinaga et al., 2012). These mutant sodium channels open at 
potentials where the channel would normally be closed. A small hyperpolarising shift 
(~5mV) in the voltage dependence of activation can cause a large depolarisation of the 
membrane potential (Cannon, 2002; Trivedi, Cannon, & Griggs, 2014b).  
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Figure 1-5 Causative genes in skeletal muscle channelopathies 
Skeletal muscle channelopathies show a spectrum of electrical excitability due to significant amount of overlap in terms of causative gene and disease 
mechanism. This leads to further overlap in terms of patient symptoms. Adapted from Cannon 2006.  
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1.7.2 Hypokalemic Periodic Paralysis 
Early functional studies of Hypo PP mutations using heterologous expression systems 
demonstrated reduced current density and small shifts in channel kinetics (i.e. a small shift 
in voltage dependence of inactivation), suggesting a loss of channel function (Bulman et al., 
1999; Kuzmenkin et al., 2002; Struyk et al.,2000). However, small loss of function defects 
could not explain the paradoxical depolarisation of Hypo PP muscle fibres in low potassium 
or the pathophysiological basis of paralytic attacks of weakness in low potassium. 
The key to elucidating the mechanism for Hypo PP came through structure-function voltage 
sensor experiments of the Shaker K+ channel which revealed that mutations of the S4 
arginine residues provided a pathway for cations to move through the voltage sensing 
domain (Starace & Bezanilla, 2001; Tombola et al.,2005). These aberrant currents were 
described as “gating pore currents”- or “omega currents”. Coincidently, Hypo PP mutations 
affect the conserved arginine residues within the S4 voltage sensor of both NaV1.4 and 
CaV1.1 causing loss of these charged residues. Thus, it was hypothesised that Hypo PP 
mutations might cause an aberrant ionic leak current through the gating pore of the CaV1.1 
and NaV1.4 VSDs resulting in the depolarization seen in Hypo PP muscle fibers (See Figure 
1-6).  
An aberrant gating pore current in Hypo PP mutant channel was first reported by Sokolov et 
al. 2007 who demonstrated a hyperpolarization activated cationic leak through the voltage 
sensing domain in the Hypo PP mutations R672G, R672H and R669H of NaV1.4. The findings 
on R669H mutant channels were confirmed by Struyk et al. 2007. This current was shown to 
be carried by protons rather than other cations, such as Na+ ions, which act as the charge 
carriers for the R672G mutation. In addition, the domain III mutations R1132Q and 
R1135C/H have been reported to cause gating pore currents. R1132Q is activated at 
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potentials more negative than -60 mV and has a preference Na+ ions as the charge carrier 
(Francis et al.,2011). In contrast R1135C/H mutations result in outward gating pore currents 
at positive potentials but inward gating pore currents following S4 immbolization during 
channel inactivation (Groome et al., 2014). A further type of periodic paralysis, referred to 
as normokalemic periodic paralysis, is caused by R675G mutations in NaV1.4. As seen with 
R1135C/H, R675G mutant channels carry gating pore currents at depolarising potentials but 
also cause inward currents following channel inactivation (Sokolov et al., 2008). 
In addition to a depolarising gating pore current, it has been suggested that sarcolemmal 
depolarisation is a result of impairment of the potassium conductance which governs the 
resting membrane potential (Vrest). In vitro studies of Hypo PP muscle fibres have shown the 
muscle fibres depolarise in the presence of low external potassium, whereas normal muscle 
hyperpolarises when exposed to the same conditions (Rudel et al.,1984; Ruff, 1999). 
Additionally, inhibition of the outward currents from inward rectifying potassium (Kir) 
channels have been shown to cause paradoxical depolarisation of muscle fibres exposed to 
low potassium (Jurkat-Rott et al.,2009; Struyk & Cannon,2008). It is suggested that a 
modest impairment of Kir conductance increases the susceptibility of the muscle to 
depolarisation in response to low extracellular potassium concentrations (Struyk & 
Cannon,2008). The presence of a depolarising gating pore current is thought to increase the 
probability that low extracellular potassium will cause depolarisation of Vrest (Jurkat-Rott et 
al., 2009; Jurkat-Rott et al., 2012; Struyk et al., 2008).  
However it is not fully understood how disruption to Cav1.1 or Nav1.4 reduces the Kir 
conductance. One suggestion is that the gating pore current disrupts the sarcolemma 
intracellular pH homeostasis, leading to intracellular acidification which is known to inhibit 
Kir channels (Matthews & Hanna, 2010).    
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Figure 1-6 Schematic representation of gating pore domain and ionic leak currents for 
normal and R2 mutant sodium channels 
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1.8 Aims of Project 
The overall aim of this thesis was to improve our fundamental understanding of the genetic 
heterogeneity and mechanism of disease of the skeletal muscle channelopathies, in 
particular, periodic paralysis. My work had two main components: a genetic study of 
skeletal muscle channelopathy cohorts and a functional analysis of mutant skeletal muscle 
ion channels with the specific aims of: 
1. Investigating the genetic causes of periodic paralysis in cohorts without the 
common mutations (Chapter 3). 
2. Investigating the genetic causes of myotonia in cohorts without the common 
mutations within SCN4A and mechanisms of dual mode of inheritance in myotonia 
congenita (Chapter 4). 
3. Assessing the functional impact of novel sodium channel mutations which cause 
Hypo PP (Chapter 5). 
4. Structure- function studies of the gating pore domain (Chapter 5). 
5. Assessing the functional impact of novel sodium channel mutations which cause 
myotonia (Chapter 6). 
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2 Chapter 2: Methods 
2.1 Patient Cohort 
The MRC Centre for Neuromuscular Diseases is the NHS England centre for 
channelopathies and provides the national diagnostic clinical screening service. Patients 
were chosen from the database of cases that had been referred to the MRC Centre for 
Neuromuscular Diseases with a suspected skeletal muscle channelopathy but were 
negative for the common mutations. Informed consent was given for all samples used.  
2.1.1 Periodic paralysis cohort 
A large cohort of periodic paralysis patients who lacked mutations in the known genes 
(CACNA1S, or SCN4A) was identified. The cohort was then divided into two sub groups: well 
characterised cohort and the less characterised cohort. Those patients in the well 
characterised cohort had a well characterised phenotype, which followed the documented 
phenotype for periodic paralysis. All patients in this cohort had supportive electrical studies 
and were thought to have a high likelihood of finding a genetic cause. Patients in the 
second cohort had a wide range of phenotypes with some uncharacterised symptoms for 
periodic paralysis. Not all patients had supportive electrical testing.  
2.1.2 Myotonia cohorts 
Two cohorts of myotonia patients were chosen for candidate gene screening. The first 
contained patients with a well characterised PMC or SCM phenotype and supportive 
electrical studies. Mutations in SCN4A and CLCN-1 had been previously ruled out. The 
second cohort consisted of 10 dominant myotonia congenita families where a single 
60 
 
mutation in CLCN-1 had been identified through genetic screening. For all families the 
mutation identified had been previously reported as showing dominant and recessive 
patterns of inheritance. 
2.2 Genetic Screening of Patient Cohorts 
2.2.1 Exonic Sequencing 
Sequencing of four candidate genes: SCN4A, CACNA1S, KCNJ18, MT-ATP6 and MT-ATP8 was 
undertaken to identify new causative mutations in the cohort of patients. Primers for the 
target exons were designed against SCN4A, CANCA1S and KCNJ18 (GenBank accession 
numbers NM_000334, NM_000069 & FJ434338 respectively) using Primer3 (See Appendix 
for primer sequences). 
2.2.1.1 SCN4A & CACNA1S PCR reactions 
To amplify the desired exons for SCN4A and CANCA1S a PCR mastermix was made 
containing 12.5 µl of AmpliTaq Gold 360 mastermix (Applied Biosystem ABI, USA), 
10pmol/µl primers and DNA in a 25µl reaction. PCR conditions consisted of an initial 
denaturing step of 95 °C for 10mins followed by 30 cycles of 95 °C for 30 seconds, 58 °C for 
30 seconds, 72 °C for 30 seconds and a final step of 72 °C for 7 minutes. Samples were then 
run on a 2 % agarose gel for 30minutes at 60 V to determine the success of the reaction. 
Following PCR, samples were diluted to 100 µl with nanopure water, transferred to a PCR 
cleanup filter plate (Millipore, USA) and placed on a vacuum for 5minutes. 50 µl of water 
was then added to resuspend and the plate was placed on a shaking platform for 
30minutes. 
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2.2.1.2 KCNJ18 PCR Reaction 
The whole coding exon of KCNJ18 was amplified by PCR using 12.5 µl of AmpliTaq Gold 360 
mastermix (Applied Biosystem ABI, USA), 10pmol/µl primers, 1.5 µl of GC enhancer and 2 µl 
of DNA in a 25µl reaction. PCR conditions consisted of an initial denaturing step of 95 °C for 
10mins followed by 30 cycles of 95 °C for 30 seconds, 50 °C for 30 seconds, 72 °C for 2 
minutes and a final step of 72 °C for 7 minutes. Samples were then run on a 0.8% agarose 
gel. Following PCR, samples were diluted to 100 µl with nanopure water, transferred to a 
PCR cleanup filter plate (Millipore, USA) and placed on a vacuum for 5minutes. 50 µl of 
water was then added to resuspend and the plate was placed on a shaking platform for 
30minutes.  
2.2.1.3 Mitochondrial genes: MT-ATP6 & MTP-8 PCR Reaction 
The mitochondrial genes MT-ATP6 and MT-ATP8 were amplified through PCR using three 
primer pairs. PCR mastermix was made containing 6.5 µl of AmpliTaq Gold 360 mastermix 
(Applied Biosystem ABI, USA), 5pmol/µl primers and DNA in a 12µl reaction.PCR conditions 
consisted of an initial denaturing step of 95 °C for 10mins followed by 30 cycles of 95 °C for 
30 seconds, 58 °C for 30 seconds, 72 °C for 30 seconds and a final step of 72 °C for 
7 minutes. Samples were then run on a 2 % agarose gel for 30minutes at 60 V to determine 
the success of the reaction. Following PCR, samples were diluted to 100 µl with nanopure 
water, transferred to a PCR cleanup filter plate (Millipore, USA) and placed on a vacuum for 
5minutes. 75 µl of water was then added to resuspend and the plate was placed on a 
shaking platform for 30minutes. 
2.2.1.4 Sequencing of PCR products 
Sequencing of PCR products was done using ABI Big Dye terminator kit version 1.1 (ABI), 
primers (3.2pmolµl) and 2 µl of clean PCR product. M13 primers were used for CACNA1S 
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and SCN4A, whilst primers designed against the gene sequence were used for KCNJ18, MT-
ATP6 and MT-ATP8 (see primer sequences).  
PCR conditions consisted 25 cycles of 95 °C for 10 seconds, 50 °C for 5 seconds, 60 °C for 4 
minutes. Samples were then diluted to 20µl with nanopure water and a dye terminator 
kit(Thermo Scientific, USA) was used to remove excess dye from the sequencing reaction. 
Samples were then run on a 3730x sequencing machine and the sequencing data obtained 
was analysed using SeqScap V2.5 (Applied Biosystems, USA). In silico analysis using alamut 
software and PolyPhen was used to determine whether mutations were likely to be 
pathogenic (Adzhubei et al. 2010). Mutations found were confirmed by repeating from 
initial PCR.  
2.2.2 Whole-Exome Sequencing 
Samples were selected on the basis of good family history and exclusion of mutations in 
known genes. Genomic DNA was characterized by whole-exome sequencing by Neuromics, 
who dealt with data acquisition and primary data analysis. Data was then analysed using 
the online DeCode Health software (sequence miner and sequence analyser). Synonymous 
and non-coding variants that didn’t affect splice sites were filtered out. An autosomal 
dominant inheritance pattern was predicted for the family and thus variants which had a 
frequency of >0.01 using 1000genomes were filtered out. Additionally, a skeletal muscle 
gene list was used to filter out any variants which are not expressed in the skeletal muscle. 
SNPs in public databases, read dept and predicted impact on protein were also used to 
filter variants. The Decode Health software focuses on filtering for candidate genes or 
known variants. Candidate genes were selected based on the association with the known 
symptoms of the patients. All known pathogenic variants were also highlighted by the 
software. All other variants were then filtered based on read dept, inheritance pattern and 
predicted impact on the protein. 
63 
 
2.3 Functional Analysis of mutations 
2.3.1 Plasmids 
The wild type human SCN4A and rat SCN4A clones were gifts from Prof. Steve Cannon 
(University of Texas Southwestern Medical Center, Dallas, USA). The human SCN4A vector 
is a mammalian expression vector, pRc/CMV. The rat SCN4A vector is a pGEMHE vector and 
the untranslated regions of a Xenopus β-globin gene for expression within Xenopus 
oocytes. It contains a NHeI restriction site for linearization during RNA preparation and a T7 
promotor site for RNA transcription. 
2.3.2 Transformation of chemically competent cells & DNA Prep 
30µl of Top10 competent cells (Invitrogen, USA) were mixed with at least 50ng of plasmid 
DNA in round bottomed tubes (BD Biosciences, USA) and incubated for 30 minutes on ice. 
Tubes were then heat shocked at 42 °C for 40 seconds in water bath before returning to ice 
for a further 2 minutes. 200 µl of fresh LB was added to each tube, which were then 
incubated at 37 °C shaking at 200rpm. Following incubation 100 µl was then plated onto LB 
agar plates with 100 µg/µl of ampicillin and incubated overnight at 37 °C. Tubes containing 
2-6 ml of LB with 100µg/µl of ampicillin were then inoculated with single colonies and 
incubated shaking at 37 °C overnight. Transformed plasmid DNA was then extracted using a 
GenElute Plamid mini prep kit (Sigma-Aldrich, USA). The concentration of purified DNA was 
measured using a nanodrop spectrophotometer. 
2.3.3 Mutagenesis 
Either human or adult rat wild type skeletal muscle Na+ channel α subunit (hNav1.4 or 
rNav1.4) subcloned into the mamlian expression vector pRC-CMV or the Xenopus 
expression vector pGEMHE respectively (a kind gift from Prof Cannon, UT Southwestern, 
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USA), were used as a template for site directed mutagenesis using the QuickChange 
Mutagenesis kit (Stratagene, USA). Primers were designed to introduce the substitution 
mutation by altering the appropriate codons. Direct sequencing was used to confirm 
correct point mutation had been introduced.   
2.3.4 Functional analysis within oocytes 
2.3.4.1 RNA preparation & Oocyte Injection 
Circular plasmid DNA containing the rat SCN4A insert was linearized with the restriction 
enzyme NheI (NEB, USA) (10 µg of DNA, 10µl of 10x buffer 2 (NEB), 100x BSA, 5 µl NheI in a 
total volume of 100 µl at 37 °C for 2 hours). Following linearization the DNA was cleaned 
using Geneclean II kit (MP bio) or QIAquick PCR purification kit (Qiagen, Netherlands). 2µg 
of linearised DNA was used for in vitro transcription of cRNA using Ambion T7 mMessage 
mMachine kit (Life Technologies, USA). The reaction mixture contained: 10µl 2x NTP, 2 µl 
10x Reaction buffer, 2 µl Enzyme mix and 2µg of linear template DNA made up to 20  µl 
with water. Following incubation at 37 °C for 2 hours, 1 µl of DNAse was added to the 
reaction and incubated at 37 °C for a further 15minutes. Lithium chloride precipitation was 
used to extract the RNA. 30 µl of H20 and 30 µl of LiCl prepcipation solution was added to 
the reaction. The mixture was put at -20 C overnight. The mixture was then centrifuged for 
15mins at 13,000rpm and 4 °C. The supernatant was removed, 500µl of 70% ethanol added 
and spun again at 4 °C. The supernatant was removed and the pellet was resuspended in 
20 µl of RNAse free H20. RNA concentration was measured using nanodrop spectrometer. 
Stage V-VI Xenopus laevis oocytes were harvested from female Xenopus laevis frogs and 
stored in MBS media (87 mM NaCl, 1 mM KCl, 1.68 mM MgSO4, 10 mM Hepes, 0.94 mM 
NaNO3, 2.4 mM NaHCO3, 0.88 mM CaCl2). The follicular layer was removed by incubation 
with 2mg/ml Collagenase A (Roche diagnostics, Switzerland) in MBS for 90minutes. Healthy 
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stage V –VI oocytes were selected and stored in OR-2 media (82.5 mM NaCl, 2 mM KCl, 
1 mM MgCl2, 5 mM Hepes) with 100 U/ml penicillin-streptomycin and stored at 14-16 °C. 1 
to 3 days after harvest oocytes were injected with ~50 ng of cRNA using a Drummond 
Nanoject microinjector pipette (Drummond Scientific Company, USA). 3.5” glass capillaries 
(Nanolitre replacement tubes, Drummond Scientific) were formed using a multistage-stage 
puller (Zeitz DMZ Universal Puller, AutoMate Scientific, USA). The tip was broken manually 
and the electrode backfilled with mineral oil (Sigma-Aldrich, USA). For NaV1.4 experiments, 
WT or mutant channels were mixed in equal volumes with β1 subunit and injected into the 
oocyte cytoplasm. Injected oocytes were incubated at 18 °C in L-15 medium supplemented 
with Horse Serum, Pen/strep and Gentamycin. 
2.3.4.2 Gating Pore Current Analysis 
To analysis gating pore currents in Hypo PP mutations, two different techniques were used: 
Cut open voltage clamp (COVC) and Two Electrode Voltage Clamp (TEVC). COVC was used 
to validate the data obtained through TEVC experiments.  
2.3.4.3 Two Electrode Voltage Clamp 
A two electrode voltage clamp set up was used to investigate the mutations expressed in 
Xenopus oocytes 2-6 days after injection. The voltage clamp was controlled by an 
GeneClamp 500B amplifier (Axon Instruments, USA). The amplifier was controlled and 
signals recorded using pClamp 7 software together with a DigiData1200A A/D converter 
(Axon Instruments, USA). Microelectrodes were fabricated from borosilicate glass (Harvard 
Apparatus, USA) using a multi stage puller (AutoMate Scientific, USA ) to an O.D of 3-5µm 
for the voltage electrode and 7-9 µm for the current electrode. The tip resistance of the 
electrodes were <2MΩ and <1MΩ respectively with both electrodes filled with 3M KCl. 
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Ag+/AgCl coated electrodes were connected the amplifier headstage and glass agar bridges 
used to connect the bath electrodes to the main camber.  
Ionic currents were measured in response to ms voltage steps from the holding potential of 
-100 mV to test potentials of -100 to +45mV in 5 mV increments. Steady state currents 
were measured in response to 300 ms voltage steps from the holding potential of -100 mV 
to test potentials of -140 mV to + 50 mV. The holding potential was varied for some 
experiments was changed to 0 mV. 
In experiments studying the voltage dependence of gating pore currents a Cl- free Na+ bath 
solution (referred to as NaMes: 120 mM NaMes, 1.8 mM CaS04 and 10mM Hepes, pH7.4 
with NaOH) was used. 1 µM TTX was present to block sodium currents. For ion selectivity 
experiments, Names was substituted for different solutions: Kmes (120 mM potassium 
methanesulfonate, 1.8mM calcium sulfonate & 10 mM Hepes, pH7.4 with KOH), 
Guanidinium (120 mM Guanidinium methanesulfonate, 1.8mM calcium sulfonate & 10 mM 
Hepes, pH7.4 with NaOH), NMDG-Mes (120 mM NMDG, 1.8mM calcium sulfonate & 
10 mM Hepes, pH7.4 with methanesulfonic acid) and NMDG-Cl (120 mM NMDG, 1.8mM 
calcium sulfonate & 10 mM Hepes, pH7.4 with HCl). 
2.3.4.4 Cut Open Voltage Clamp  
Oocytes were voltage clamped in the cut open configuration and controlled by a CA-1B 
amplifier (Dagan Corportation, USA). The amplifier was controlled and signals recorded 
using pClamp 7 software together with a DigiData1200 A/D converter (MDS Analytical 
Technologies, USA).The lower oocyte membrane was permeabilized with 0.1% saponin to 
allow ionic control over the intracellular solution. Electrodes were fabricated from 
borosilicate capillary glass (1.5mm OD thin wall with filament; WPI) using a multi-stage 
puller (Sutter Instrument Co., USA) and were filled with 3M KCl.  
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The external bath solution containedto approximate the mammalian physiologic 
monovalent cation gradient contained:  112 mM NaOH, 3 mM KOH, 1.5 mM CaOH2, 
4.5 mM BaOH2, 10 mM HEPES, pH 7.4 with methane sulfonic acid. The external solution 
contained 1 µM TTX. The internal solution contained: 103 mM KOH, 7 mM NaOH, 10 mM 
EGTA, 10 mM HEPES, pH 7.4. 
Currents were filtered at 5kHz and sampled at 100kHz for gating charge displacement 
measurements or filtered at 1kHz and sampled at 10kHz for steady state currents. 
Gating pore currents were measured following a 30 ms voltage step from a holding 
potential of -60 mV to test potentials of -130 to +40 mV. 
2.3.4.5 Data Analysis 
Gating pore currents were analysed by removing non-specific leak currents through leak 
subtraction at linear  using the linear component of currents occurred after recording to 
remove background non-specific leak from across the oocyte membrane allowing isolation 
of gating pore currents. The peak Na+ α currents were recorded for all cells before the 
addition of TTX to the bath solution. Gating pore currents were normalised to the peak Na+ 
currents in order to compensate for differences in expression levels. Data was analysed 
using a combination of ClampFit 9 (Molecular Devices), Excel (Microsoft) and Origin Pro 9 
(OriginLab) software packages. 
2.3.5 Functional analysis in HEK cells 
2.3.5.1 HEK cell culture & Transfection 
HEK293 cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma-Aldrich, 
USA) with 10% fetal bovine serum within T25 flasks. using GFP as a marker, hSCN4A DNA 
was transfected into HEK293 with Lipofectamine 2000(Invitrogen, USA) as per the 
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manufactures instructions . After 24 hours, cells were passaged onto 10 mm round 
coverslips. 
2.3.5.2 Whole cell patch clamp 
Whole cell patch recordings were made at room temperature, 1-3 days following 
transfection, using an Axopatch 200B amplifier (Axon Instruments, USA). All data were 
sampled at 50kHZ and filtered at 10kHZ. Any junction potential errors were not corrected 
for. Electrodes were formed from borosilicate glass tubes ((G150F, Harvard Apparatus) 
using a multistage puller (AutoMate Scientific, USA). The external bath solution contained: 
145 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2, 10 mM Hepes, pH 7.4 with NaOH. The 
internal pipette solution contained: 145 mM CsCl, 5 mM NaCl, 10 mM EGTA, 10 mM HEPES, 
pH 7.35 with CsOH. A custom in house written program was used in LabView software for 
data acquisition (DM Kullmann, Institute of Neurology, UCL).  
2.3.5.3 Protocols 
The voltage dependence of activation was measured from voltage steps from holding 
potential of -80 mV to test potentials of -130 mV to +60 mV in 10 mV increments. The 
voltage dependence of fast inactivation was measured using a 300 ms conditioning voltage 
step from -130 mV to 60 mV in 10 mV incremenets, followed by a constant test pulse step 
to -10 mV. The voltage dependence of slow inactivation was measured using a 10s 
conditioning prepulse to test voltages(-130 mV to -60 mV), then a 20 ms step to -100 mV to 
allow recovery from fast inactivation, followed by a 20 ms test pulse to 0 mV. 
2.3.5.4 Data Analysis 
Any recordings resulting in series resistance errors greater than 5 mV were discarded 
straight away. All data were fitted to a Boltzmann function in order to obtain voltage values 
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at which half of the channels were activated (or inactivated) (V0.5) and the offset current 
(C). The resulting current responses were analyzed using LabView, Clampfit (Axon 
Instruments) and Origin9.0 (Originlab). 
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3 Chapter 3: Sequencing of Patients with Periodic 
Paralysis 
3.1 Summary 
In periodic paralysis about 20-30% patients remain without a genetic diagnosis following 
sequencing of the known common mutations. Normal diagnostic testing is targeted to 
specific areas containing the common mutations in either the sodium or calcium channel, 
which leaves a large part of the gene unsequenced. In addition, mutations have been 
identified which are located outside of the common sequencing areas suggesting that 
further areas require screening. The aim of this study was to identify novel mutations that 
cause periodic paralysis in order to further the understanding of the genetic heterogeneity 
present in the disease.  
The S4 segments of CACNA1S and the whole coding region of SCN4A were screened in a 
small cohort of patients. Five novel mutations were found in SCN4A, two causing Hypo PP 
(c.502T>G, p.Try168Asp and c.4259A>G, p. Asp1420Gly) and three associated with Hyper PP 
(c.665G>A, p.Arg222Gln; c.1207A>C, p.Met403Leu and c1957A>G, p.Ser653Gly). Both 
Hypo PP mutations were found in areas of the channel not normally associated with 
disease; indicating that Hypo PP mutations are not restricted solely to the voltage sensor. 
The Hyper PP mutations identified were all located in areas close to known mutations and 
together with the Hypo PP mutations support the notion that diagnostic screening should 
be extended to the whole gene.   
Three candidate genes were screened in a larger cohort of patients: MT-ATP6, MT-ATP8 
and KCNJ18, in order to investigate whether pathogenic mutations in these genes could 
cause a pure periodic paralysis phenotype. 60 samples were screened for mutations in 
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these genes. No mutations were found in MT-ATP6 or MT-ATP8. One mutation was 
identified in KCNJ18, although this is unlikely to be the causative mutation as the patient 
was also found to have a normokalemic periodic paralysis SCN4A mutation, p.Arg675Gln. 
These findings indicate that mutations in these genes could not be a common cause of 
periodic paralysis phenotype for MT-ATP6 and MT-ATP8 or a non Asian population for 
KCNJ18.  
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3.2 Introduction 
Mutations in two genes have been identified to be the main cause of periodic paralysis – 
SCN4A and CACNA1S. Mutations identified to date within these genes account for ~75% of 
all periodic paralysis cases. Targeted testing for diagnostics of periodic paralysis involves 
the sequencing of only four exons: two SCN4A exons (exons 13 & 24) and two exons in 
CACNA1S (exons 11 & 30). Hypo PP is caused by mutations in both SCN4A and CACNA1S, 
whilst Hyper PP is caused by mutations only in SCN4A (Jurkat-Rott et al. 1994; Jurkat-Rott et 
al. 2000; Sternberg et al. 2001; Davies et al. 2001; Miller et al. 2004; Vicart et al. 2004). 
Whilst for most cases the causative mutation is found in these areas, the full genetic and 
mutation spectrum of the disease is not known. This is highlighted by studies which have 
identified mutations areas outside the hotspots, indicating the importance of expanding the 
screening area in the causative genes(Sugiura et al. 2003; Matthews et al. 2009; Lee et al. 
2009; Ke et al. 2009; Fan et al. 2013).  
Recent studies have discovered three new genes which play a role in the causation of 
periodic paralysis: KCNJ18 and MT-ATP6 and MT-ATP8. KCNJ18 encodes the potassium 
channel, Kir2.6. Mutations in this gene have been shown to result in thyrotoxic periodic 
paralysis and sporadic periodic paralysis in Asian populations(Ryan et al. 2010; Cheng et al. 
2011) . While these studies are focused solely on patients within the Asian population, it is 
possible that mutations in KCNJ18 could cause periodic paralysis in other populations. MT-
ATP6 and MT-ATP8 are mitochondrial genes that have been recently associated with an 
atypical periodic paralysis like phenotype(Auré et al. 2013). This is the first non channel 
gene to be associated with transient attacks of paralysis and offers the exciting potential to 
further our understanding of the causative pathways of the disease. Both KCNJ18 and the 
mitochondrial genes highlight the likelihood that some patients will not have a mutation in 
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the known genes but could have mutations in currently unknown genes which can be 
investigated through next generation sequencing techniques such as exome sequencing. 
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3.2.1 Aims 
The aims of this study were to identify novel mutations in the known genes associated with 
periodic paralysis, in two well defined cohorts, through screening which encompasses the 
areas of the gene normally not covered during diagnostic sequencing. In addition, new 
genes associated with rare or atypical forms of periodic paralysis were screened in order to 
expand the current understanding of genetic causes. This offers the potential to further the 
understanding of the genetic heterogeneity of periodic paralysis.  
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3.3 Periodic Paralysis Patient Cohort 
In order to expand our knowledge of periodic paralysis, genetic analysis was undertaken in 
a cohort of 68 patients who were negative for the common periodic paralysis mutations. 
This large cohort was divided into two groups in order to enable two different approaches 
to be used (See Figure 3-1 for overview of cohort investigation strategy). The first group 
consisted of 21 patients who have a well characterised phenotype consistent with either 
Hypo PP or Hyper PP, with positive electrical tests that support the clinical examinations. 
Patients in this group were then divided into Hypo PP and Hyper PP and the associated 
genes were screened. This enabled the screening of areas of the gene which are not 
normally screened during routine diagnostic testing. The second group was composed of 47 
patients with more variable phenotypes. This group contained a broad spectrum of 
phenotypes which were less well defined, and were rated based on the likelihood of finding 
an ion channel mutation. A different approach for genetic screening of this group was 
undertaken since there was a lower chance of success for screening the known genes 
through Sanger sequencing of individual exons. Samples were run on a customised TSCA ion 
channel gene panel to rule out mutations in the known genes before undertaking a 
candidate gene screening of  for three recently identified periodic paralysis genes, KCNJ18, 
MT-ATP6 and MT-ATP8. In the future, those patients with no mutations following these 
steps will be selected for exome sequencing depending on the availability of other family 
members.  
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Periodic Paralysis 
Cohort
(68 samples)
Well Characterised 
Phenotype
(21 samples)
Less Characterised 
Phenotype
(47 samples)
Hyper PP
(8 samples)
Hypo PP
(13 samples)
Know Genes
SCN4A & CACNA1S
(15 samples)
Customised 
Channel Panel
(62 samples)
New PP Genes
KCNJ18, MT-ATP6 &MT-ATP8
(62 samples)
Exome
Sequencing
Patients with  family 
members available
Patients with no 
mutations found
Patients with no 
mutations found
Rule out other known 
genes – KCNJ2, 
CACNA1S & CLCN-1
Patients with no 
mutations found (62)
 
Figure 3-1 Strategy for investigating causative mutations in periodic paralysis cohort 
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3.4 Well Defined Cohort: Hypokalemic periodic paralysis  
3.4.1 CACNA1S Sequencing in Hypokalemic Periodic Paralysis 
Mutations in Cav1.1 S4 segments have been shown to cause 70% of Hypo PP cases(Davies et 
al. 2001; Matthews et al. 2009) with all known mutations causing loss of charge of an 
arginine residue. However, only mutations in residues R1-R3 in domains II, III and IV have 
been identified. To identify novel mutations in Hypo PP cases where the known causative 
mutations had been ruled out, all the exons which encode for S4 segments of the calcium 
channel were sequenced using the Sanger sequencing method. Following sequencing of 
exons 4, 11, 21 and 30 of CACNA1S no mutations were identified in the 13 samples 
screened. It is possible that the causative mutation for some of these patients is located in 
other areas of the channel or another gene. CACNA1S consists of 44 exons therefore to use 
Sanger sequencing to investigate the whole gene is costly. In cases where no mutation was 
found the DNA was then sequenced on a custom designed TSCA gene panel that covers all 
the known skeletal muscle channelopathy genes(SCN4A, CACNA1S, KCNJ2 & CLCN-1), this 
enabled the whole coding region of CACNA1S to be covered. No mutations were identified 
following full CACNA1S screening.  
3.4.2 SCN4A Sequencing 
Following CACNA1S S4 segment sequencing, the whole coding region of the SCN4A gene, 
which encodes the sodium channel Nav1.4, was sequenced. Mutations in Nav1.4 account for 
~10% of HypoPP cases, with 18 out of 21 reported mutations causing a loss of charge of an 
arginine residue. All 24 coding exons of SCN4A were sequenced for mutations using the 
Sanger sequencing method. 3 out of 13 samples (23%) were found to have a missense 
mutation in areas of SCN4A not normally covered by diagnostic screening of the common 
78 
 
mutations (Table 3-1& Table 3-2). Of the mutations identified two were found to be novel 
and predicted to be pathogenic through in silico analysis using PolyPhen (Adzhubei et al. 
2010), while the other was a known well characterized Hypo PP mutation, p.Arg669His.  
The first novel mutation identified was p.Tyr168Asp which is located in the S2 segment of 
DI while the second was p.Asp1420Gly found within the S3 segment of DIV. Both mutations 
are found in areas of the sodium channel which have not been associated with Hypo PP 
before and require functional investigations in order to determine the effect they might 
have on the functioning of the normal channel.  
In the remaining samples of the cohort, in which no mutation was identified (77%), a 
number of different approaches were taken to identify a causative mutation, including 
custom gene panel sequencing.  
3.4.2.1 Patient and Mutation overview 
Patient 1 
Patient 1 is a 30 year old man who showed onset of symptoms at the age of 2 years old 
when he had difficulty walking. Throughout childhood he showed problems with running 
and jumping with his first paralytic attack appearing at the age of 11. This occurred during 
the night affecting his arms and legs with recovery by the morning. Two nights later he 
suffered another attack which resulted in hospitalization where his potassium level was 
measured and found to be low during attacks. The attacks can be triggered by cold 
weather, rest after exercise and eating of a carbohydrate rich meal. He is able to abort the 
onset of attacks by taking Sando-K. On physical examination the patient was revealed to 
have mild proximal weakness of arms and legs. The patient has an affected mother who 
shows no distinct attacks, with onset during pregnancy where her arms and legs were 
affected for 8 hours (Figure 3-2A). She now has severe proximal weakness and requires a 
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wheelchair for long distances. Muscle biopsies have been taken of both patients and show 
extensive vacuolation of muscle fibres, typical of periodic paralysis. The condition of both 
patient and mother is made worse when treated with acetazolamide and daranide. 
Sequence analysis of DNA from this patient revealed a T to G substitution at nucleotide 502 
of SCN4A which results in a Tyrosine to Aspartic Acid change at position 168 (p.Tyr168Asp) 
of the sodium channel Nav1.4 (Figure 3-2B). The same mutation was also found in the 
patient’s affected mother. The mutation was found to be absent in over 300 control 
chromosomes as well as dbSNP, 1000 genomes and NHLBI exome sequencing project. The 
amino acid is located in the transmembrane S2 segment of domain I and is highly conserved 
amongst several species. Through in silico analysis using PolyPhen p.Try168Asp was 
predicted to be possibly damaging with a score of 0.557.  
In 2011 Payandeh et al. used NavAb to determine the first crystal structure of a sodium 
channel. The bacterial channel, NavAb, is formed from four identical subunits which 
correlate to a single Nav1.4 domain. Sequence alignment using ClustalW of the human 
Nav1.4 amino acid sequence to NavAb revealed Tyr168 aligns with the NavAb Phe56 residue 
(Figure 3-2C). Phe56 together with three other residues forms part of the hydrophobic 
constriction site, indicating that Tyr168 might also be involved in this role. 
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c.502T>G
p.Tyr168Asp
A
B
C
c.4259A>G
p.Asp1420Gly
?
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F
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2 SCN4A mutations in Hypo PP  
A & D, Pedigrees of families, arrow indicates proband mutation was originally identified in. B & E, Chromatograms of partial sequences of SCN4A showing on 
heterozygous point mutation with Thymidine 502 changes to Guanine resulting amino acid substitution Tyrosine to Aspartic Acid and one heterozygous 
point mutation of Adenine 4259 to Guanine leading to an amino acid substitution Aspartic Acid to Glycine.  C & F, Amino acid sequence alignment of Nav1.4 
domains with bacterial channel NavAb.  
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Patient 2 
This patient is a 19 year old man who before the onset of symptoms had reached all major 
childhood milestones without problems and was able to keep up with peers during sporting 
activities at school. His first attack of paralytic weakness affecting his arms and legs 
appeared at the age of 14 years old following a period of extensive exercise. During this 
attack he was admitted to hospital and recovered after 3-4 days. A second attack followed 
a week later where his potassium levels were measured and found to be 1.2. Since this, he 
experiences a number of severe episodes a year for which he has to be admitted to 
hospital, all of which are associated with low potassium. Due to the frequency of attacks he 
had a Portacath inserted to allow for emergency potassium supplementation. In between 
the severe attacks, the patient experiences milder attacks, with weakness observed in some 
limbs upon waking in the morning, which lasts a few hours and is followed by full recovery. 
On examination the patient showed positive for the McManus long exercise test with a 
maximum decrement of 62% with no myotonia. All family members of the patient are 
healthy and show no symptoms.  
Upon sequence analysis of the SCN4A gene, it was found that the patient had a missense 
mutation c.2006G>A which results in the amino acid change p.Arg669His. This is a known 
mutation of the S4 segment in domain II of the skeletal muscle sodium channel. Previous 
studies have shown that this mutation results in a gating pore current which is suggested to 
be the main pathomechanism behind Hypokalemic periodic paralysis (Sokolov et al. 2007; 
Struyk et al. 2008). 
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Table 3-1 Clinical Features of Hypo PP patients  
 
Patient Gender Age of 
onset 
(years) 
Affected Family 
Members 
Clinical Features Phenotype SCN4A 
mutation 
1 Male 11 Mother Periodic paralysis with muscle 
weakness affecting arms and legs 
associated with hypokalemia; attacks of 
weakness triggered after strenuous 
exercise and carbohydrate. 
Hypo PP p.Tyr168Asp 
2 Male 14 Not known Periodic paralysis with generalised 
muscle weakness associated with 
hypokalemia; attacks triggered by 
exercise and carbohydrate. 
Hypo PP p.Arg669His 
3 Male 13 Brother Periodic paralysis with weakness 
affecting arms and legs associated with 
hypokalemia. Attacks triggered by 
exercise, stress and glucose 
Hypo PP p.Asp1420Gly 
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Patient 3 
Patient 3 is a 28 year old male who shows episodes of weakness affecting arms and legs 
that began at the age of 13. The patient experiences a mixture of severe and minor attacks, 
with minor attacks occurring once a week with normal strength returning within 3 to 4 
hours. The minor attacks mainly result in some proximal weakness and rarely full paralysis. 
Severe attacks that affect the neck, arms and legs occur every few months lasting on 
average 7-8hours. Administering of Sando-K is often enough to ameliorate attacks but in 
some cases this is not sufficient and hospitalisation occurs. The longest attack of weakness 
experienced lasted 27 hours. Potassium levels have been found to be low during attacks of 
weakness. A McManus exercise test has been conducted during an attack, showing a drop 
in CMAP and loss of reflexes. Additional McManus tests during normal muscle functioning 
have also been positive. Interestingly, on examination the patient shows no myotonia but 
appears to have calf muscle hypertrophy. The proband has a possibly affected younger 
brother while both parents are thought to be unaffected (Figure 3-2D). 
In order to find a causative mutation, sequence analysis of the whole coding region of the 
SCN4A gene was undertaken. Upon sequencing of exon 23, a substitution c.4259A>G was 
found which leads to an amino acid change Aspartic Acid to Glycine at position 1420 
(p.Asp1420Gly).The amino acid change was absent from over 300 control chromosomes as 
well as the dbSNP, 1000 genomes and NHLBI exome sequencing project databases. The 
aspartic acid residue is a highly conserved amino acid down to Tetradon and is located in 
the transmembrane segment S3 in domain IV of the sodium channel, Nav1.4. Polyphen was 
used for in silico analysis to determine if the mutation was likely to be pathogenic. 
Asp1420Gly is predicted to be probably damaging with a score of 1.000.  
To gain a further understanding of the importance of the Aspartic Acid residue involved in 
this mutation, the human Nav1.4 sequence was aligned against the NavAb bacterial 
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channel sequence using Clustal W. Through alignment to this channel it was found that 
Asp1420 aligns to the NavAb residue Asp80 (Figure 3-2F). Asp80 is found within the 
intracellular negative charge cluster (INC) and interacts with the R4 residue of the S4 when 
the voltage sensor is in the active position. This indicates that Asp1420 would have a similar 
role although functional data would be needed to confirm this.  
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Table 3-2 SCN4A mutations found in periodic paralysis 
 
DNA Change Location 
within Gene 
Amino Acid 
Change 
Location within 
Protein 
Pathogenic  
(In silico Analysis) 
Known 
mutation? 
Functional Analysis 
c.502T>G Exon 4 p.Tyr168Asp Domain II S2 Yes No To be done, see Chapter 6 
c.665G>A Exon 5 p.Arg222Gln Domain I S4 Yes No To be done, see Chapter 6 
c.1207A>C Exon 8 p.Met403Lue Domain I S5-S6 Loop Yes No To be done 
c.1957A>G Exon 12 p.Ser653Gly Domain II S3 Yes No To be done 
c.2006  G>A Exon 13 p.Arg669His Domain II S4 n/a Yes Known to cause an aberrant 
ionic leak called a gating pore 
current (Bulman et al. 1999; 
Struyk & Cannon 2007) 
c.4259A>G Exon 23 p.Asp1420Gly Domain IV S3 Yes No To be done, see Chapter 5 
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3.5 Well Defined Cohort: Hyperkalemic Periodic Paralysis 
3.5.1 SCN4A Sequencing 
Mutations in SCN4A account for ~ 60% of Hyper PP cases, with the remaining cases without 
a genetic diagnosis. With 40% of cases without a genetic diagnosis, it is likely another gene 
is involved but no other gene has been identified to date. During diagnostic testing only two 
exons, containing the common mutations, are routinely sequenced (exons 13 and 24), 
resulting in the possibility of missing causative mutations in SCN4A. Therefore, to expand 
the current knowledge of Hyper PP causative mutations, the whole SCN4A coding region 
was sequenced in a well defined cohort of Hyper PP patients in order to identify new areas 
of the sodium channel involved in Hyper PP. Furthermore, any new mutations in SCN4A 
found in novel locations would provide us with further insight into the workings of the 
voltage gated sodium channel. 
All 24 exons of SCN4A were analysed through Sanger sequencing for 8 well defined Hyper 
PP patients who all had electrical examinations consistent with periodic paralysis. 3 out of 8 
patients (37.5% of samples) were found to have a novel missense mutation in SCN4A, in an 
area of the gene not normally covered by routine genetic testing (Table 3-2 &Table 3-3). 
These mutations were predicted to be pathogenic by in silico analysis by Polyphen 
(Adzhubei et al. 2010). The first mutation is p.Met403Leu located in the loop region of S5 
and S6 segments of Domain II, the second p. Ser653Gly located in S3 segment of Domain II, 
and the final mutation is p.Arg222Gln located in S4 segment of Domain II. Arg222Gln is 
particularly interesting as this mutation is located in a region of the channel not normally 
associated with Hyper PP but with Hypo PP.  
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In the remaining samples of the cohort, in which no mutation was identified (62.5% of 
cohort), a number of different approaches were taken to identify a causative mutation or 
novel genes involved, including custom gene panel sequencing. 
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Table 3-3 Clinical Features of Hyper PP Patients 
 
Patient Gender Age of 
onset 
(years) 
Affected Family 
Members 
Clinical Features Phenotype SCN4A 
mutation 
1 Male 14 Son Periodic paralysis with muscle 
weakness lasting for a few weeks; brief 
myotonia like runs of single fibre 
discharges; attacks induced by 
extremes of temperature. 
Hyper PP Met403Leu 
2 Male 13 Mother Periodic paralysis with attacks lasting 
several hours along with myotonia 
Hyper PP Ser653Gly 
3 Male 14 Maybe mother’s 
brother & 
Father’s sister 
Myotonia with possible episodes of 
weakness. Also has a silent CLCN-1 
mutation. 
PMC/Hyper 
PP 
Arg222Gln 
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3.5.1.1 Patient & mutation overview 
Patient 1 
Patient 1 is a 56 year old male affected by Hyper PP. Onset of symptoms began at 14 years 
old with episodes of weakness and stiffness. Before treatment with acetazolamide was 
started the patient experienced night time attacks occurring every couple of days taking a 
couple of days to weeks to reach full recovery. Upon treatment the patient now 
experiences fewer night time attacks, with a frequency of once or twice a year, affecting his 
arms and legs and occasionally his face. He also experiences daytime attacks several times a 
year. Triggers of attacks include extremes of temperature and a heavy breakfast. EMG 
showed brief myotonia like runs of single fibre discharges. A 43% decrement was found on 
testing of the long exercise test. Serum potassium levels were measured and found to be 
within the normal range. The patient has a son who presents with a similar phenotype. 
Through sequencing of the whole SCN4A coding region it was found that this patient had a 
missense mutation in exon 8. The A>C change at position 1207 results in an amino acid 
change of a methionine to a leucine at position 403 in the sodium channel (p.Met403Leu, 
Figure 3-3B). This mutation is located in the loop region between the S5 and S6 segments of 
domain I (Figure 3-4). A methionine residue at this position is highly conserved between 
many species. In addition, the mutation was found to segregate with disease (Figure 3-3 A). 
In silico analysis showed that p.Met403Leu is predicted to be possibly damaging, suggesting 
that this mutation is probably the causative mutation for this patient.  
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Figure 3-3 Novel mutations found in Hyper PP cohort. 
A, C & D, Pedigrees of families, arrow indicates proband with affected members are shaded in. B, D & E, Chromatograms of partial sequences of SCN4A 
showing one heterozygous point mutation of Adenosine for Cytosine resulting in an amino acid change of Methonine to Leucine, one heterozygous point 
mutation of Adenine to Guanine which causes the amino acid change Serine to Glycine and finally a Guanine to Adenine change causing the amino acid 
change Arginine to Glutamine  
A
B
C
D
E
F
c.1207A>C
p.Met403Leu
c.1957A>G
p.Ser653Gly
c.665G>A
p.Arg222Gln
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Patient 2 
Patient 2 is a 51 year old male who shows symptoms of Hyper PP with PMC overlap. The 
patient showed normal development during childhood with onset of symptoms noted at 
the age of 13 years old with cramps in legs. Symptoms present as short episodes of 
weakness that last between 1–4 hours as well as intermittent weakness affecting the eyes 
and hands. These attacks can be triggered by tiredness and exertion, stress and cold 
temperatures. The patient also has type II diabetes. Laboratory tests show the patient has a 
CK level of 116 and TSH of 6.89. Upon electrophysiological testing the patient showed 
myotonic bursts and had a normal short exercise test at room temperature. The CMAP was 
shown to fall upon cooling of the muscle and then slowly recovered. Furthermore, testing 
revealed possible mild myopathy of some muscles. His mother is also affected with attacks 
of weakness affecting her arms and legs as well as her grip (Figure 3-3C). These attacks are 
short in duration lasting at most 10 minutes. In addition to this she also experiences 
stiffness and cramps. First symptoms appeared at the age of 12 years old but she did not 
experience her first attack of weakness until she was 17 years old during her first 
pregnancy.  
Through sequencing of the patient DNA they were found to have a mutation in exon 12 at 
position 1957 of SCN4A substituting an A to G, resulting in the amino acid change 
p.Ser653Gly (Figure 3-3D). This highly conserved Serine residue is located in the S3 segment 
of domain II, an area that doesn’t contain any known Nav1.4 mutations. p.Ser653Gly is 
predicted to be pathogenic through in silico analysis which predicts the amino acid change 
would not be tolerated. In addition, the mutation was found to segregate with disease. 
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Patient 3 
Patient 3 is a 26 year old Kurdish male from a consanguineous family who is affected by 
myotonia with some episode muscle weakness (Figure 3-3E). At the age of 14 years this 
patient began to experience stiffness of muscles. He experiences grip myotonia without 
eyelid myotonia. In addition, he has had gradual onset of weakness in his right thigh. 
Symptoms are thought to be worse in cold. The potassium serum levels of this patient were 
measured and found to be normal. EMG shows the patient has short bursts of myotonia 
which are consistent with his symptoms of muscle stiffness, he also showed a positive long 
exercise test with an abnormal amplitude decrement from maximum CMAP of >40% and an 
abnormal amplitude decrement from baseline of >30%.   
This patient was initially thought to have myotonia congenita and underwent whole CLCN-1 
sequencing where he was found to have a heterozygous synonymous variant c.1650G>A 
which is predicted to affect splicing and has been associated with myotonia congenita, in a 
homozygous state(Horga et al. 2013). It is not known what effect this mutation has and 
whether it has an impact on channel function in the heterozygous state and no muscle 
sample from the patient was available for confirmation of correct splicing of the CLCN-1 
gene. Following this analysis of common SCN4A mutations that cause myotonia were found 
to be negative. Therefore, the patient’s DNA was analysed for mutations in the entire 
coding region of SCN4A through Sanger sequencing and was found to have a missense 
mutation in exon 5 c.665G>A which results in a change in the arginine residue at position 
222 to a glutamine residue (Figure 3-3F). Arg222Gln is predicted to be possibly damaging by 
PolyPhen with a score of 0.640. The Arg222 residue is a highly conserved amino acid 
located within the S4 segment of domain I of Nav1.4.  
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Figure 3-4 Location of Novel Periodic Paralysis Mutations on the Sodium Channel α Subunit 
A schematic representation of the Nav1.4 α subunit transmembrane domains I-V and transmembrane segments S1-S6 with location of novel mutations.  
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3.6 New Periodic Paralysis Genes 
To further the understanding of the genetic causes of periodic paralysis, both groups of the 
periodic paralysis cohort had the coding region of three potential candidate genes: MT-
ATP6, MT-ATP 8 and KCNJ18. These genes have been associated with periodic paralysis in 
recently published papers with phenotypes that differ slightly from the standard clinical 
symptoms of Hyperkalemic periodic paralysis or Hypokalemic periodic paralysis. This cohort 
of patients consisted of 60 patients who were diagnosed with Hypo PP, Hyper PP or a 
general periodic paralysis phenotype but were not found to have mutations in the known 
genes. Known genes were previously ruled out through the use of a custom skeletal muscle 
channel gene panel (designed, run and analysed by A. Gardiner). Patients were also rated 
on the strength of their phenotype with a likelihood of finding a mutation.  
3.6.1 MT-ATPase6/8 Sequencing 
For sequencing of the mitochondrial genes MT-ATP6 and MT-ATP8, 60 samples were 
analysed. Following this, no mutations were found in the cohort of patients in either gene, 
suggesting that the full periodic paralysis phenotype does not fully expand to this specific 
subset.  
3.6.2 KCNJ18 Sequencing 
For KCNJ18 sequencing, 60 samples were analysed for mutations using Sanger sequencing. 
Due to the high sequence identify of KCNJ18 with KCNJ12 (99%), it can be difficult to 
determine which gene has been amplified during PCR. All samples were analysed to check 
that the target gene had been amplified and sequenced correctly through the presence of 7 
variations that distinguish KCNJ18 from KCNJ12(Table 3-4). In all 60 samples KCNJ18 was 
correctly amplified. Out of 60 samples, one sample was found to have a possible mutation 
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in KCNJ18. The variation, c.35 T>C is located at the beginning of the third exon of KCNJ18, 
which is the only coding exon of the gene, and results in an amino acid change of Isoleucine 
to Threonine at position 12 (p.Ile12Thr). This mutation is predicted to be pathogenic 
through in silico analysis, however due to the homology of this gene with KCNJ12 and it’s 
relatively new discovery there is no information available on polymorphisms in the online 
databases such as NLHBI, db SNP and 1000 genomes. Ptacek et al highlighted 20 SNPs in 
KCNJ18 that they came across during identification and sequencing of the gene. However, 
c.35T>C is not present on the list. 
The patient is a 45 year old male who has experienced transient attacks of paralysis since 
the age of 15 following normal childhood milestones. Since his first attack this patient has 
experienced only a few episodes of mild muscle weakness affecting the lower limbs and 
occasionally arms. The attacks last for up to an hour before the restoration of full muscle 
strength. No apparent triggers have been noted. The patient has a long family history of 
attacks of paralysis with 6 affected individuals, whom all suffer from intermittent weakness 
usually affecting the lower limbs and sometimes arms for an hour or more. These 
symptoms and family history are suggestive of Hyperkalemic periodic paralysis, although 
the frequency of attacks and lack of triggers are atypical. 
Before investigating this variant further, a MiSeq custom panel screen was used to rule out 
other mutations. Following this the patient was found to have a known Nav1.4 mutation, p. 
Arg675Gln. This mutation is located within DII S4 segment and is a well established 
normokalemic periodic paralysis mutation. 
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Table 3-4 Variations that distinguish between KCNJ12 and KCNJ18 
 
Nucleotide Residues 
KCNJ12             KCNJ18 
Nucleotide 
Position 
Amino Acid Residues 
Kir2.2                     Kir2.6 
Amino Acid 
Position 
C T 44 Ser Leu 15 
G C 243 Arg Arg 81 
T C 648 Gly Gly 216 
G A 819 Glu Glu 273 
C T 1131 Tyr Tyr 377 
C T 1206 Asp Asp 402 
A G 1290 Glu Gly 430 
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3.7 Discussion 
3.7.1 Further Screening of Known Genes 
In order to further understand the genetic spectrum of periodic paralysis, a cohort of 68 
periodic paralysis patients negative for the common mutations were investigated. This 
cohort was subdivided into two groups: the well defined cohort comprised of 21 samples 
and the less defined cohort comprised of 47 samples. The first group contained patients 
with clear, well defined phenotypes for both Hypo PP and Hyper PP. For this group of 
samples Sanger sequencing of the known genes was undertaken in order to find a causative 
mutation.  
In the Hypo PP group, 13 patients were analysed for mutations in both causative genes, 
SCN4A and CACNA1S. In the case of CACNA1S sequencing, it was only possible to sequence 
those exons relating to the S4 voltage sensors using Sanger sequencing, due to the large 
size of this gene. No mutations were identified in these exons of CACNA1S for all the 
samples tested. In order to be sure that there were no mutations in this gene; patients 
were put on a customised gene panel which covered the whole coding region of the 
CACNA1S gene, as well as other known channelopathy genes. Of the 13 samples tested, 
none were found to have mutations in this gene. One explanation for these negative results 
could be that mutations in this gene are only localised to the regions of the gene tested for 
in routine genetic screenings. Thus, this cohort would have been negative selection for 
mutations in this gene due to selection of samples that have already been screened for the 
common mutations. However, this is unlikely to be the case as there have been two 
mutations reported to date which are located outside the S4 segment of CACNA1S that do 
not cause neutralisation of a gating charge, suggesting that future sequencing of the whole 
CACNA1S gene might identify causative mutations in regions outside the S4 segment.  
Sequencing of the whole coding region of CACNA1S on a customised gene for this cohort 
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showed that no mutations were located outside the S4 region. Therefore, mutations in 
other genes or within intronic or promoter regions are likely to explain the phenotypes of 
this cohort.  
Following sequencing of the whole coding region of SCN4A, 3 out of 13 patients, were 
found to have a likely causative mutation (Table 3-2). Of these three mutations, two were 
identified as novel mutations located in areas of the channel which have not previously 
been associated with disease. The first mutation is a known pathogenic variant, 
p.Arg669His, and was found in a patient who presents with a phenotype of transient 
attacks of weakness affecting his arms and legs associated with low potassium levels. This 
mutation has been reported as pathogenic through functional analysis and is clearly the 
causative mutation (Bulman et al. 1999; Struyk et al. 2000; Struyk & Cannon 2007). In the 
remaining two cases, novel mutations, p.Tyr168Asp and p.Asp1420Gly, were identified in 
patients with Hypo PP phenotypes. The former, p.Tyr168, is located in domain I within the 
S2 segment of the channel (Figure 3-4). It was found in a patient who presents with attacks 
of paralysis that have led to hospitalisation and are associated with low potassium. In this 
case the tyrosine residue at position 168 is highly conserved throughout species and is 
predicted to be pathogenic. The latter, p.Asp1420Gly, is located within the S3 segment of 
domain IV and affects a highly conserved negatively charged residue (Figure 3-4). The 
mutation was found in a male patient who experiences short attacks of paralysis lasting 7-8 
hours which have been shown to be associated with low potassium levels. Both mutations 
were not found in over 300 control chromosomes and were absent from the known 
databases, including 1000 genomes, NLHBI and dbSNP. In addition, these mutations both 
affect highly conserved residues and in silico analysis predicts them to be pathogenic, 
indicating that these amino acid changes are likely to be the causative mutation of Hypo PP 
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in these cases. However, how these mutations might fit in with the current knowledge of 
the Hypo PP mechanism of disease requires further discussion.  
It is now well established that Hypo PP mutations localise to the voltage sensor of Cav1.1 or 
Nav1.4 resulting in neutralisation of positively charged arginine residues, known as gating 
charges (Bulman et al. 1999; Matthews et al. 2009). The positive charges of the voltage 
sensor are enclosed within the voltage sensing domain, which is formed by S1, S2 and S3 
segments. Negatively charged residues within the surrounding segments form electrostatic 
interactions with the voltage sensor gating charges (Seoh et al. 1996; Tiwari-Woodruff et al. 
2000; DeCaen et al. 2008; DeCaen et al. 2009). Substitution of the positive charge is known 
to disrupt the integrity of the voltage sensing domain through loss of ion pair interactions, 
providing an alternative pathway for ionic movement across the channel (Tombola et al. 
2005; Sokolov et al. 2007; Struyk & Cannon 2007). This aberrant ionic leak is thought to be 
the mechanism by which muscle depolarisation occurs resulting in the Hypo PP phenotype. 
Both the novel mutations in question, p.Try168Asp and p.Asp1420Gly, are located outside 
the voltage sensor. However they are found within the S2 and S3 segments respectively, 
which play an important role in maintaining the integrity of the voltage sensing domain and 
preventing leak through the domain.  
Located in the S2 segment of Domain I, p.Tyr168Asp aligns to Phe56 of NavAb, the bacterial 
sodium channel used to elucidate the first crystal structure of the sodium channel (Figure 3-
2). Tyrosine and Phenylalanine are both polar residues which are highly similar as both 
contain a side chain of a 6 carbon aromatic ring (benzene ring), suggesting that both could 
perform the same function when substituted for one another within a protein. Phe56 
together with three other residues (Ile33, Ile96 and Val97) is suggested to form part of the 
hydrophobic restriction site (HSC) of the voltage sensing domain. These residues line the 
narrowest part of the gating pore domain, forming a hydrophobic seal (Payandeh et al. 
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2011). The hydrophobic constriction site (HCS), is thought to prevent aberrant ionic leakage 
through the gating pore (Payandeh et al. 2011). No other Hypo PP mutations have been 
identified within the HCS of Nav1.4. It is possible that substitution of the tyrosine residue to 
the smaller negatively charged residue of aspartic acid could result in disruption to the HCS 
through unwanted electrostatic interactions of the negative charge, providing an 
alternative pathway for ions and thus result in a gating pore current. As the HCS is not 
involved in the movement of the voltage sensor it is possible that any gating pore current 
produced by this mutation might not show voltage dependence making it difficult to detect 
through the electrophysiological methods normally used. Furthermore, it is difficult to 
know whether loss of one residue would be sufficient to disrupt the HCS as the importance 
of each residue in the formation of the HCS is not known. Functional analysis is needed to 
look at the effect of Tyr168Asp on Nav1.4 to determine whether it causes a gating pore 
current or affects the main pore.  
The second Hypo PP mutation identified was p.Arg1420Gly, located in S3 segment of DIV. It 
is the first Hypo PP mutation identified which results in loss of a negative charge rather 
than a positive gating charge. Loss of the negative charge at position 1420 to the smaller 
uncharged glycine residue is likely to cause a disturbance in the protein structure, which 
could destabilise the movement of the voltage sensor and disrupt the integrity of the 
voltage sensor domain as is seen with conventional Hypo PP mutations.  
The Asp1420 residue aligns with Asp80 from the sodium channel NavAB. Asp80 is one of 
many negatively charged residues within the intracellular negative charge cluster (INC) 
which interacts with R4 when the voltage sensor is activated (Payandeh et al. 2011). The 
INC forms ion-pair interactions with the gating charges which catalyse voltage sensor 
movement by providing a low energy pathway for movement (Catterall 1986; DeCaen et al. 
2008; DeCaen et al. 2009; Catterall 2010). In conventional Hypo PP mutations loss of a 
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positively charged arginine residue causes loss of the electrostatic interactions with the 
negative charges in ENC and INC of the surrounding voltage sensing domain. Disruption of 
these interactions by loss of one positive charge is sufficient to allow for an aberrant 
pathway for ionic leak across the channel (Sokolov et al. 2007; Struyk & Cannon 2007; 
Sokolov et al. 2008; Struyk et al. 2008; Francis et al. 2011). Thus, it is possible that loss of a 
negatively charged aspartic acid residue to the small uncharged glycine residue will cause 
similar disruption to the voltage sensing domain through interruption of the electrostatic 
interactions that hold it together. If Asp1420G were to result in a gating pore current as 
seen in known Hypo PP mutations, it would be the first non S4 segment Hypo PP mutation 
to cause a gating pore current. Such a discovery would help to confirm and further establish 
the gating pore current as the causative mechanism of disease in Hypo PP.  
To date, all but one substitution mutation of an S4 arginine residue has been shown to 
disrupt the voltage sensing domain by opening up the tight pore to allow a gating pore 
current(Francis et al. 2011). Francis et al. 2011 showed that the PMC mutation Arg1448Cys 
located in Domain IV does not result in a gating pore current. Interestingly, this mutation is 
in a homologous location to the R4 in the NavAb channel which Asp80 and so Asp1420 
interacts with(Payandeh et al. 2011; Vargas et al. 2012). However, this interaction occurs 
when the voltage sensor is in the activated position suggesting that Asp1420 is likely to 
interact with other residues enabling a gating pore current to be produced upon loss of the 
negative charge.  
A similar analysis approach was taken for genetic screening of the Hyper PP group. This 
group contained eight patients all of whom had a strong Hyper PP phenotype with some 
possible myotonia overlap. In this approach we screened the whole SCN4A gene in order to 
indentify the causative mutation in this cohort. Following sequencing of all 24 exons of 
SCN4A, 3 out of 8 samples (37.5%) were found to have a novel mutation in SCN4A (Table 
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3-2). All three mutations were predicted to be pathogenic through in silico analysis, were 
absent from over 300 control chromosomes and are not present in the known genome 
databases including 1000 genomes. This indicates that these mutations are likely to be the 
causative mutations in these cases, although functional analysis is needed to confirm this.  
The first mutation, p.Ser653Gly, was found in a middle aged man with a clear Hyper PP 
phenotype with some PMC overlap and was observed to segregate with disease. The serine 
residue at position 653 is a highly conserved residue which is found within the S3 segment 
of Domain II. The S3 segment forms part of a larger structure of the sodium channel called 
the voltage sensing domain (VSD). The VSD is composed of the S4 voltage sensor which is 
surrounded by the gating pore formed by S1-S3 segments (Catterall 1988; Sato et al. 2001; 
Payandeh et al. 2011). Movement of the S4 segment within the gating pore occurs through 
ion pair exchange with negatively charged residues in the S1-S3 segments(Yang et al. 1996; 
Pérez-García et al. 1996; Starace & Bezanilla 2001; Gandhi 2002; Mantegazza & Cestèle 
2005). These interactions are supported by hydrogen bonds between the S4 and the 
carbonyl backbone of certain residues of the VSD (Payandeh et al. 2011). Ser653 aligns to 
Ser 87 of the bacterial NavAb. From the crystal structure of NavAb, Ser87 was highlighted as 
one of the gating pore residues that forms the network of hydrogen bonds and specially 
interacts with R3 (Payandeh et al. 2011).  
Hyper PP mutations are known to result in disruption to channel activation or inactivation 
and are often located in areas of the channel which are known to be associated with 
channel gating(Cannon 2006). To date, the mutations found with Nav1.4 DII are located in 
either the S4 segment (Hypo PP) or the S4-S5 loop (Hyper PP). Only two mutations within 
Nav1.4 have been reported within a S3 segment, Leu1433Arg and Leu1436Pro, which are 
found within the S3 of DIV and are associated with PMC (Ptacek et al. 1993; Matthews et al. 
2008). Functional studies of Leu1433Arg have found that it results in slower inactivation of 
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the channel, a common effect of Hyper PP or PMC mutations, indicating that Ser653Gly 
might have the same effect on Nav1.4 gating(Yang et al. 1994; Ji et al. 1996). However, it is 
known that the individual domains of Nav1.4 have distinct functions within the channel, for 
example, it has been shown that DIII and DIV voltage sensors are associated with fast 
inactivation, whilst DI, DII and DIII are associated with activation(Cha et al. 1999; Chanda 
2002; Chanda et al. 2004). This functional asymmetry seen between the voltage sensors of 
different domains is likely to be present in other parts of the channel, thus functional work 
is needed to determine the effect of Ser653Gly on channel functioning.  
The second novel mutation, p.Met403Leu, was identified in a patient who presents with a 
typical Hyper PP phenotype and was found to segregate with disease. Met403Leu is located 
in the loop region between S5 and S6 segments of Domain I and affects a highly conserved 
methionine residue. The S5-S6 interlinking loops are often referred to as the P loops and 
help to form the central pore of the channel. P loops have been shown to be important for 
conductance and selectivity of channels(Zagotta & Aldrich 1990; Qu et al. 1999; Catterall 
2012). These loops have been found to partially re-enter the membrane, with MTS cysteine 
experiments showing that some residues within the S5-S6 loop are buried within the 
protein(Pérez-García et al. 1996). This enables the S5-S6 loops from each domain to come 
together to form the outer vestibule of the channel and part of the narrow ion selectivity 
filter (Fozzard & Hanck 1996; Marban et al. 1998; Ertel et al. 2000).A number of Hyper PP 
and PMC mutations are located within the pore forming areas of Nav1.4. In particular, the 
two most common Hyper PP mutations, p.Thr704Met and p.Met1592Val, are located in the 
DII S5 and DIVS6 segments, respectively. Both mutations have been shown to cause 
disruptions to channel inactivation resulting in a persistent Na+ current(Rojas et al. 1999; 
Bendahhou et al. 1999). Moreover, two mutations are located nearby Met403Leu within DI 
S6 segment: p.Asn440Lys and p.Val445Met (Trip et al. 2007; Lossin et al. 2012; Lehmann-
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Horn et al. 2011). Functional analysis has shown p.Asn440Lys results in a depolarised shift 
in voltage dependence of fast inactivation and increase recovery from inactivation resulting 
in a persistent Na+ current(Lossin et al. 2012). Ergo, it is highly likely that p.Met403Leu is 
the causative mutation within this patient and will result in disruption to Nav1.4 gating, 
further functional studies are necessary to confirm this hypothesis.  
Finally, p.Arg222Gln was found in a 26 year old Kurdish man from a consanguineous family 
who presents with myotonia as a main symptom. This patient has a history of myotonia 
from childhood but in recent years has experienced episodic weakness in legs, suggesting 
Hyper PP with a PMC overlap. Initial genetic investigations revealed a heterozygous silent 
sequence variant in CLCN-1 c.1650G>A, which is predicted to effect gene splicing and is 
associated with myotonia congenita within a homozygous recessive family. This variant has 
not been studied functionally to determine the effect on channel functioning and it is not 
known whether the variant would have an effect in the heterozygous state. It is possible 
that the variant might act as an exacerbating factor to the phenotype without being the 
causative mutation. Further analysis of other known genes revealed the mutation 
p.Arg222Gln which is located within the S4 segment of Domain 1 and affects a highly 
conserved residue. Most reported Hyper PP mutations are widely spread across Nav1.4, in 
areas important for channel gating such as loops regions, and have been shown to result in 
disruption of fast inactivation or activation, leading to a persistent inward Na+ current. 
Interestingly, Arg222Gln affects the R2 gating charge of the S4 voltage sensor – normally 
the target for Hypo PP mutations. Hypo PP voltage sensor mutations are known to give rise 
to a gating pore current due to disruption of the ion-pair interactions which hold the gating 
pore domain together and protect the channel from unwanted ionic leak(Sokolov et al. 
2007; Struyk & Cannon 2007; Struyk et al. 2008; Sokolov et al. 2008; Sokolov et al. 2010; 
Francis et al. 2011). It is possible that substitution of the Arginine residue at position 222 for 
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the uncharged polar glutamine could cause a gating pore current, especially as a Hypo PP 
mutation has been found at the same residue, p.Arg222Trp. Matthews et al. reported 
Arg222Trp in two unrelated patients with a clear Hypo PP phenotype with no atypical 
features. Although no further studies have been conducted to establish what effect this 
particular mutation could have on the channel, it has recently has been reported that 
neutralisation of the Arg222 results in a gating pore current. Holzherr et al. showed that the 
mutation Arg222Gly produces a gating pore at voltages negative to -50 mV. Furthermore, 
similar mutations to Arg222Gln/Trp have been found in the gene SCN5A; which encodes the 
cardiac sodium channel Nav1.5. Nav1.5 mutations are spread throughout the channel and 
cause a complex array of disorders including cardiomyopathy and Brugada Syndrome, with 
a variety of defects in channel functioning. Of particular interest are Nav1.5/Arg219His and 
Nav1.5/Arg222Gln, which affect Domain 1 R1 and R2 residues respectively(Gosselin-
Badaroudine et al. 2012; Mann et al. 2012; Nair et al. 2012). Gosselin-Badaroudine et al. 
showed that p.Arg219His results in a conduction pathway through the VSD which allows a 
proton carrying gating pore current. This leads to questions as to how Arg222Gln causes a 
predominantly myotonic phenotype when the affected residue is implicated in a case of 
Hypo PP. The studies highlighted suggest that neutralisation of Arg222 is likely to cause a 
gating pore current; however this would not fit in with the established mechanisms of 
disease for Hyper PP mutations.  
There have been a few Hyper PP and PMC mutations which result in the neutralisation of 
positive S4 gating charges, without the formation of a gating pore current. Francis et al. 
2011, studied the PMC mutation p.Arg1448Cys and found that neutralisation of this 
Domain IV R1 arginine had no effect on the structure of the gating pore domain, but rather 
causes a gain-of-function defect manifested as a reduced rate of inactivation for the Na 
current through the main pore. Similarly, Lee et al. reported a mutation affecting the R3 
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residue of the Domain I S4, p.Arg225Trp, in a case of mild non-painful myotonia. However, 
no further studies have occurred to show what effect this mutation has on the channel. 
Arg222Gln and Arg222Trp offer an interesting opportunity to study the connection 
between the disease mechanisms for Hyper PP and Hypo PP as well as giving insight into 
the effect different amino acids can have on the integrity of the voltage sensor domain. 
Prior studies of gating charge mutation suggest that both Arg222Gln and Arg222Trp should 
result in an aberrant ionic leak through the VSD despite resulting in different in phenotypes. 
Can the difference in amino acid between Arg222Gln and Arg222Trp explain the difference 
in phenotype? Further investigations are needed to determine how this mutation causes 
disease and whether it might break the established consensus that only Hypo PP voltage 
sensor mutations can result in a gating pore current. 
3.7.2 Implications for future diagnostics strategy 
 
Through sequencing of the known genes patients who were negative for the common 
mutations but have a well defined phenotype, mutations were identified in ~30 % of 
patients. In the case of the Hypo PP samples, this has identified mutations in areas of the 
gene which have not previously been associated with the disease. Both p.Tyr168Asp and 
p.Asp1420Gly defy the current consensus that Hypo PP mutations are solely localised to the 
S4 voltage sensor. Through functional work it will be possible to determine whether these 
mutations will also challenge the current proposed mechanism of disease – the gating pore 
current. However, for the Hyper PP samples screened, all 3 mutations identified were 
located within areas of the channel that have been previously associated with the disease. 
Of the 3 identified, p.Arg222Gln offers a slight deviation from the previously described 
mutations as it is affects a residue that has been previously associated with Hypo PP.  
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All mutations found within the periodic paralysis well defined cohort are located in areas 
not routinely investigated during diagnostic genetic screening. Accordingly, this study 
highlights the importance of full screening of the whole coding region of at least SCN4A and 
possibly other genes which are involved in periodic paralysis.  
At the time of the study routine diagnostic genetic screening for periodic paralysis focused 
on targeted exon sequencing of only four exons of SCN4A. Since the findings of this study, a 
screen has been developed to enable the sequencing of the whole gene through a 
customised gene panel. This targets all the known channelpathy genes and sequences all 
exons.  
3.7.3 Screening of new genes 
Three genes have been recently associated with episodic weakness or periodic paralysis 
with secondary symptoms. These are MT-ATP6 and MT-ATP8 and KCNJ18(Ryan et al. 2010; 
Cheng et al. 2011; Auré et al. 2013). These genes were sequenced in a larger cohort of 
patients in order to investigate if the phenotypes associated with these genes could be 
expanded to include periodic paralysis without secondary symptoms. In addition, KCNJ18 is 
associated with periodic paralysis in Asian populations, thus this study provided an 
opportunity to determine if KCNJ18 mutations can be identified in a non Asian population.  
The first genes investigated were MT- ATP6 and MT-ATP8 which are mitochondrial genes 
which have recently been associated with a phenotype of episodic weakness mimicking 
periodic paralysis with later onset of distal motor neuropathy(Auré et al. 2013). MT-ATP 6 is 
normally associated with Leigh Syndrome and NARP (Neurogenic muscle weakness, Ataxia 
and Retinitis Pigmentosa) as well as CMT type 2 (Charot Marie Tooth), Spastic paraplegia 
and Cerebellar ataxia(Holt et al. 1990; Santorelli et al. 1996; Y et al. 1997; Moslemi et al. 
2005; Verny et al. 2011; Pitceathly et al. 2012; Synofzik et al. 2012; Craig et al. 2007; Pfeffer 
et al. 2012). The MT-ATP6 and MT-ATP8 genes encode components of the large protein 
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complex, F0F1 ATP synthase (complex V), the final enzyme in the oxidative phosphorylation 
pathway. ATP synthase drives the synthesis of ATP from ADP +phosphate (Pi) using energy 
provided by the proton gradient across the mitochondrial membrane.  
Auré et al. reported six families with episodic weakness and distal motor neuropathy which 
showed homogeneity in terms of onset of symptoms and trigger factors. Following genetic 
investigations in which they ruled out the known periodic paralysis genes, mutations were 
found in MT-ATP6 and MT-ATP8 genes which segregated with disease in all families. 
Molecular studies of patient fibroblasts revealed oxidative defects with reduced ATP 
production and decrease complex V and I activity. Furthermore, whole cell patch clamp 
recordings showed the fibroblasts had a partially depolarised membrane with a reduced 
outward K+ current density. These findings offer support for the mitochondrial genes 
causing the episodic weakness phenotype. Thus, the periodic paralysis cohort was screened 
for mutations within these genes in order to determine whether the MT-ATP6 and MT-
ATP8 associated phenotypes could be further expanded to include periodic paralysis 
without secondary symptoms. 60 patients were screened (Figure 3-1); however no 
mutations were identified in either gene. This suggests that with the current cohort it is not 
possible to expand the phenotypes associated with MT-ATP6 and MT-ATP8 mutations 
further to include a purely periodic paralysis phenotype.  
KCNJ18, the final gene screened in the periodic paralysis cohort, encodes the inwardly 
rectifying potassium channel Kir2.6. Kir2.6 is expressed within the skeletal muscle and is 
vital for muscle functioning due to its role in stabilizing the resting membrane potential. 
KCNJ18 has been associated both Thyrotoxic Hypo PP (TPP) and Sporadic Periodic Paralysis 
(SPP) (Ryan et al. 2010; Cheng et al. 2011). TPP is associated with attacks of weakness, 
hypokalemia and thyrotoxicosis and is highly prevalent in men from Asian and Latin 
American population. 10% of men in these populations develop TPP compared with 0.1% of 
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Caucasians(Okinaka et al. 1957; Kelley et al. 1989; Kung 2006). SPP is a non familial form of 
periodic paralysis which is normally found within the Asian population who are not affected 
by altered thyroid hormone levels(Cheng et al. 2011). Ryan et al. identified KCNJ18 in TPP 
following genetic screening of 151 patients within the Asian population. Subsequently, 
Cheng et al found KCNJ18 mutations within a cohort of Asian SPP patients. Both reported 
mutations that caused non functional channels, reduced surface expression, decrease 
current density and disrupted interaction with PIP2. 
KCNJ18 was screened for 60 patients with periodic paralysis in order to determine if KCNJ18 
can cause periodic paralysis in non Asian populations. The majority of the patients in the 
cohort screened are from a Caucasian background, with a few from other non Asian 
backgrounds. Before analysis of sample sequences occurred it was confirmed that KCNJ18 
was amplified correctly rather than the homologous KCNJ12, with which it shares 99% 
sequence identity. Following this it was found that one sample out of 60 had a variant in 
exon 3 of KCNJ18, p.Ile12Thr. The mutation is located in the N-terminal end of the protein 
which has previously been associated with the SPP mutation p.Arg43Cys. However, due to 
the relatively recent discovery of KCNJ18, there is little information available on the channel 
and polymorphisms of the gene, making it difficult to determine the effect of the mutation 
without functional characterisation. Thus, the MiSeq custom gene panel data for this 
patient was checked for mutations in the known genes. A known mutation in SCN4A, 
p.Arg675Gln, was identified. Arg675Gln is a known normokalemic periodic paralysis 
mutation that has been shown to cause a gating pore current which is activated by 
depolarised potentials (Sokolov et al. 2008). The symptoms experienced by this patient fit 
in with the phenotype associated with p.Arg675Gln, indicating that this is the causative 
mutation. Subsequently, as the patient does not present with an atypical phenotype it was 
concluded that no further investigations should occur for the KCNJ18 p.Ile12Thr mutation 
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due to the presence of the known SCN4A mutation and difficultly in determining the 
likelihood of pathogenicity for the variant. This indicates that for this cohort of periodic 
paralysis patients, it is not possible to expand the KCNJ18 phenotype to include periodic 
paralysis in familial and non Asian populations.  
3.7.4 Limitations of sequencing approach 
Although a number of mutations were identified during this study, there is still a significant 
portion of the cohort sequenced who do not have a genetic diagnosis. Whilst this may be 
explained by mutations in as yet unidentified genes; it is possible that the strategy used has 
resulted in some mutations within the known genes being missed. Since the 
channelopathies in question are known to have a dominant inheritance pattern, the 
present study focused on exonic sequencing and the identification of non-synonymous 
mutations within the genes sequenced. Only a small part of the intronic region of each gene 
was sequenced to ensure full coverage of the exon. Furthermore, any synonymous 
mutations not located near the end of an exon were not investigated further. As a result, it 
is possible that synonymous variants or intronic splice site variants were missed which 
could disrupt channel functioning. Although such mutations are not normally associated 
with a dominant inheritance within ion channels, it is possible that they may be able to 
effect channel functioning in a way consistent with mechanism of disease. For example, 
Kubota et al identified an intronic mutation in SCN4A which affect channel splicing and 
caused disruption to channel gating. Accordingly, it is possible that investigating intronic 
mutations may result in identification of further mutations within the ion channel genes.  
3.8 Conclusion 
From sequencing of SCN4A in a periodic paralysis cohort, 6 mutations were identified; five 
of which were novel. Two mutations found within Hypo PP cases were located in areas of 
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the channel which have not normally been associated with disease. This genetic study 
highlights the importance of full sequencing of the known genes in order to provide the 
patient with a genetic diagnosis. Next generation sequencing methods such as targeted 
gene panels and exome sequencing provide cost effective methods to sequence all the 
known genes. In addition, this study has widen the current knowledge of mutations 
associated with Hypo PP. 
3.9 Further Work 
 A number of cases within the cohorts where no mutation was identified. In order to find 
the causal mutation within the remainder of this cohort, patients with a strong 
phenotype and family history should be selected and exome sequencing used. This 
would enable identification of the genetic cause of disease. 
 The mutation Y168D needs to be functionally characterised in order to determine if it is 
the pathogenic mutation.  
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4 Chapter 4: Sequencing of Patients with Myotonia 
4.1 Summary 
The non-dystrophic myotonias are caused by mutations in two ion channels: SCN4A and 
CLCN-1. Over 150 CLCN-1 pathogenic mutations have been identified in relation to 
myotonia congenita. Interestingly, 10 of these mutations have been reported as having 
both dominant and recessive inheritance, leading to questions as to the mechanism behind 
this. Furthermore, ~20% of paramyotonia congenita and sodium channel myotonia patients 
remain without a genetic diagnosis following routine testing of the causative gene, SCN4A. 
The aim of this study is to address these questions, investigate the causative mutations of 
myotonia and the mechanism of dual mode of inheritance of mutations in myotonia 
congenita. 
The whole coding region of SCN4A was screened in a small cohort of patients with well 
characterised PMC or SCM phenotypes who had undergone routine testing and were found 
to be negative for the known common mutations. 3 out of 8 patients were found to have a 
mutation in SCN4A. Of these, two mutations were known, well characterised mutations 
(p.Val1293Ile and p.Val1589Met) with one novel mutation (p.Ser1159Pro). The novel 
mutation is located in the S4-S5 loop near other PMC mutations, and is predicted through 
in silico analysis to be pathogenic, which is indicative of p.Ser1159Pro being the causative 
mutation of PMC in this case. The second study investigated the mechanism behind dual 
inheritance mutations in myotonia congenita. 10 dominant MC pedigrees with CLCN-1 
mutations which have been reported as having a dual mode of inheritance were screened 
for mutations in three known myotonia genes: SCN4A, DMPK5 and ZNF9. No mutations 
were found all three genes. These findings indicate that in this cohort, mutations in other 
genes cannot explain dual inheritance of the CLCN-1 mutations. Finally, exome sequencing 
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was undertaken to identify the causative mutation for a large PMC family without any 
mutations following fully SCN4A screening.  
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4.2 Introduction 
Both paramyotonia congenita and sodium channel myotonia are caused by mutations in 
SCN4A and show autosomal dominant inheritance. Studies have shown that the most 
common PMC mutations are p.Thr1313Met and p.Arg1448Cys ( McClatchey et al., 1992; 
Ptacek et al., 1993; Ptácek et al., 1992; Yang et al., 1994) whilst for SCM they are 
p.Val1589Met and p.Gly1306Glu(Heine et al. 1993; Lerche et al., 1993; Mitrović et al., 
1995). These gain of function mutations, along with all other SCM/PMC mutations, have 
been shown to cause a defect of channel inactivation or enhanced activation. This results in 
an increased level of sodium entering the muscle which causes an increase of the 
sarcolemma excitability(Cannon, 2006; Jurkat-Rott et al.,2002). Routine diagnostic testing 
often only involves the targeted screening of exons 22 and 24 which cover the common 
mutations. However, over 45 mutations, spread widely across the gene, have been 
identified in relation to these disorders, leading to a negative diagnostic test for some 
patient. 
In contrast to the other forms of NDM, myotonia congenita is caused by CLCN-1 mutations 
with over 150 mutations reported in this gene. Interestingly, MC inheritance has been 
reported as both autosomal dominant and recessive. The dominant and recessive forms of 
MC can be distinguished based on onset of disease and severity of symptoms but the main 
distinguishing point is the causative mutation. Mutations causing dominant MC are largely 
missense mutations often found in one hotspot in exon 8 of CLCN-1(Fialho et al., 2007), 
while recessive MC mutations show greater variety in the type of mutation and are widely 
distributed across the gene. Myotonia congenita genetics is complicated by the knowledge 
that 10 CLCN-1 MC mutations to date, have been reported to have both dominant and 
recessive inheritance (Table 4-1). The presence of dual mode of inheritance mutations is an 
unusual and almost unique feature of myotonia congenita. This phenomenon is interesting 
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due to the vastly different effects on channel function dominant and recessive mutations 
have been shown to have. Possible explanations include incomplete penetrance of 
dominant mutations, differential allelic expression, unidentified modifying factors or 
mutations in other genes. However, DunØ et al 1994 studied the relationship between 
inheritance pattern and mRNA levels in pedigrees carrying p.Arg894X and found no 
difference with dominant and recessive pedigrees. Interestingly, within the ALS associated 
gene SOD-1, one mutation has been reported with dual inheritance, in which a common 
founder was identified providing a protective factor(Al-Chalabi et al., 1998). As mentioned 
one possible explanation for dual inheritance mutations is the presence of mutations in 
other genes. The most likely genes to play a role would be the other myotonia related 
genes: SCN4A, DMPK5 and ZNF9 which cause paramyotonia congenita, muscular dystrophy 
type 1 and muscular dystrophy type 2, respectively. Misdiagnosis or phenotype overlap is 
well document between mutations in these genes and CLCN-1 for example, Suominen 2008 
showed that 5% of patients with the DM2 ZNF9 repeat expansion also had a CLCN-1 
mutation(Suominen et al., 2008). Although this finding might be explained by experimental 
bias, it highlights the possibility that MC might be caused by mutations in other genes, both 
known or unknown. 
 
116 
 
Nucleotide Change Amino Acid Change Effect on Channel Reference 
c.598G>A Gly200Arg Dominant shift of po (Mailänder et al. 1996; Wollnik et al. 1997; Zhang 
et al., 1996) 
c.689G>A Gly230Glu Slightly dominant negative; altered gating (Brugnoni et al., 1999; Fahlke et al.,1997; Meyer-
Kleine et al.,1995; Plassart-Schiess et al., 1998; 
Steinmeyer et al.,1994; Zhang et al., 1996) 
c.803C>T Thr268Met n/a (Brugnoni et al., 1999) 
c.937G>A Ala313Thr Dominant negative shift of po (Kubisch et al.,1998; Plassart-Schiess et al.,1998; 
Sun et al.,2001) 
c.950G>A Arg317Gln Dominant negative shift of po (Esteban et al., 1998; Meyer-Kleine et al.,1995; 
Pusch et al.,1995) 
c.1013G>A Arg338Gln Slight shift in po (Meyer-Kleine et al.,1995; Zhang et al., 1996; 
Zhang, Bendahhou, Sanguinetti, & Ptácek, 2000) 
c.1592C>T Ala531Val n/a (Papponen et al., 1999; Sun et al., 2001) 
c.1655A>G Gln552Arg Dominant shift of po (Meyer-Kleine et al.,1995; Pusch et al.,1995) 
c.1667T>A Ile556Asn Recessive shift of po (Kubisch et al.,1998; Plassart-Schiess et al., 1998; 
Saviane, Conti, & Pusch, 1999) 
c.2680C>T Arg894X Slightly dominant negative (Dunø et al., 2004; George et al., 1994; Meyer-
Kleine et al.,1995) 
Table 4-1 Dual Inheritance myotonia congenita mutations and their effect on the channel 
Po = open probability  
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4.2.1 Aims 
This study investigated two cohorts of patients which had a main symptom of myotonia. 
The patients were clinically diagnosed with Myotonia Congenita; Paramyotonia Congenita 
or Sodium Channel Myotonia, but following routine diagnostic testing had been none of the 
common mutations. For the PMC/SCM cohort we aimed to identify new causative 
mutations, through the screening of non-routinely tested areas. Whilst with the MC cohort, 
dominant families were sequenced for the known genes in order to further our 
understanding of the presence of mutations described as both dominant and recessive. 
Furthermore, next generation sequencing techniques was used in the case of a well defined 
PMC family, who were found to have no SCN4A mutations, in order to indentify novel genes 
involved in the disease. 
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4.3 Myotonia Patient Cohorts 
Two small cohorts of patients with myotonia as the main overriding symptom were 
selected for two different gene screening studies. The first contained eight patients who 
have been clinically diagnosed with either PMC or SCM who did not have the common 
mutations within SCN4A, following routine diagnostic testing. The second cohort was 
composed of 10 dominant families who have been clinically diagnosed with myotonia 
congenita and have been found to have one CLCN-1 mutation. However, these mutations 
have been reported to show dual inheritance even though dominant and recessive forms of 
myotonia congenita showing different disease mechanisms. Thus, it is possible that another 
causative mutation in the known genes might be found in these dominant families. In this 
cohort, SCN4A was initially screened, followed by the myotonic dystrophy genes: DMPK5 
and ZNF9.Finally, exome sequencing was used to identify possible causative mutations in a 
PMC family, who had previously been sequenced for both CLCN-1 and SCN4A, and found to 
be negative.  
4.4 PMC and SCM Cohort 
4.4.1 Screening SCN4A in PMC and SCM patients 
In order to identify new mutations in the PMC/SCM cohort of patients, the whole coding 
region of SCN4A was screened. DNA from the cohort was amplified using primers targeted 
to all 24 SCN4A coding exons and then sequenced. 3 out of 8 patients were found to have 
mutations in SCN4A. Of these mutations, one was found to be novel and predicted to be 
pathogenic through in silico analysis, c.3475T>C, p.Ser1159Pro. The other two mutations, 
c.4765G>A, p.Val1589Met and c.3877G>A, p.Val1293Ile, are known well characterised 
mutations. 
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Table 4-2 Clinical features of myotonia patients 
 
Patient  Gender Age at onset 
(years) 
Affected Family 
Members 
Clinical Features Phenotype SCN4A 
mutation 
1 Female Infancy Father & 
Brother 
Nonpainful myotonia mainly affecting eyes and 
grip; slight muscle hypertrophy; myotonia 
provoked by cold exposure, tiredness and 
alcohol 
SCM Ser1159Pro 
2 Female Childhood Maybe Mother Myotonia affected by cold and exercise. SCM Val1589Met 
3 Male 3 years old Father, sister & 
daughter 
Myotonia on EMG. Also has a CLCN-1 
mutation. 
MC Val1293Ile 
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Patient 1 
Patient 1 is a 36 year old female who has shown symptoms of myotonia from infancy with 
eyelid myotonia as a baby. While growing up she always noted impaired relaxation of her 
muscles associated with intermittent stiffness. Cold, alcohol and tiredness exacerbate her 
symptoms particularly eyelid myotonia. She has a 63 year old father and 26 year old 
brother who are similarly affected (Figure 4-1A). On examination she shows clear eyelid 
myotonia which improves on repetition as well as grip and percussion myotonia. Detailed 
electrophysiological testing has been conducted showing profuse myotonic discharges in all 
muscles. On the short exercise test there was a small increase in CMAP on cooling while the 
long exercise test is negative. These symptoms along with electrophysiological tests suggest 
the patient has sodium channel myotonia.  
Sequencing of the coding exons of SCN4A for the proband found a substitution mutation at 
position 3475 of a T to a C resulting in an amino acid change Ser1159Pro (Figure 4-1B). 
Ser1159Pro is a novel mutation located in the loop region between the S4 and S5 segments 
of domain III and affects a highly conserved amino acid. Furthermore, in silico analysis 
predicts this mutation to be probably damaging with a score of 0.999. The mutation was 
found to segregate with disease in the proband’s family suggesting that it is the causative 
mutation. 
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A
B
C
D
E
Fc.3475T>C
p.Ser1159Pro
c.4765G>A
p.Val1589Met
c.3877G>A
p.Val1159Ile
 
Figure 4-1 SCN4A mutations identified in the sodium channel related myotonia cohort 
A, C & E, Pedigrees of families, arrow indicates proband and affected members are shaded in. B, D & F, Chromatograms of partial sequences of SCN4A 
showing one heterozygous point mutations. 
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Patient 2 
Patient 2 is a 46 year old woman who has been affected with stiffness from childhood. She 
experiences muscle stiffness with no warm up and is not affected by episodes of muscle 
weakness. The stiffness is brought on by cold temperatures and exercise. From 
electrophysiological testing the patient was found to have profuse myotonia in all muscles 
tested but showed normal long and short exercise tests. This is consistent with sodium 
channel myotonia. It is thought that the patient’s mother is also affected although she is 
unavailable for testing (Figure 4-1C). 
All coding exons in SCN4A were sequenced revealing a substitution in exon 24 at position 
4765 of a G to A resulting in an amino acid change p.Val1589Met (Figure 4-1D). Val1589Met 
is a known Nav1.4 mutation which has previously been reported to cause Sodium Channel 
Myotonia (Heine et al. 1993; Orrwll et al. 1998). It is located in S6 of domain IV and is found 
nearby the Hyper PP causing mutation p.Met1592Val (Ptacek et al., 1993; Rojas et al., 
1991). 
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Table 4-3 SCN4A mutations identified in myotonia patients 
 
DNA 
Change 
Location 
within Gene 
Amino Acid 
Change 
Location within 
Protein 
Pathogenic  
(In silico Analysis) 
Known 
mutation? 
Functional Analysis 
c.3475T>C Exon 19 p.Ser1159Pro DIII S4-S5 loop Yes No To be done 
c.4765G>A Exon 24 p.Val1589Met DIV S6 Segment n/a Yes Defect of inactivation(Heine et 
al., 1993; Orrell et al. 1998) 
C.3877G>A Exon 21 p.Val1293Ile DIII S6 Segment n/a Yes Defect of inactivation and shift in 
voltage dependence of 
activation(Koch et al. 1995) 
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Patient 3 
Patient 3 is a 51 year old male affected with myotonia congenita with dominant 
inheritance. During childhood he reached all normal milestones with symptoms occurring at 
the age of 3 years old with stiffness in legs. The patient’s symptoms are not made worse by 
cold temperatures but are exacerbated by lack of sleep and emotional stress. Examination 
of the patient shows mild myotonia of the face especially around the eyes. In addition, the 
patient is being treated for hypothyroidism with thyroxine. The family history suggests a 
dominant pattern of inheritance with both father and grandfather of the patient potentially 
affected. The patient has two younger sisters, one of which shows mild symptoms although 
not as severely as her brother, and two young daughters; one affected and one unaffected 
(Figure 4-1E). 
An initial investigation into the causative mutation of the patient revealed a deletion in 
CLCN-1 c.1872delG in exon 16 which results in a frame shift mutation p.Glu624fs. A single 
frame shift mutation of this kind in CLCN-1 usually causes recessive myotonia congenita. 
Interestingly, this mutation was also found in the patient’s apparently unaffected daughter 
but none of the other family members tested. Therefore, the patient was put forward for 
further sequencing of other genes. Through sequencing of the all the coding exons of 
SCN4A it was found that this patient had a mutation in exon 21, c.3877G>A which results in 
an amino acid change p.Val1293Ile (Figure 4-1F). Val1293Ile is located near the cytoplasmic 
face of S6 in Domain III and is a known variant which has been previously reported to cause 
a milder form of PMC where paralysis does not occur even upon cooling (Koch et al. 1995). 
The mutation was also found in the patient’s sister who shows mild symptoms but not in 
the unaffected sister or daughter. Unfortunately, the patient’s affected daughter is 
unavailable for testing. 
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Figure 4-2 Schematic diagram of the sodium channel α subunit showing the localisation within the channel of the SCN4A mutations identified in the 
myotonia cohort. 
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4.5 Dominant Myotonia Congenita Cohort 
4.5.1 Screening for SCN4A mutations 
In order to identify a secondary mutation in dominant myotonia congenita families with a 
dual inheritance CLCN-1 mutation, the whole coding region of SCN4A was screened through 
amplification of individual exons from patient DNA which were then sequenced. 10 samples 
were screened for SCN4A mutations, however, no mutations were found in this gene in all 
samples following analysis.  
4.5.2 Screening Myotonic Dystrophy Genes 
Following screening of SCN4A, the dominant MC cohort were screened for expansions in 
both myotonic dystrophy genes, DMPK and ZNF9, which cause myotonic dystrophy type 1 
(DM1) and myotonic dystrophy type 2 (DM2). Following fragment analysis of both genes no 
samples were found to have expansions in either gene which are sufficient to cause 
disease. 
 
127 
 
4.6 Exome Sequencing  
Exome sequencing provides a helpful tool for the identification of a causative mutation with 
the potential of finding a new gene for those patients who have a clear phenotype and a 
strong family history, yet are found to be negative for mutations in the known genes. For 
this study exome sequencing was used to identify the causative mutation within a family 
with a history of paramyotonia congenita, without any mutations in the known genes. The 
family is a large Sicilian family with a number of members who show symptoms of 
paramyotonia congenita. Samples were obtained from three affected family members: 
Mother (proband) and two children.  
The proband is a middle-aged Sicilian woman who has experienced muscle stiffness and 
paralysis from infancy. Onset occurred at the age of three with muscle stiffness upon 
exposure to cold temperatures. Myotonia is present in her peripheral muscles, eyelids and 
extraocular muscles. Without treatment the proband experiences muscle cramp and pain 
upon waking in the morning. Triggers for attacks include old temperatures, exercise and 
some foods. EMG reveals extensive myotonia especially upon cooling. The proband has 
responded well to a low dose of mexiletine. Other family members are known to be 
similarly affected although details and samples are only available for the proband’s son and 
daughter who are exhibit similar symptoms.  
DNA from each family member was sequenced with Neuromics and the data obtained was 
analysed and filtered using Neuromics Decode software.Variants were filtered based on low 
predicted protein impact, presence in databases, frequency within the general population 
and read dept. Variants within all members were then filtered based on the inheritance 
pattern, relation to known symptoms and diseases and against a skeletal muscle gene list.  
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Following multistep filtering 10 variants were identified. Of these three genes were 
identified as clinically relevant with potentially causative variants: RYR-1, AGRN and COL6A3 
(see Table 4-4 for variant list). RYR-1 is a vital component of the excitation-contraction 
coupling machinery and is associated with malignant hyperthermia and central core 
disease. Mutations of RYR-1 have been shown to be inherited in a dominant and recessive 
manner. In this family three RYR-1 mutations were identified which all have been previously 
reported and associated with disease, c.4711A>G, p.1571I>C (rs146429605), c.10097G>A, 
p.3366R>H (rs137932199) and c.11798A>G, p.3933Y>C (rs147136339). These mutations 
have been previously shown to co-segregate with disease; Klein et al 2011 and Tammaro et 
al have shown that c.4711A>G is inherited in cis with c.11798A>G whilst Duarte et al 2011 
showed that c.10097G>A and c. 11798A>G are inherited together(Duarte et al., 2011; Klein 
et al., 2012; Tammaro et al., 2011). AGRN is a component of the synaptic basal lamina and 
is crucial for the formation of the neuromuscular junction. Mutations of AGRN have been 
associated within limb girdle congenital myasthenic syndrome. In this family we identified a 
novel variant, c.497C>G, p.166P>R and is predicted to be pathogenic. Finally, COL6A3 forms 
one of three α chains of type VI collagen and forms a part of the extracellular matrix which 
surrounds muscle cells. COL6A3 is necessary for muscle cell stability, growth and 
movement. Mutations associated with COL6A3 cause Bethlem myopathy or Ullrich 
congential muscular dystrophy and are inherited dominantly or recessively, respectively. A 
novel variant, c.4510G>A, p.1504R>W, was identified and is predicted to be pathogenic.  
In order to establish which variants are responsible for disease in this family, it is necessary 
to confirm the presence of the mutation through Sanger sequencing and to check for 
segregation within the rest of the family members. Unfortunately, due to time constraints it 
has not been possible to confirm these mutations via Sanger sequencing. 
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Table 4-4 Table showing variants identified through whole exome sequencing following filtering of data 
Allele frequency data taken from Exome Aggregation Consortium (ExAC) database. 
Gene Protein Function Expressed in 
skeletal muscle 
Associated with disease Variants identified Known variant? Clinically 
Relevant 
AGRN Agrin Component of the 
synaptic basal lamina 
Yes Limb-girdle congenital myasthenic 
syndrome 
c.497C>G, p.P166R No Yes 
CLCNKB CIC-kb Important for the 
reabsorption of salt 
from urine into the 
bloodstream 
No –Kidney Bartter Syndrome c.403C>G, p.P135A Yes – SNP 
rs1057857 
(Allele frequency 
=0.6207)  
No 
RYR1 Ryanodine 
receptor 
Excitation-Contraction 
coupling within 
skeletal muscle 
Yes Malignant hyperthermia 
Central Core Disease 
Minicore myopathy 
c.4711A>G, p.I1571V 
c.10097, p.R3366H 
p.11798A>G p. Y3933C 
Yes – associated 
with disease 
Yes 
TTN Titin Important for 
contraction of striated 
muscle 
Yes Hereditary myopathy with respiratory 
failure 
Llimb-girdle muscular dystrophy type 
2J 
Tibial muscular dystrophy 
c.13316T>C, p.Y4439C Yes – rare SNP 
 rs72648942 
(Allele frequency 
=0.005848) 
Yes 
COL6A3 Collagen, 
type VI, 
alpha 3 
Forms part of the 
extracellular matrix 
surrounding muscle 
cells.  
Yes Bethlem myopathy  
Ullrich congenital muscular dystrophy 
c. 4510G>A, p.R1504W 
 
No Yes 
COL9A3 Collagen, 
type IX, 
alpha 3 
An important 
component of cartilage 
No – Hyaline 
Cartilage 
Multiple Epiphyseal dysplasia c.3008G>A, p.R103Q 
c.520-6C-T 
Yes – both rare 
SNPs 
rs142639450 
(Allele frequency 
= 0.01459) 
rs45476191 
(Allele frequency 
=0.02267)  
No 
GARS Glycine 
tRNA 
ligase 
Important for protein 
synthesis 
Low expression Distal hereditary motor neuropathy 
type V  
CMT type 2D 
c.11C>T, p.P4L Yes – rare SNP 
rs62636572 
(Allele frequency 
=0.02066) 
No 
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4.7 Discussion 
The non-dystrophic myotonias are a group of disorders characterised by increased muscle 
excitability due to mutations within the ion channel genes: CLCN-1 and SCN4A.In order to 
further our understanding of the genetic causes of non dystrophic myotonia two small 
cohorts of myotonia patients were sequenced. The first consisted of patients with clear, 
well characterised phenotypes of either: myotonia that worsens with cold and occasional 
weakness (PMC) or myotonia with no weakness and some potassium sensitivity (SCM). 
These patients had undergone routine diagnostic testing without a causative mutation 
being identified. The second cohort contained 10 families with dominant myotonia who 
had been found to carry a single mutation in CLCN-1 which has been reported as either 
dominant or recessive. For both myotonia cohorts, Sanger sequencing of SCN4A was 
undertaken in order to expand the current knowledge of the genetic causes of myotonia. In 
the dominant MC cohort the myotonic dystrophy genes ZNF9 and DMPK were also 
sequenced. Finally, exome sequencing was undertaken for a family with a myotonia 
phenotype, without mutations in any of the known channelopathy genes in order to further 
the genetic spectrum of channelopathy genes. 
4.7.1 Sequencing of known genes in myotonia 
The skeletal muscle sodium channel gene, SCN4A was analysed in a cohort of eight patients 
with either PMC or SCM. Following sequencing of all 24 exons within SCN4A, 3 out of 8 
samples (37.5%) were found to have a likely causative mutation. Of the three mutations 
identified two were previously reported and associated with a myotonia phenotype: 
p.Val1589Met and p.Val1293Ile (Table 4-2 and Table 4-3). The final mutation is a novel 
variant, p.Ser1159Pro which was absent from controls and is not present in the online 
databases including 1000 genomes, NLHBI and HGMD. 
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The first mutation, p.Val1589Met, was identified in a patient who presents with muscle 
stiffness without weakness which can be exacerbated cold temperatures and exercise. The 
mutation is located near the cytoplasmic region of the DIV S6 segment, which has been 
implicated as a potential docking site for the inactivation gate of the channel. p.Val1589Met 
is a known pathogenic mutation which has previously been associated with a myotonia 
phenotype which is aggravated by cold and potassium (Heine et al., 1993; Orrell et al., 
1998).This phenotype is consistent with that of the proband. Whole cell and single channel 
recordings of HEK293 cells expressing both WT and Val1589Met mutant have shown that 
the mutant causes a defect in normal channel inactivation (Mitrović et al., 1994). This 
results in a clear instability of the inactivated state as the mutant channels show faster 
recovery from inactivation and a larger steady-state currents compared with the WT 
channel (Mitrović et al., 1994). Thus, it is possible to conclude that p.Val1589Met is the 
causative mutation in this patient.  
The second known mutation, p.Val1293Ile, was identified in a middle aged male who has 
presented with myotonia since the age of three years old and does not experience any 
weakness or aggravation with cold or potassium. The patient’s family history is suggestive 
of dominant inheritance with a mildly affected sister and one affected daughter. Val1293Ile 
is located within the DIII S6 segment which has been shown to play a critical role in fast 
inactivation (McPhee et al. 1995). This is a known pathogenic mutation which has 
previously been associated with a mild myotonia phenotype which is aggravated by cold 
but shows no paralysis (Koch et al., 1995). Studies in expression systems have shown that 
p.Val1293Ile causes a reduced rate of fast inactivation, accelerated recovery, altered 
voltage dependence of inactivation as well as a small hyperpolarised shift in 
activation(Green et al. 1997). These disruptions to channel gating although mild are 
sufficient to cause the myotonic bursts responsible for the phenotype. This sodium channel 
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mutation appears to segregate with disease for this family suggesting it is at least partially 
accountable for the symptoms these patients experience. Interestingly, upon initial 
investigations a deletion in CLCN-1 exon 16, c.1872delG, which causes a frameshift, 
p.Glu624fs, was identified in the patient. However, this mutation did not segregate with 
disease as the proband’s affected sister did not carry the variant whilst the unaffected 
daughter did. It is feasible that the proband experiences more severe symptoms in 
comparison to his affected sister due to the combination of the CLCN-1 mutation with the 
SCN4A mutation. 
The final mutation found within the PMC/SCM cohort was a novel variant, p.Ser1159Pro. 
The proband carrying this mutation presents with eyelid, grip and percussion myotonia that 
is exacerbated by cold without paralysis. Ser1159Pro is located near the COOH terminal end 
of the DIII S4-S5 loop, an area which has been shown to be important for the fast 
inactivation of the channel. The mechanism for inactivation is suggested to occur through a 
ball and chain mechanism whereby an inactivation gate occludes the central pore through 
binding of an inactivation gate receptor site(Armstrong & Bezanilla, 1977). It has been 
shown that the loop between DIII and DIV forms the inactivation gate with three critical 
residues which form the IFM (Ile-Phe-Met) motif. The exact structure of the inactivation 
gate receptor is not known, however a number of amino acids within the sodium channel 
DIII and DIV S4-S5 loops have been highlighted for their interaction with the IFM motif 
(McPhe et al. 1998; Popa et al. 2004; Smith & Goldin, 1997). Additionally, Ser1159Pro is 
located near a number of other myotonia mutations: Ala1152Asp, Ala1156Thr and 
Ile1160Val (Figure 4-2)(Bouhours et al., 2005; McClatchey et al., 1992; Ptacek et al., 1993; 
Richmond et al. 1997; Yang et al., 1994b). These mutations have been previously studied to 
identify the effect they have on the sodium channel. All three have been shown to cause an 
altered rate of inactivation, accelerated recovery and altered voltage dependence of 
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inactivation. Ile1160Val and Ala1152Asp also showed an accelerated rate of 
deactivation(Richmond et al. 1997; Bouhours et al. 2005) . These are common defects 
amongst myotonia mutations and have been well documented to result in a prolonged 
influx of Na+ ions leading to the increased excitability which results in myotonia. Thus, it is 
possible that loss of the polar serine residue for a non polar cyclic proline could cause 
sufficient disruption to the S4-S5loop to effect channel inactivation, as seen in the nearby 
myotonia mutations, which cause a similar phenotype to that seen in the proband. 
Functional work is needed to confirm that this mutation results in the expected defect of 
inactivation. 
Following screening of the whole SCN4A gene in this myotonia cohort, 37.5% of patients 
were found to have a mutation that would not have been identified during routine 
diagnostic testing where just two exons are sequenced (exon 22 and 24). This result 
suggests that mutation screening for myotonia patients should extend to the whole gene as 
now happens with CLCN-1. However, during routine investigations it can be time consuming 
and costly to sequence large genes when a large proportion of mutations are found within 
two exons. Thus, the development of next generation sequencing techniques such as 
customised gene panels which is run on Illumina’s MiSeq and enables the quick sequencing 
of genes, will greatly improve diagnostic output in the future.  
For PMC/SCM it is well documented that 20% of patients are still without a causative 
mutation following sequencing of SCN4A (Horga et al., 2013; Matthews et al., 2008). 
Conversely, in this study we found that the proportion of patients without a mutation 
following SCN4A sequencing was actually 62.5%. This proportion is unlikely to be 
representative of the wider patient population due to positive bias for patients without an 
SCN4A mutation during the selection of patients who had had the common mutations 
already ruled out. However, we cannot completely rule out mutations in SCN4A from this 
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study as only the exonic regions were sequenced. Kubota et al. have shown that PMC can 
be caused by mutations within the intronic regions of SCN4A; therefore it is possible that 
further mutations would be indentified in SCN4A by screening intronic areas. This was not 
conducted during this study due to time and cost required to screen large intronic regions 
within this gene. The negative findings within this study give further support to the notion 
that other genes, which remain as of yet unidentified, are likely to play a role in the 
mechanism of disease of the NDMs. Thus next generation sequencing such as exome 
sequencing will be important for the identification of mutations within this proportion of 
patients and enable more understanding of the mechanism of disease.  
4.7.2 Dominant families 
In order to further understand the presence of dual mode of inheritance mutations in 
myotonia congenita, a small cohort of dominant families that were found to have dual 
inheritance mutations in CLCN-1 were investigated to see if the phenomenon of dual 
inheritance mutations can be explain by the presence of mutations in other genes. 10 
individuals were sequenced for mutations within known genes which have been associated 
with myotonia: SCN4A, DMPK and ZNF9.  
Initially the whole SCN4A coding region was sequenced in 10 samples. No mutations were 
identified in SCN4A gene for all cases screened. This indicates that in this cohort, sodium 
channel mutations cannot explain the disease as seen in other dominant MC patients who 
have been shown to carry mutations in both CLCN-1 and SCN4A (Hehir et al. 2013; Trip et 
al., 2008). Following this, the muscular dystrophy genes were investigated. Muscular 
dystrophy type 1 is caused by repeat expansions of a CTG trinucleotide repeat in DMPK. 
DM1 is caused by between 50 to 5,000 copies of this unstable motif with disease severity 
correlating with the copy number of the repeat. All patients in this cohort were found to 
have CTG repeat numbers within the normal limit. A similar disease mechanism has been 
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identified in DM2, which is caused by expansion of the repeat CCTG in intron 1 of ZNF9 
within a complex repeat motif. In order to cause disease the number of CCTG repeats in 
expanded alleles has an average of 5,000 repeats. As with DMPK all samples analysed were 
found to have repeats within the healthy range. Thus in this cohort expansions within the 
muscular dystrophy genes are not accountable for disease causation. This was surprising as 
some cases have been reported with patients with a single CLCN-1 gene were also found to 
carry a repeat expansion associated with one of the muscular dystrophies. In these cases 
the presence of a CLCN-1 mutation is thought to intensify the myotonic symptoms of 
muscular dystrophy leading to initial misdiagnosis of myotonia congenita(Suominen et al., 
2008). However, following screening of this cohort it is clear that repeat expansions in 
these genes cannot explain the description of these CLCN-1 mutations as dominant and 
recessive. 
Although no mutations were identified in this dominantly inherited MC family cohort it 
does not completely rule out the hypothesis that the phenomenon is due to dominant 
families carrying a CLCN-1 that is in fact a recessive mutation. It is possible that there are 
mutations within intronic or promoter regions as well as in currently unidentified genes 
which may play a role within this phenomenon. Furthermore, other mechanisms such as 
modifying factors, incomplete penetrance or mutations in unknown genes which have not 
been investigated in this study might be better placed to explain the role of mutations in 
the causation of both dominant and recessive forms of the same disease. For example, it 
has been suggested that the mutation p.Ala531Val could be a dominant mutation that 
shows reduced penetrance, however, it is not clear due to the small number of pedigrees it 
has been reported in(Colding-Jørgensen, 2005; Papponen et al., 1999; Sun et al. 2001). On 
the other hand, p.Arg894X has been identified in four highly penetrant pedigrees and in 10 
recessive pedigrees and has been shown through expression studies to have a dominant 
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style effect on channel functioning which is suggestive of a tightly associated modifying 
factor(Colding-Jørgensen et al. 2003; Colding-Jørgensen, 2005; George et al., 1994; Meyer-
Kleine et al. 1995; Papponen et al., 1999; Sun et al. 2001; Zhang et al., 1996). Interestingly, 
in the case of the dual mode of inheritance mutation identified in ALS within the SOD-1 
gene, p.Asp90Ala, the recessive families were found to share a common founder suggesting 
a tightly linked protective factor(Al-Chalabi et al., 1998). These mutations are suggestive of 
multiple explanations for dual inheritance mutations that could be specific to the individual 
mutations and the pedigrees in which they are identified.  
4.7.3 Exome Sequencing 
For this study whole exome sequencing was chosen to further investigate the causal 
variants for a family with a history of paramyotonia congenita who were found to be 
negative for the known genes. Affected members experience muscle stiffness which can be 
triggered by cold which is suggestive of paramyotonia congenita. Three affected individuals 
were available for analysis (Mother and two children).  
Exome sequencing was conducted by Neuromics and analysed using the DeCode Health 
software. Variants were filtered based upon low predicted protein impact, presence in 
databases, frequency within the general population and read dept. Following filtering, 10 
variants were identified. After looking at expression patterns of all genes, only three genes 
were found to be clinically relevant due to expression within skeletal muscle: RYR-1, AGRN 
and COL6A3.  
RYR-1 is a large gene composed of 105-107 exons and encodes the ryanodine receptor 
which plays a crucial role in excitation-contraction coupling within skeletal muscle. The 
ryanodine receptor interacts with the calcium channel Cav1.1 and regulates the release of 
calcium from the sarcoplasmic reticulum in response to an action potential. Mutations 
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within RYR-1 are associated with the congenital myopathies: central core disease, 
multiminicore disease and malignant hyperthermia susceptibility. Central core disease 
(CCD) often presents in infancy (although adult onset can occur) with hypotonia, muscle 
weakness and susceptibility to malignant hyperthermia. Muscle biopsies from CCD patients 
show a characteristic histology of central cores – areas of reduced oxidative enzyme 
activity. CCD is an autosomal dominant disease. Multiminicore disease shows more 
variability than CCD in the clinical presentation. Muscle biopsies show multiple cores within 
the muscle fibre which do not extend along the entire fibre length (Jungbluth, 2007). RYR-1 
mutations associated with Multiminicore Disease (MmD) are inherited in an autosomal 
recessive manner. Malignant hyperthermia is triggered in susceptible patients during 
exposure to aesthetic agents. Upon exposure to triggers, patients experience muscle 
rigidity, tachycardia, increased temperature and hypermetabolism due to defective calcium 
homeostasis resulting in an unregulated increase in the intracellular calcium concentration. 
Continued muscle contraction depletes ATP levels and leads to rhabdomyolysis and 
hyperkalemia. Unless aborted, malignant hyperthermia is fatal.  
Over 300 RYR-1 variants have been identified to date, with three hotspot regions within the 
protein: N-terminal, central and C-terminal. However, only a small number have been fully 
characterised (Brislin & Theroux, 2013; Kraeva et al., 2013; Roesl et al.,2014; Schiemann et 
al., 2014; Shepherd, Ellis, Halsall, Hopkins, & Robinson, 2004). Functionally characterised 
mutations have been shown to result in a disruption to the calcium flux through the 
channel through three main mechanisms: loss of calcium conductance due to reduced 
protein levels, increased permeation of calcium and uncoupling of calcium release to 
sarcolema depolarisation(Bannister, 2007; Brislin & Theroux, 2013). The three variants 
identified in the PMC within the RYR-1 gene have been previously reported and are 
associated with central core disease and malignant hyperthermia susceptibility(Duarte et 
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al., 2011; Klein et al., 2012; Tammaro et al., 2011). The functional consequences of these 
mutations have not been studied to date. Due to the important role of RYR-1 within 
excitation-contraction coupling within the muscle it is possible that the variants identified 
within RYR-1 are the causative of disease in the family studied, however it is not possible to 
determine without further investigation. 
AGRN is composed of 36 exons and encodes a heparin sulphate proteoglycan, Agrin, which 
is a basal lamina protein important for the formation and stabilisation of the neuromuscular 
junction(Bezakova & Ruegg, 2003; Gautam et al.,1996; Singhal & Martin, 2011). Agrin is a 
multidomain protein synthesized by motor neurons and secreted at the site of contact with 
muscle fibers to stimulate AChR aggregation (Cohen & Godfrey, 1992; Nitkin, Smith, & 
Magill, 1987; Reist et al.,1992; Rupp et al., 1992).  
Mutations within AGRN are associated with congenital myasthenic syndrome (CMS). 
Congenital myasthenic syndromes are a heterogenous group of disorders resulting from 
defects in signalling within the neuromuscular proteins. CMS is caused by mutations in a 
number of neuromuscular junction proteins, with each genetic cause forming a distinct 
subtype. Patients exhibit a wide variety of symptoms with a common symptom of muscle 
weakness upon exertion. AGRN mutations form a rare subtype of recessive CMS with only a 
few cases reported worldwide(Huzé et al., 2009; Maselli et al., 2012; Nicole et al., 2014). 
Patients with AGRN mutations exhibit a limb-girdle pattern of involvement and age of onset 
usually occurs between infancy and 5 years (Barišić et al.,2011; Huzé et al., 2009; Maselli et 
al., 2012; Nicole et al., 2014). Symptoms include difficulty walking during childhood, 
bilateral ptosis, and muscle weakness, which worsen during pregnancy. Muscle biopsies 
show disorganised neuromuscular junctions.  
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Within the PMC family studied, a novel AGRN variant was identified which is predicted to 
be pathogenic. The mutation is located within the NtA (N-terminal Agrin) domain of the 
protein and is known to be required for binding laminin and connecting to the basal lamina 
(Denzer et al.,1997; Ruegg et al., 1992). Binding of agrin to laminin is important for the 
clustering of AChR receptors at the neuromuscular junction. Due to the important role of 
agrin within skeletal muscle it is possible that the novel variant identified could be the 
causal variant within the family. Although, AGRN has only been associated with recessive 
inheritance, it is not impossible for a gene to be associated with autosomal dominant and 
recessive disorders. Further investigation is needed to determine whether the AGRN 
variant identified is a causal mutation within the family and if so determine the effect of 
this variant on the protein functioning.  
COL6A3 is one of three chains which form collagen type VI, a. microfibrillar component of 
the extracellular matrix that interacts with a number of matrix molecules. Collagen type VI 
is thought to have a role in binding cells with the extracellular matrix and plays an 
important role within muscle(Bönnemann, 2011; Haliloglu & Topaloglu, 2011). The three 
chains of collagen type VI fold into a complicated polymeric structure. Mutations within 
COL6A3 are associated with the collagen VI-related myopathies: Bethlem myopathy and 
Ullrich congenital muscular dystrophy(Bönnemann, 2011; Jöbsis et al.,1999; G. Jöbsis, 
Keizers, & Vreijling, 1996; T. C. Pan et al., 1998; Yonekawa & Nishino, 2014). Both disorders 
represent a spectrum of disease ranging from Ullrich congenital muscular dystrophy at one 
end and the milder form Bethlem myopathy at the other. Patients experience muscular 
weakness, hypotonia, joint contractures affecting ankles and elbows. Mutations result in 
the formation of abnormal collagen VI and disruption to the extracellular matrix(G. J. Jöbsis 
et al., 1999; G. Jöbsis et al., 1996; T.-C. Pan et al., 2013).  
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A novel COL6A3 mutation was identified through exome sequencing of the three PMC 
family members. The mutation is located with the N-terminal globular domain, N2, which 
resembles a vWA (vWF type A) domain. These domains are thought to mediate cell-cell, or 
cell-matrix interactions. Disruption to one of the three collagen type VI chains has been 
shown to prevent correct assembly of collagen type VI causing disruption to the 
extracellular matrix(T. C. Pan et al., 1998). Thus, it is possible that the COL6A3 mutation 
identified could be the casual mutation within the PMC family described and further 
investigation is needed. 
Due to the overlap in symptoms between PMC and the diseases associated with the 
identified genes it is possible that the family have been originally misdiagnosed. 
Interestingly, a number of cases have been reported where exome sequencing has lead to 
the correct clinical diagnosis following identification of the casual variant. For example, Choi 
et al used exome sequencing to identify mutations in the gene SLC26A3 in a case with an 
initial diagnosis of Bartter syndrome. Identification of the SLC26A3 mutations resulted in a 
change of the clinical diagnosis to congenital chloride diarrhea - a disease already known to 
be caused by mutations of the gene. It is important to determine if this is the case as it can 
help with the clinical management of disease of the patients. The presence of the variants 
identified within this study has not been confirmed via Sanger sequencing due to time 
constraints. Further work is needed to confirm the presence of these variants, to determine 
whether they segregate with disease and the functional consequences of the casual variant. 
4.8 Conclusion 
From sequencing the whole coding region of SCN4A in a myotonia cohort, three mutations 
were identified, one of which was novel. The novel mutation was identified in a part of the 
channel which contains a number of other myotonia related mutations and is likely to be 
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pathogenic, although functional data is needed to support this. In addition, dominant 
myotonia congenita families were screened for mutations in known genes in order to 
investigate the presence of CLCN-1 mutations which are reported as having dual 
inheritance. No mutations were identified in any of the genes studied indicating that in 
these families mutations in other genes cannot explain the dual inheritance of the 
mutations. Finally, exome sequencing was used to identify the causative mutation in a PMC 
family which did not have mutations in the known genes. Variants were identified in three 
possible genes, however Sanger sequencing is needed to confirm the presence of these 
mutations  
This genetic study highlights the importance of full sequencing of the known genes in order 
to provide the patient with a genetic diagnosis. Next generation sequencing methods such 
as targeted gene panels and exome sequencing provide cost effective methods to sequence 
all the known genes. 
4.9 Further Work 
 A number of cases within the cohorts where no mutation was identified. In order to find 
the causal mutation within the remainder of this cohort, patients with a strong 
phenotype and family history should be selected and exome sequencing used. This 
would enable identification of the genetic cause of disease. 
 The variants identified in the PMC family through exome sequencing need to be 
confirmed by Sanger sequencing. In order to confirm which gene holds the causal 
variants, confirmation of the mutations via Sanger sequencing needs to occur. Following 
this DNA needs to be collected from other family members who are both affected and 
unaffected in order to look at segregation of the variants with disease for the family. 
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 Ser1159Pro needs to be functionally characterised in order determine whether they are 
pathogenic mutations.  
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5 Chapter 5: Functional Analysis of a possible Hypo PP 
mutation and other related Nav1.4 S3 segment 
negative charge mutations 
5.1 Summary 
Hypokalemic periodic paralysis is caused by mutations in two genes: CACNA1S and SCN4A 
which encode the voltage gated calcium (Cav1.1) and sodium channels (Nav1.4). Mutations 
within these channels have been found to localise to the S4 voltage sensor of both 
channels. 18 out of 21 mutations are found with the voltage sensor and cause loss of 
positively charged arginine residues called gating charges. Studies of Hypo PP arginine 
mutations revealed an aberrant ionic leak called a gating pore current which is activated by 
negative voltages and is carried by cations (Sokolov et al.,2007a, 2010; A. F. Struyk & 
Cannon, 2007a; Struyk et al.,2008).  
Through Sanger sequencing a novel mutation (D1420G) was identified in a Hypo PP patient. 
D1420G is located in the S3 segment of DIV and is predicted to interact with the R4 residue 
when the voltage sensor is activated. Analysis of the biophysical effect of D1420G revealed 
a small hyperpolarised shift of 4 mV in the voltage dependence of fast inactivation; 
however this is not the disease causing mechanism. D1420G was found to produce a gating 
pore current activated by negative voltages which is permeable to Na+. The currents were 
still present with only NMDG+ as the extracellular cation, unlike for gating pore currents in 
S4 arginine mutant channels. An additional Cl- component was identified within the D1420G 
gating pore current. These findings suggest that D1420G is indeed a pathogenic mutation.  
Additionally, the role of homologous negatively charged residues within other Nav1.4 
domains was investigated. S3 segment negative charges from DI, DII and DIII, were 
substituted to a glycine and steady state currents were measured. All three mutations were 
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found to cause a gating pore current, although differences were identified between 
domains. D197G and D1094G revealed a gating pore current activated by positive voltages 
which is carried solely by Cl- ions. In contrast, D640G showed a gating pore current that had 
similar voltage dependence and ion selectivity to D1420G.  
From this study it can be seen that negatively charged residues of the voltage sensing 
domain, which form part of the electrostatic network of interactions to stabilise the 
movement of the S4 voltage sensor, occlude the gating pore from ionic leak. Mutations 
affecting these residues may lead to gating pore currents and could play a role in causation 
of disease.  
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5.2 Introduction 
Hypokalemic periodic paralysis is caused by mutations within Nav1.4 and Cav1.1. 18 out 21 
mutations are located within the S4 voltage sensor, and result in the neutralisation of the 
gating charges. Expression studies of seven Hypo PP Nav1.4 arginine mutations have shown 
that they cause an ionic leak current through the gating pore which is activated by 
hyperpolarised potentials. Furthermore, studies of muscle fibres from a R669H mouse 
model and human fibres have provided further evidence for the gating pore current as the 
mechanism of disease (Jurkat-Rott et al., 2009; Rudel et al.,1984; Wu et al.,2011). Until 
recently no experimental evidence has been available to link Cav1.1 mutations with the 
gating pore current hypothesis. In 2012, Wu et al, showed a small anomalous inward 
current present at the resting potential in the mouse model of the Cav1.1 R528H mutation. 
In addition, Fan et al., have shown that the Cav1.1 mutation R1242G results in a gating pore 
current with two phases: an outward current at positive potentials and an inward current 
present at negative potentials(Fan et al., 2013).  
Whilst the mechanism has been identified for Hypo PP S4 arginine mutations, there is still 
no viable explanation for the 3 mutations (V876E, H916Q (Cav1.1) and P1158S (Nav1.4)) 
which have been identified outside of the S4 voltage sensor. No functional studies have 
been conducted to date on a Hypo PP mutation located outside the S4 segment. It is not 
known whether mutations outside of S4 voltage sensor could cause a sufficient disruption 
to the integrity of the voltage sensing domain to cause the consequential aberrant ionic 
pathway. Until this has been done the gating pore current Hypo PP mechanism cannot be 
fully validated.  
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5.3 Aims 
The aim of this study was to determine if the novel Hypo PP mutation D1420G a pathogenic 
mutation. Hypo PP mutations are normally localised to the S4 voltage sensor, neutralise 
positively charged residues and cause an aberrant ionic leak. Therefore, D1420G was 
investigated in order to determine if it causes a gating pore current. 
In addition, mutations of homologous negatively charged residues to D1420 in other 
domains were studied in order to determine if other S3 negative charges are important for 
the stability of voltage sensing domain.  
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5.4 Functional Analysis of Hypo PP mutation D1420G 
As discussed in Chapter 3, a novel mutation in SCN4A was identified within a patient with a 
Hypo PP phenotype. This mutation causes loss of a negative charge of an S3 segment 
aspartic acid (D1420G). D1420G is predicted to be pathogenic through in silico analysis 
(using PolyPhen) and was found to segregate with disease (see Chapter 3). However, this is 
not sufficient to determine whether D1420G is the causative mutation in this case. 
Functional analysis is needed to determine the mechanism by which this mutation could 
act. It is possible that loss of a negative charge such as D1420G could result in disruption of 
the voltage sensing domain and leading to an aberrant pathway for ionic leak as is seen in 
Hypo PP S4 arginine mutations. Here the functional consequences of D1420G are 
determined through analysis of the effects on alpha currents and gating pore currents. 
5.4.1 Characterization of alpha pore currents 
To determine the mechanism by which D1420G may cause Hypo PP WT and mutant sodium 
channels were transiently expressed in HEK-293 cells to allow whole cell recordings of α 
currents. HEK cells are a widely used heterologous expression system for ion channels. They 
were used for this study since they provide a similar cellular environment to the natural ion 
channel environment and allow for the detection and measurement of sodium currents as 
endogenous currents can easily be blocked and are not selective to sodium ions. However, 
the expression levels can be difficult to control and therefore HEK cells were only used to 
measure the sodium channel kinetics.  
As can be seen from the G-V curves in Figure 5-1, D1420G has no effect on the voltage 
dependence of activation (WT V0.5 = -20.6±0.8mV, n=19; D1420G V0.5= -19.5±0.7mV, n=15, 
p<0.05).  
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It has been shown that some Nav1.4 mutations associated with Hypo PP cause a small shift 
in the voltage dependence of fast inactivation. Therefore, the voltage dependence of 
D1420G channel fast inactivation was measured. Figure 5-1 shows the inactivation curve for 
WT and mutant channels. D1420G induced a small but significant hyperpolarised shift of 
4 mV in the voltage dependence of fast inactivation (WT V0.5 =-66.5 ±0.9 mV, n=20; D1420G 
V0.5= -70.2 ±0.8 mV, n=15, p<0.005). This results in enhancement of fast inactivation, follows 
what has been seen in other Nav1.4 Hypo PP mutations. 
Finally, as some periodic paralysis Nav1.4 mutations have also previously been shown to 
disrupt steady state slow inactivation, the effect of D1420G on this was measured. As it can 
be seen from Figure 5-1C, D1420G has no effect on the slow inactivation showing WT –like 
curve (WT V0.5 = -46.2 mV ±1.7 mV, n=7; D1420G V0.5  = -48.9 mV±0.7 mV, n=6, p<0.05). 
 
149 
 
Figure 5-1 Central pore Na
+
 currents for Nav1.4 channels 
Whole cell currents from WT and D1420G transfected cells. A = Conductance/voltage relationship of 
activation. Whole cell Na
+ 
currents were evoked by a series of voltage steps from -130 to +60 mV 
from a holding potential of -80 mV. B= Voltage dependence of fast inactivation measured using a 
300 ms conditioning voltage step from -130 mV to 60 mV in 10 mV increments, followed by a 
constant test pulse step to -10 mV. Normalised averages were fitted with a Boltzmann equation, C= 
The voltage dependence of steady state slow inactivation induced by a 10s conditioning prepulse to 
test voltages, with a 20 ms step to -100 mV to allow recovery from fast inactivation, followed by a 
20ms test pulse at 0 mV, Data was normalised and fitted using a Boltzmann equation. 
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5.4.2 Gating pore current  
The small loss-of-function effect found in the functional analysis of the alpha-
currents cannot explain depolarization of the muscle fiber often associated with 
Hypo PP. For most Nav1.4 Hypo PP mutations it has been shown that these effects on 
alpha current are secondary to the gating pore current. These mutations cause loss of 
integrity to the voltage sensing domain, providing a pathway for ionic leak through the 
channel independent to the main pore.  
Since D1420G was identified in a Hypo PP patient and is located within the voltage sensing 
domain, the effect of the mutation on the voltage sensing domain was investigated. The 
D1420G mutation was introduced into the rat ortholog skeletal muscle sodium channel 
(rNav1.4-D1413G, rat numbering used from here onwards). Xenopus oocytes were injected 
with RNA encoding either wild type or mutant rNav1.4 together with the rat β1 subunit. The 
biophysical properties of WT and mutant were measured using two electrode voltage 
clamp technique (TEVC). The main pore was blocked using 1 μM tetrodotoxin (TTX) to allow 
detection of gating pore currents.  
Xenopus oocytes were used for this part of the study since the enable the control of ratio of 
channel subunits, have a short expression time and enable high expression levels. However, 
these cells have calcium dependent chloride currents which can make ion selectivity studies 
difficult in some circumstances.  
Figure 5-2A shows currents measured in response to 300 ms voltage steps from a holding 
potential of -100 mV to test potentials of -140 mV to +50 mV, with a Cl- free Na+ bath 
solution. The current amplitudes at hyperpolarised voltages were larger for D1413G 
expressing channels compared to wild type channels. Studying the current-voltage 
relationship reveals that the mean current of wild type and D1413G channels are similar at 
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depolarised voltages (between +50 mV to -40 mV) but at voltages negative to -40 mV, 
D1413G expressing channels show larger currents compared to wild type channels.  
Leak subtraction was performed on data for both WT and mutant using the linear 
component at positive voltages (0 to +20 mV), and the leak-subtracted gating pore current 
was then normalised to the peak sodium currents for each cell and averaged (WT n=9, 
D1413G n=23). D1413G shows an inwardly rectifying current that is not present in WT 
expressing cells. Figure 5-2C shows no significant change in the steady state currents of WT 
expressing cells, even at extreme voltages. In contrast, D1413G shows a clear inward 
current which is activated at voltages negative to -40 mV, which suggests that the gating 
pore current will be present at physiological conditions. At potentials negative to -100 mV 
the current saturates, which is similar to other Hypo PP Nav1.4 mutants studied by Struyk et 
al 2008.  
It has been possible in favourable conditions to measure the peak Na+ currents without TTX 
followed by measuring the D1413G gating pore current, with TTX, from the same cell. This 
enables normalisation of gating pore currents to peak Na+ currents. In our setup the 
D1413G gating pore currents were found to be between 1% and 5% of the peak Na+ 
currents, which is much larger than previously described gating pore currents (Figure 5-3C), 
and what was seen in Chapter 6 for S4 arginine mutant channels.  
Previous studies of gating pore currents in Nav1.4, have been investigated using the cut 
open voltage clamp (COVC) technique rather than TEVC. The COVC technique shows faster 
voltage clamp compared to TEVC and allows intracellular solution control, enabling higher 
resolution recordings of the small gating pore currents. Thus, to validate the gating pore 
current results obtained through TEVC, COVC was also used to measure the gating pore 
currents of D1413G. Both COVC and TEVC recordings showed similar voltage dependence 
for D1413G gating pore currents (See Figure 5-2 & Figure 5-3 for comparison). TEVC was 
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used for the rest of the characterisation for D1413G since the COVC set-up was not 
available at the time for use in further characterisation of the mutation. 
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Figure 5-2 Voltage dependence of gating pore currents in D1413G measured with TEVC  
Currents were recorded in the presence of 1µM TTX in response to 300 ms voltage steps ranging 
from -140 mV to +50 mV from a holding potential of -100 mV. External bath solution contained 
120 mM NaMes, 1.8 mM CaSO4 & 10 mM HEPES, pH7.4 with NaOH. A) The representative steady-
state currents for oocytes expressing WT or D1413G channels. B) Representative voltage 
dependence of currents before leak subtraction. C) Voltage dependence of mean leak subtracted 
gating pore currents for WT (Red circles) and D1413G (Black Squares). Error bars show SEM. 
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Figure 5-3Voltage dependence of gating pore currents in D1413G measured with COVC 
Voltage dependence of gating pore currents measured using COVC in WT or D1413G expressing cells 
for A) non leak subtracted data or B) leak subtracted (0 to +30 mV) data normalised to maximal 
gating charge displacement. Currents measured following a 30 ms voltage step from holding 
potentials of -60 mV to test potentials of -130 to +40 mV. 
-120 -100 -80 -60 -40 -20 0 20 40
-120
-80
-40
0
40
S
te
a
d
y
-S
ta
te
 C
u
rr
e
n
t 
(n
A
)
Voltage (mV)
 WT
 D1420G
-120 -100 -80 -60 -40 -20 0 20 40
-50
-40
-30
-20
-10
0
S
te
a
d
y
-S
ta
te
 C
u
rr
e
n
t 
(n
A
/n
C
)
Voltage (mV)
 WT
 D1420G
A
B
155 
 
5.4.2.1 Ion Selectivity of Gating pore current 
In order to further characterise the gating pore currents produced by D1413G, the ion 
selectivity of the currents was studied by substituting Na+ within the bath solution for other 
cations in the presence of 1µM TTX. A holding potential of 0 mV was used in order to 
improve the size and stability of the gating pore currents recorded. The currents measured 
from holding voltage of 0 mV show larger amplitude but similar voltage dependence to the 
currents measured using holding voltage of -100 mV.  
Figure 5-4 shows averaged data from D1413G cells in different bath solutions, normalised 
to the peak Na+ currents measure in the same cell. With K+ as the extracellular cation, 
currents were observed showing the same voltage dependence as seen in Na+, although 
currents are smaller (p<0.05 at -100 mV).  
Guanidinium can be used in Nav1.4 S4 arginine mutations to increase the size of the gating 
pore up to 10 fold (Sokolov et al.,2007b; Sokolov et al., 2010). Gating pore currents for 
D1413G expressing cells in the presence of guanidinium did not increase. In comparison to 
Na+, guanidinium was found to decrease the currents (Figure 5-4B, p<0.05 at -100 mV). 
The large organic molecule NMDG+ has previously been shown to be impermeable through 
the gating pore caused by S4 arginine mutation, since the size of the molecule means it is 
unable to pass through the gating pore. In the presence of NMDG, large magnitude gating 
pore currents were still observed in cell expressing D1413G channels, although the currents 
were smaller than those seen in Na+ and guanidinium (p=0.013 at -100 mV).  
There are two possible reasons why currents remain when NMDG is the only extracellular 
cation. First, NMDG can pass through the channel. Second, there is another component to 
the currents is present which is not carried by cations. Since the cation NMDG is very large, 
the second possibility was investigated.  
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Figure 5-4 Ion selectivity of gating pore currents in D1413G 
Leak subtracted gating pore currents of D1413G in response to 300 ms voltage steps from -140 mV to +50 mV from a holding potential of 0 mV, following substitution of the 
external bath solution to contain different cations in the presence of the anion methansulfonate: A) Na
+
 (black squares) or K
+
 (red circles), B) Na
+
 (black squares) or 60 mV 
Guandinium  (red circles), C) Na
+
 or NMDG (red circles). Data are normalised to peak Na
+
 currents with error bars denoting s.e.m. 
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5.4.3 Chloride component of D1413G gating pore current 
The gating pore currents of the D1413G channels remain of considerable amplitude even 
when the only extracellular cation is NMDG. NMDG is a very large cation and is unable to 
pass through the gating pore pathway formed by other mutations in the voltage sensing 
domain. It is thus possible that the gating pore currents may be carried by other ions.  
As D1413G results in the loss of a negatively charged residue, it is possible that negatively 
charged ions such as chloride ions may pass through the aberrant pathway with the voltage 
sensing domain. To investigate the possibility that Cl- might pass through the voltage sensor 
domain and carry a part of the gating pore current, the anion within the extracellular 
solution was changed whilst the cation was kept constant i.e. the sodium ion remained 
constant whilst the chloride ion was replaced by methanesulfonte. The raw I-V curves 
revealed a difference in the currents seen in Cl vs Mes solutions. At positive voltages the 
slope of I-V curve becomes steeper in the presence of NMDG-Cl compared to both NMDG-
Mes and NaMes solutions (Figure 5-5A). WT expressing cells did not show such a large 
difference difference between Cl- and Mes solutions. Furthermore, it was found that 
currents were the same even in the cations were Na+ or K+ (Figure 5-5B). 
 
158 
 
Figure 5-5 Cl
-
 component of gating pore currents in D1413G 
Cl
-
 component of D1413G gating pore currents was investigated by exchanging the anion present in the bath solution to contain Cl
-
. Raw currents in the presence of: A) NaCl 
or NaMes, B) KCl or KMes, C) NMDG with Methanesulfonate or NMDG with Cl
-
Currents. D) Raw WT currents in the presence of NaCl or NaMes  
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5.5 Do other intracellular negative charge cluster mutations 
cause gating pore currents?  
Since D1413G was found to result in a gating pore current, it is possible that homologous 
negative charges within the other domains of Nav1.4 also have a role in maintaining the 
electrostatic interactions which protect the voltage sensing domain from ionic leak. 
Therefore, the role of homologous negatively charged residues in preventing ionic leak 
through the voltage sensor domain was investigated. 
5.5.1 S3 negative charge mutations 
Three S3 segment aspartic acids in DI, DII and DII were identified as being in a homologous 
position within the S3 segment to D1413 (D197, D646 & D1100). Each mutation was 
introduced into the rat ortholog of Nav1.4 (rD197, rD640 & D1094), all mutations will be 
referred to by the rat homolog numberings from now on. Voltage dependence and ion 
selectivity of gating pore currents were analysed for all three mutations. 
5.5.1.1 Domain I – D197G 
To detect possible gating pore currents, the central pore was blocked with 1 µM TTX and 
currents were recorded in response to a 300 ms voltage step from a holding potential of -
100 mV to test potentials of -140 to +50 mV. In  
Figure 5-6A, a difference can be seen between WT and D197G steady state currents, with 
NaCl as the main salt of the bath solution. WT non-leak subtracted currents show an almost 
linear voltage-current relationship over the full range studied, while in contrast, the I-V 
curve for D197G shows a non-linear component at depolarised voltages, revealing a gating 
pore current through the voltage sensor domain which is different from that of D1413G ( 
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Figure 5-6B). To determine the voltage dependence of the gating pore current, leak 
subtraction was conducted using the linear component at hyperpolarised potentials.  
Figure 5-6C shows the I-V curves for D197G and WT following leak subtraction. D197G 
shows an outward current activated at potentials positive to -50 mV. This activation occurs 
at a similar voltage to the activation of the central pore.  
Next, the gating pore currents in D197G expressing cells was further characterised by 
determining the ion selectivity. Figure 5-6 shows the results of substitution experiments of 
the main ions in the external bath solution. Currents were recorded in the presence of NaCl 
or NaMes extracellular recording solutions. Gating pore currents in both solutions followed 
the same voltage dependence, with activation around -50 mV. In the presence of NaCl 
currents were 6 times larger compared to NaMes currents at +50 mV. This shows a clear Cl- 
selective component of D197G gating pore currents (Figure 5-6). Oocytes have endogenous 
current Cl- currents which can be activated by a high concentration of Cl- within bath 
solutions. However, no such difference was seen between the solutions was observed in 
WT expressing cells, suggesting that endogenous currents could not explain the difference.  
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Figure 5-6 Voltage dependence of D197G gating pore currents.  
Currents were recorded in the presence of 1µM TTX in response to 300 ms voltage steps ranging from -
140 mV to +50 mV from a holding potential of -100 mV. External bath solution contained 120 mM NaCl, 
1.8 mM CaSO4 & 10 mM HEPES, pH7.4 with NaOH. For some recordings NaCl was substituted with 
NaMes. A) The representative steady-state currents for oocytes expressing WT or D197G channels. B) 
Representative recordings of voltage dependence of currents before leak subtraction. C) Voltage 
dependence of leak subtracted gating pore currents for WT (Red circles) and D197G (Black Squares). 
Data are normalised to peak Na
+
 currents. D) Averaged raw data for D197G expressing cells in the 
presence of NaCl (black squares) or NaMes (Red circles). E) Voltage dependence of leak subtracted 
gating pore currents in the presence of NaCl (black squares) or NaMes (Red circles). Error bars denoting 
s.e.m. 
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5.5.1.2 Domain II – D640G 
Figure 5-7 shows currents measured from WT and D640G expressing cells in response to 
the voltage protocol used to study the gating pore currents. Steady state currents observed 
in D640G deviated from WT currents. I-V curves for WT expressing cells show a linear 
relationship for all ranges tested in the presence of a Cl- free Na+ extracellular solution. In 
contrast, D640G currents were found to have a non-linear component present at 
hyperpolarised potentials, similar to D1413G. Leak subtraction was performed on data for 
both WT and mutant using the linear component at positive voltages. The gating pore 
current amplitude was normalised to the peak sodium currents for each cell and averaged 
(Figure 5-7, WT n=9, D640G n=9). D640G expressing cells show an inward current which is 
activated at voltages negative to -30 mV. The voltage dependence of D640G gating pore 
currents is similar to that seen for D1413G. However, the D640G currents were often very 
small and difficult to record consistently.  
The gating pore currents of D640G were further characterised by determining the ion 
selectivity. The steady state currents were measured with holding potential of 0 mV. When 
Na+ in the bath solution was substituted for K+, gating pore currents were observed with the 
same voltage dependence  but with reduced amplitude (n=1)(Figure 5-7D). This observation 
was similar to D1413G currents but differed from those of D197G.  
Finally, the possibility that D640G gating currents also have a Cl- component was explored. 
Currents were measured in Na+ bath solutions with and without Cl- (NaCl and NaMes). A Cl- 
component of the gating pore currents is observed for D640G. However this is only shown 
with an n of two and more recordings are necessary to confirm this. (Figure 5-7D). 
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 Figure 5-7 Voltage dependence of D640G gating pore currents. 
Currents were recorded in the presence of 1µM TTX in response to 300 ms voltage steps ranging 
from -140 mV to +50 mV from a holding potential of 0 mV. External bath solution contained 120 mM 
NaMes, 1.8 mM CaSO4 & 10 mM HEPES, pH7.4 with NaOH. In some experiments NaMes was 
substituted for NaCl. A) The representative steady-state currents for oocytes expressing WT or 
D640G channels. B) Representative recordings of voltage dependence of currents before leak 
subtraction. C) Voltage dependence of leak subtracted gating pore currents for WT (Red circles) and 
D640G (Black Squares), data are normalised to peak Na
+
 currents. In order to determine the whether 
D640G shows a Cl
-
 component, D640G gating pore currents were measured in the presence of 
different extracellular bath solutions D) NaMes or NaCl. Error bars denoting s.e.m. 
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5.5.1.3 Domain III – D1094G 
Figure 5-8 shows steady state currents measured in WT and D1094G expressing cells 
following a gating pore current protocol with NaCl as the main extracellular salt. Raw I-V 
curves for D1094G show a non linear component at positive voltage which is not present in 
WT expressing cells. Following leak subtraction using the linear component at negative 
voltages and normalisation to peak Na+ currents, D1094G shows an outward gating pore 
current which is activated at voltages positive to -50 mV(Figure 5-8C). The voltage 
dependence of this outward gating pore current is similar to currents observed in D197G 
expressing cells. Steady state currents of WT expressing cells do not show this outward 
current. 
As D1094G currents show similar characteristics to D197G, the possibility that D1094G 
gating pore currents are carried by Cl- ions was explored. Currents were measured using 
Na+ bath solutions with methanesulfonate or Cl- as the anionic species. Larger gating pore 
currents were observed in the presence of NaCl compared to NaMes (Figure 5-8). This data 
is similar to D197G.  
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Figure 5-8 Voltage dependence of D1094G gating pore currents.  
Currents were recorded in the presence of 1µM TTX in response to 300 ms voltage steps ranging 
from -140 mV to +50 mV from a holding potential of -100 mV. External bath solution contained 
120 mM NaCl, 1.8 mM CaSO4& 10 mM HEPES, pH7.4 with NaOH. A) The representative steady-state 
currents for oocytes expressing WT or D1094G channels. B) Voltage dependence of currents before 
leak subtraction. C) Voltage dependence of leak subtracted gating pore currents for WT (Red circles) 
and D1094G (Black Squares). In order to confirm that currents were conducted by Cl
-
 ions, currents 
were recorded in the presence of NaCl or NaMes, voltage dependence of currents is shown D) raw 
currents and E) Leak subtracted normalised to peak Na
+
 currents. Error bars denoting s.e.m. 
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Figure 5-9 Location of D1420 within channel 
A) Schematic diagram showing location of D1420 residue B) Shows the VSD of domain IV: 
The six outermost arginine residues are shown in red spheres. D1420 is shown in blue 
sphere, based on homology model of rat NaV1.4 constructed by D Kuzmin, UCL 
(unpublished).  
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5.6 Discussion 
5.6.1 Is D1420G a pathogenic mutation? 
A novel Nav1.4 mutation, D1420G was identified in a Hypo PP patient during a genetic 
screen of Hypo PP patients who lack the common mutations. The patient is 28 year old 
male who presented with attacks of paralysis associated with low potassium levels (see 
Chapter 3 for the detailed phenotype). Attacks of paralysis mainly affect arms and legs and 
last on average 7 to 8 hours. The probands younger brother is similarly affected and was 
also found to carry the D1420G mutation.  
Unusually for a Hypo PP mutation D1420G is located outside of the S4 segment. D1420G is 
found within the S3 segment of DIV resulting in the loss of a negative charge. The negative 
charge at position 1420 is highly conserved and is part of the intracellular negative charge 
cluster (INC) which stabilises S4 arginine residues in the hydrophobic transmembrane 
region (DeCaen et al.,2008; Payandeh et al., 2011; Yarov-Yarovoy et al., 2012). This study 
aimed to investigate whether D1420G was the causative mutation for the Hypo PP family 
studied within Chapter 3. It was hypothesized that loss of a negative charge within the 
voltage sensor domain could cause a similar gating pore current as conventional S4 arginine 
Hypo PP mutations.  
D1420G mutant channels expressed in HEK-293 cells showed a small but significant 
hyperpolarising shift in the voltage dependence of fast inactivation. This was the only effect 
the mutation was found to have on the central pore alpha currents. Similar loss of function 
changes have been observed for Hypo PP arginine mutations, for example the Nav1.4 
mutation R669H causes hyperpolarized shift in the voltage dependence of slow 
inactivation, whilst R672H/G causes a hyperpolarized shift in the voltage dependence of 
fast inactivation and reduced current density (Sternberg et al., 2001; Struyk et al., 2000). 
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Such loss of function changes have been shown to be insufficient to cause the attacks of 
paralysis associated with hypokalemia (Bendahhou et al.,2001; Bulman et al., 1999; Carle et 
al., 2006; Fan et al., 2013; Jurkat-Rott, Groome, & Lehmann-Horn, 2012; Kuzmenkin et al., 
2002; Lapie et al.,1996; Sokolov et al., 2007a; Struyk et al. 2000; Struyk & Cannon,2007a). 
Thus, the shift in the voltage dependence of fast inactivation caused by D1420G is unlikely 
to be sufficient to cause the attacks of paralysis observed in the Hypo PP family. 
Next the presence of gating pore currents was studied in D1420G expressing cells. It was 
found that D1420G causes an aberrant gating pore current activated at voltages negative to 
-40 mV. Basic selectivity experiments showed that this hyperpolarizing gating pore current 
is carried primarily by Na+ ions. These findings are consistent with previous studies of Hypo 
PP arginine mutations which show that loss of the positive arginine residues results in a 
gating pore current carried by cations and activated at hyperpolarised potentials. Such 
aberrant inward currents have been shown to contribute towards depolarisation of the 
skeletal muscle. The gating pore currents produced by D1420G are likely to be active at 
physiological conditions in the resting skeletal muscle. Thus, these D1420G gating pore 
currents are likely to contribute to the attacks of paralysis associated with the Hypo PP 
phenotype observed.  
Unexpectedly, gating pore currents at hyperpolarized voltages were clearly evident in 
absence of small monovalent cations in extracellular solution. It is possible that at least a 
part of this current is carried by outflow of chloride ions. However, due to the limitations of 
TEVC, with regards to controlling the intracellular ionic concentrations, further work is 
needed to characterise this part of the D1420G gating pore current. By controlling the 
intracellular concentration, it would be possible to fully determine the presence of an 
inward Cl- flow. 
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Furthermore, these findings are consistent with the newly identified role of chloride 
conductance in the development of attacks of paralysis. Both bumetanide (a blocker of 
sodium potassium chloride transporter) and 9-anthracene carboxylic acid (9-AC, a CLC-1 
blocker) have been shown to prevent depolarization in muscle fibres(van Mil et al., 1997; 
Wu et al., 2013; Wu et al., 2013). It has also been shown that a high intracellular [Cl-] 
predisposes the skeletal muscle to paradoxical depolarisation (Geukes Foppen et al.,2002; 
van Mil et al.,1997; Wu et al.,2013). It is thought that the inward flow of chloride ions at 
depolarized voltages might hyperpolarize the cell and counteract the sodium driven action 
potentials. However, it is unclear if this would contribute to the development of the 
episodes of periodic paralysis that are commonly associated with depolarization of the 
muscle fibre, although increased chloride conductance might, in D1420G muscles, 
depolarize the reversal voltage of chloride ions and consequently lead to depolarization of 
the muscle membrane.  
5.6.2 D1420G and Hypo PP 
Over the last 10 years, the mechanism of Hypo PP has been unravelled. Through a series of 
studies we now know that 18 out of 21 Hypo PP mutations are localised to the S4 segment 
of Cav1.1 or Nav1.4. Of those Hypo PP S4 mutations studied, all have shown to bring about a 
pathway permeable to cations. Hypo PP arginine mutations cause a sustained inward 
current with steep voltage dependence at hyperpolarised potentials (Francis, Rybalchenko, 
Struyk, & Cannon, 2011; Groome et al., 2014; Jurkat-Rott et al., 2009; Sokolov et al., 2010; 
A. F. Struyk & Cannon, 2007b). (Francis et al.,2011; Jurkat-Rott et al.,2012; Matthews et al., 
2009; Sokolov et al.,2007a, Sokolov et al.,2010; Starace & Bezanilla,2004; Struyk & 
Cannon,2007a). However, the three non S4 mutations associated with Hypo PP have not 
been characterised. 
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In this study, the first non S4 arginine Hypo PP mutation has been studied and shown to 
cause gating pore currents. The observations made for the novel D1420G mutation are 
consistent with previously studied Hypo PP mutations, with the exception of the possible Cl- 
component. Furthermore, the functional properties of D1420G suggest that it is likely to be 
the causative pathogenic mutation for the family described. The findings described in this 
thesis lend further support to the hypothesis that the Hypo PP is caused by a common 
dysfunction of the voltage sensing domain. Additionally, the presence of a gating pore 
current in a non S4 segment mutation will hopefully lead to characterisation of the three 
non S4 segment mutations: V876E, H916Q (Cav1.1)and P1158S(Nav1.4). Identification of 
gating pore currents within these mutations will complete the picture of the Hypo PP 
mechanism of disease.  
The data presented in this chapter has shown that Hypo PP mutations cannot be solely 
isolated to the S4 voltage sensor. In fact, it is reasonable to suggest that Hypo PP could be 
caused by any mutation which sufficiently disrupts the stability of the voltage sensor 
domain to induce the creation of a novel conduction pathway. Thus, following the exclusion 
of S4 segment mutations, genetic screening in Hypo PP should be extended to all parts of 
Nav1.4 and Cav1.1.  
 
5.6.3 S3 negative charges within the Voltage Sensing Domain and 
implications for other channelopathies 
Following the characterisation of D1420G, mutations were created in this conserved 
aspartate residue in the S3 segment of each domain (D197G, D640G & D1094G). Through 
expression of the mutant channels in Xenopus oocytes, gating pore currents were 
characterised in each mutant channel. Two different types of gating pore current were 
identified: D640G & D1413G produce an inward gating pore current which is active at 
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hyperpolarized voltages whilst D197G and D1094G produce outward gating pore currents 
active at depolarized voltages.  
It was found that gating pore currents in D197G and D1094G channels are carried by Cl- 
ions flowing into the cell since their substitution by methanesulfonate largely eliminates the 
currents. D640G and D1413G channels also display a depolarization activated gating pore 
current component carried by chloride. However, it is not understood why loss of the 
negatively charged residue might enable Cl- to permeate through the channel. The findings 
in this study highlight the significance of the highly conserved S3 negative charge residues 
within the voltage sensing domain. Mutations leading to loss of the INC aspartate residue 
all cause disruption to the voltage sensing domain and allow for an aberrant ionic leak to be 
conducted through the channel.  
Due to the presence of endogenous Cl- currents within oocytes it is difficult to confirm 
whether the Cl- component is due to the mutation or the endogenous currents. Attempts 
have been made by recording WT currents with and without Cl- in the bath solution. It 
appears that the difference in currents observed in the mutant channels is not replicated in 
WT expressing cells. Further experiments are needed to fully characterise these currents. In 
addition, it has been difficult to fully characterise the mutant channels since the expression 
levels in oocytes were often too low for gating pore currents to be detectable.  
Although gating pore currents have been observed in a number of ion channels including 
the Shaker K+, Kv1.2, Kv3.2, Kv7.4, Hv1, Nav1.2, Nav1.4, Nav1.5 and Cav1.1 
channels(Delemotte et al.,2012; Delemotte et al.,2010; Fan et al., 2013; Francis et al., 2011; 
Khalili-Araghi et al.,2012; Klassen et al.,2008; Miceli et al.,2012; Ramsey et al.,2006; Sasaki 
et al.,2006; Sokolov et al.,2005; Sokolov et al., 2007a; Starace & Bezanilla,2001; Starace et 
al.,1997; Starace & Bezanilla,2004; A. F. Struyk & Cannon, 2007b; A. F. Struyk et al., 2008; 
Tombola et al.,2005), gating pore currents have only been associated with the pathogenesis 
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of three disorders: Hypo PP (Cav1.1 & Nav1.4) Brugada Syndrome (Nav1.5 R219H) and 
Benign Familial Neonatal Seizurers (BFNS, Kv7.4) (Gosselin-Badaroudine et al., 2012a; Miceli 
et al., 2012; Sokolov et al., 2007a; A. F. Struyk & Cannon, 2007b). 
A number of disease related mutations have been identified within the voltage sensing 
domain (Table 5-1). These mutations have been shown to cause a variety of effects on 
channel functioning (e.g. reduced current density, shifts in the voltage dependence for 
activation or inactivation and altered recovery from inactivation), but few studies have 
looked for a gating pore current.Of particular interest are the non S4 arginine mutations, 
located in the S3 segments of the ion channels. Nav1.1 and Nav1.2, Nav1.5, Nav1.7, Cav1.4, 
Kv11.1 and Kv7.1 all contain disease associated mutations which are located in homologous 
positions to the mutations studied in this chapter. It would be interesting to confirm the 
hypothesis that these mutations also cause a gating pore current. Identification of gating 
pore currents in ion channels associated with other diseases would provide an exciting 
mechanistic link between a diverse group of diseases. 
5.6.4 Use of TEVC for measuring gating pore currents 
The identification of gating pore currents in five negative charge mutations in this study 
was conducted using the TEVC set up. Most previously reported gating pore currents have 
been measured using the more sophisticated set up – cut open voltage clamp. The 
advantages of using COVC are that recordings provide a higher temporal resolution 
enabling better detection of small currents such as gating currents or gating pore currents 
and more accurate description of the Na+ central pore currents. The COVC also provides 
opportunity for intracellular solution exchange for detailed description of ion selectivity. 
However, the disadvantage for COVC is the complexity of the system which is highly time 
consuming to set up for each recording. This means that the set up is impractical for 
screening a large number of mutations. Whilst TEVC does not provide the high resolution 
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recordings of COVC, this study has shown that it can be used for the basic characterisation 
of gating pore currents. Our TEVC data is qualitatively similar to the preliminary COVC data. 
However, further COVC recordings are required to confirm and amplify our gating pore 
current findings in TEVC.  
The disadvantage of TEVC is the inability to control the intracellular ion concentration 
which resulted in conclusive characterisation of the D1413G selectivity. Additionally, WT 
recordings were not always found to be linear due to endogenous currents which could not 
be fully eliminated by removing the ions responsible for these currents.  
TEVC can be used for the basic characterisation of Nav1.4 gating pore currents and so could 
be useful for quick screening of pharmacological compounds and novel mutations. This will 
be helpful in the future for determining the functional consequences of novel Nav1.4 Hypo 
PP mutations located outside of the S4 segment and for more large scale structure-function 
studies. 
5.7 Conclusion 
D1420G was identified in a Hypo PP family that present with attacks of paralysis lasting on 
average 8 hours. Functional studies have confirmed that D1420G is the causative mutation 
for this family. Interestingly, D1420G is the first non-S4 arginine mutation associated with 
Hypo PP which has been shown to cause a gating pore current. In addition, further 
experiments showed that loss of the conserved aspartate residue in other domains also 
results in a gating pore current. This supports the notion disruption to the stability of the 
voltage sensing domain provides a pathway for the conduction of an aberrant ionic leak 
current which can contribute towards disease. 
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5.8 Further Work 
 During this study it has not been possible to fully confirm the presence of the Cl- 
current component. However, due to the presence of endogenous Cl- currents 
within oocytes it is difficult to confirm whether the Cl- component is due to the 
mutation or the endogenous currents. In order to confirm the presence of the Cl- 
component in D1420G, steady state currents were compared between mutant and 
WT expressing cells in the presence of a Cl- solution. A difference was observed 
between WT and the mutant. However, further work is needed to confirm the 
presence of a Cl- component. Control experiments are needed to confirm this: 
o Niflumic acid, 9-AC and DIDS can be used to block the endogenous Cl- 
currents present in oocytes. Blockage of the Cl- currents would show that 
the currents are in fact endogenous currents rather than as a result of the 
mutations.  
o A picospritzer pipette can be used to inject EGTA or BAPTA into an oocyte 
to chealate Ca2+ ions and prevent activation of oocyte Ca-Cl currents. Any 
alteration to the Cl- currents would suggest it a role of the endogenous Cl- 
currents. 
 For two negative charge mutations, D640G and D1094G for some conditions the 
number of cells were clear recordings were obtained was too low for statistical 
analysis. Further experiments are needed to reach a minimum of 5 cells per 
condition for each mutation. 
 TEVC was used to studying the gating pore currents for the negative charge 
mutations. Further experiments using COVC are needed to fully confirm the TEVC 
findings and confirm that TEVC can be used in place of COVC for screening novel 
mutations. 
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Gene Protein Protein Change Location Disease References 
SCN1A Nav1.1     
  p.D194N/G/H S3 DI Myoclonic epilepsy of infancy/ Dravet 
syndrome 
(Azmanov et al., 2010; Depienne et al., 
2009; Mancardi et al., 2006; Zuberi et al., 
2011) 
 
  p.E1266A S2 DIII Dravet syndrome  (Zuberi et al., 2011) 
  p.D1288N S3 DIII Dravet syndrome  (Zuberi et al., 2011) 
  p.D1608G/Y S3 DIV Myoclonic epilepsy of infancy (Marini et al., 2007; Wang et al., 2012) 
SCN2A Nav1.2     
  p.E169G S2 DI Epileptic encephalopathy, early onset (Nakamura et al., 2013) 
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  p.D1598G S3 DIV Intellectual disability, developmental delay, 
seizures & hypotonia 
(Need et al., 2012) 
  p.K1641N S4 DIV Seizures, benign infantile (Zara et al., 2013) 
SCN5A Nav1.5     
  p.E161Q/K S2 DI Brugada syndrome (Gui et al., 2010; Kapplinger et al., 2010; 
Smits et al., 2002, 2005) 
  p.E1240Q S2 DIII Brugada syndrome (Priori et al., 2002; Risgaard et al., 2013)  
  p.D1243N S2 DIII Brugada syndrome (Kapplinger et al., 2010; Risgaard et al., 
2013),  
  p.E1253G S2 DIII Brugada syndrome (Kapplinger et al., 2010)  
  p.D1275N S3 DIII Atrial standstill (Groenewegen et al., 2002; Gui et al., 
2010)  
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  p.E1574K S2 DIV Brugada syndrome (Kapplinger et al., 2010; Zumhagen et al., 
2009)  
  p. D1595N/H S3 DIV Atrioventricular conduction 
block/Cardiomyopathy  
(Nguyen et al.,2008; Olson et al.,2005; 
Wang et al.,2002)  
SCN9A Nav1.7     
  p.E1160Q S3 DIII Dravet syndrome (Singh et al., 2009) 
CACNA1A Cav2.1     
  p.E147K S2 DI Episodic ataxia 2 (Imbrici et al., 2004) 
  p.E533K S2 DII Episodic ataxia 2 (Scoggan et al.,2006), 
CACNA1F Cav1.4     
  p.D944Y S3 DIII Night blindness, congenital stationary, (Zeitz et al., 2009)  
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incomplete 
KCNH2 Kv11.1     
  p.D501N/G/H S3 Long QT syndrome (Giudicessi et al., 2012; Jongbloed et al., 
2002; Napolitano et al.,2005; Shimizu et 
al., 2009) 
  p.D509N S3 Long QT syndrome (Lieve et al., 2013)  
KCNQ1 Kv7.1     
  p.E160K/V S2 Long QT syndrome (Giudicessi et al., 2012; Kapplinger et al., 
2009; Splawski et al.,2000) 
  p.D202N/H S3 Jervell and Lange-Nielsen syndrome (Eldstrom et al., 2010; Fodstad et al., 
2004; Kapplinger et al., 2009; Wang et 
al.,2002) 
Table 5-1 VSD mutations affecting charged residues (S2-S3 segments) in other voltage gated cation channels 
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6 Chapter 6: Comparison of two S4 arginine mutations 
which affect the same residue but cause different 
phenotypes. 
6.1 Summary 
A novel Nav1.4 mutation, R222Q, was identified in a patient with a myotonic phenotype 
through Sanger sequencing. R222Q is located within the S4 segment (voltage sensor) of DI 
and causes the neutralization of a positively charged residue. A prior mutation at this 
location, R222W, has also been identified, which causes a Hypo PP phenotype. In fact, 
mutations targeted to voltage sensor gating charges are normally associated with a Hypo 
PP phenotype and cause a gating pore current. Myotonia is not found with a Hypo PP 
phenotype nor has a gating pore current been shown to cause it. Myotonic phenotypes are 
normally associated with gain of function mutations that cause disruption to inactivation or 
activation of the sodium channel.  R222Q was studied to determine if it is a pathogenic 
mutation. Additionally, the effects of both R222Q and R222W were compared in order to 
determine how they result in different phenotypes. 
The effects of both R222 mutations were compared in two different heterologous 
expression systems: HEK-293 and Xenopus oocytes. The effect of the mutations on the 
biophysical properties of the central pore α currents was studied using whole cell patch 
clamp of HEK-293 cells. R222Q was found to cause a 16 mV hyperpolarizing shift in the 
voltage dependence of channel activation. This would be consistent with a myotonic 
phenotype. In comparison, R222W showed no difference in the voltage dependence of 
channel activation compared to WT, but a reduction in the current amplitude. Next, both 
mutations were studied to determine if they cause a gating pore current, using Two 
Electrode Voltage Clamp with expressed in Xenopus oocytes expressing the mutant 
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channels. Both R222Q and R222W produced small non linear steady state currents which 
are consistent with a gating pore current. Addition of guanidinium (mimics the guanidinium 
group of the arginine side chain) to the bath solution increased the amplitude of the gating 
pore currents – a phenomenon seen in other S4 arginine mutations. R222W was found to 
conduct gating pore currents consistent with a Hypo PP phenotype. However, the myotonia 
mutant channel R222Q was found to also conduct gating pore currents but these were 
smaller than for R222W channel. R222Q is the first myotonia related mutation which has 
been shown to conduct gating pore currents similar to those found for Hypo PP mutations. 
In addition, these findings confirm that R222Q is the causative mutation for an individual 
with a myotonic phenotype.  
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6.2 Introduction 
Myotonia and Hyper PP mutations are most often found in areas important for channel 
gating where they cause defects in inactivation or activation of the channel, leading to 
either an increased number of sodium channels available for activation following an action 
potential, or a persistent depolarizing Na+ current. Hypo PP mutations affect the voltage 
sensing domain and target the positive gating charges. Neutralization of these positive 
arginine residues disrupts the tight interactions which occlude the gating pore, creating a 
conduction pathway which allows leak currents. 
Mutations causing Hyper PP and PMC, show both phenotypic and pathomechanism 
overlap, with the same mutations known to cause different either disease, for example, 
T704M, A1156T and R1448C are both associated with either Hyper PP or PMC (Brancati et 
al., 2003; Hayward et al.,1999; McClatchey et al., 1992; Vicart et al.,2005; Wagner et al., 
1997).  
However, no phenotypic or mechanistic overlap with Hypo PP has been identified thus far. 
Only a handful of myotonia mutations have been identified within the S4 segment: 
R1448C/S/P/H/L and R225W (Bendahhou et al., 1999; Jarecki et al., 2010; Lee et al., 2009; 
Matthews et al., 2008; Ptácek et al., 1992). Of these only R1448C/S/H have been 
functionally characterized. R1448 mutations have been shown to cause only small effects 
on channel activation but considerably increase the time constant of fast inactivation 
(Bendahhou et al., 1999; Dice et al., 2004; Ji et al., 1996; Yang et al., 1994). What's more, 
Francis et al. have shown that R1448C, which affects the outermost arginine residue of DIV, 
does not cause a gating pore current. This highlights that currently there is no known 
mechanistic overlap between Hypo PP and PMC or Hyper PP. 
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6.3 Aims 
The aim of this study was to determine whether R222Q is the causative mutation for an 
individual with a myotonic phenotype. Additionally, the functional effect of R222Q was 
compared to that of the Hypo PP mutation R222W in order to determine how two Nav1.4 
mutations affecting the same arginine residue cause different phenotypes. This was done 
by studying the effect of the mutations on channel function to determine if both mutations 
cause a gating pore current as expected for S4 arginine mutations. 
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6.4 Functional analysis of R222Q and R222W Nav1.4 mutations  
Two mutations affecting the same arginine residue have been identified. These cause 
different clinical phenotypes which are associated with different pathomechanisms. R222Q 
and R222W affect the R2 of DI S4 segment and are associated with PMC and Hypo PP, 
respectively. Mutations affecting the S4 arginines are usually associated with Hypo PP and 
the gating pore current. Two approaches were taken to determine the mechanism through 
which these mutations act. First, whole cell patch clamp was used to study the biophysical 
characteristics of the central pore α currents of mutant channels expressed in HEK-293 
cells. Second, two electrode voltage clamp was used to investigate the presence of gating 
pore current in mutant channels expressed in Xenopus oocytes. 
6.4.1 Characterization of alpha pore currents 
To characterize the alpha pore currents of the mutations, mutant Nav1.4 channels were 
transiently expressed within HEK-293 cells. Properties of channel α currents were analyzed 
using whole cell patch clamp.  Figure 6-1 shows sodium current traces produced by WT, 
R222Q and R222W expressing channels. Few cells expressing R222W channels were found 
to have measurable sodium currents. When sodium currents were measured in R222W 
expressing cells they had a reduced current amplitude compared to WT and R222Q 
expressing cells. On the other hand, R222Q channels expressing cells showed currents with 
WT-like current amplitude, although these currents were activated at more hyperpolarized 
voltages than WT channels.  
The voltage dependence of activation was examined using a voltage step protocol from 
holding voltages of -80 mV to test potentials of -130 to +90 mV. R222Q channels showed a 
16mV hyperpolarising shift of in the voltage dependence of activation (WT V0.5 = -
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18.6±3.4mV mV, n=13; R222Q V0.5 =-34.2±3.4 mV, n=12, p=2x10
-9). No change in the voltage 
dependence of activation was observed for R222W channels.  
A number of studied Hyper PP mutations have been shown to cause disruptions to fast 
inactivation; therefore the voltage dependence of fast inactivation was examined in both 
mutations. Both mutations were found to have a small hyperpolarizing shift in fast 
inactivation (WT V0.5 =-63.7±2.6mV n=10; R222Q V0.5= -68.5 ±4.8 mV, n= 14; R222W V0.5 = -
67.0 ±2.7, n=6). However, the 3.4 mV shift seen in R222W is not statistically significant 
(p=0.16). 
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 Figure 6-1Biophysical properties ofNav1.4 α currents of DI arginine mutations 
Whole cell currents from WT, R222Q and R222W transfected cells. Whole cell Na+ currents were evoked by a series of voltage steps from -130 to +60 mV from a holding 
potential of -80 mV. Sodium current traces for A) WT, B) R222Q and C) R222W. D) Conductance/voltage relationship of activation. E) Voltage dependence of fast 
inactivation measured using a 300 ms conditioning voltage step from -130 mV to 60 mV in 10 mV increments, followed by a constant test pulse step to -10 mV. Normalised 
averages were fitted with a Boltzmann equation. Data was normalised and fitted using a Boltzmann equation. Error bars represent SEM. 
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6.4.2 Characterization of gating pore currents 
The presence of gating pore currents was investigated in both R222W and R222Q. The 
cRNA of mutant channels was injected into Xenopus oocytes and the currents measured 3-
7days after injection.  
Figure 6-2 shows the mean current amplitude measured during the last 200 ms of a 300 ms 
voltage step from a holding potential of -100 mV to test potentials of -140 to +50 mV. Both 
mutations show a non-linear component at hyperpolarised potentials which is consistent 
with gating pore currents observed in the previously studied Hypo PP mutations. Following 
leak subtraction at positive voltages, between +5 and -20 mV, small gating pore currents 
could be observed for both mutations. Due to the small size of the gating pore currents and 
limited sensitivity of TEVC set up, it was difficult to distinguish the gating pore currents in 
every oocyte.  
Guanidinium has been used as a pharmacological tool to study gating pore currents as it 
can increase the size of arginine mutation gating pore currents up to 10 fold. Therefore, 
increasing fractions of the Cl- free Na+ bath solution were substituted with guanidinium 
methanesulfonate in order to increase the amplitude of the gating pore current and 
provide further support for the presence of the gating pore currents. In the presence of 
increasing fractions of guanidinium, larger gating pore currents could be seen for both 
mutations (Figure 6-3). R222W gating pore currents are activated by currents negative to -
30 mV (Figure 6-3A). R222Q mutant channels conduct smaller gating pore currents when 
compared to R222W (P< 0.05 at – 60mV, Figure 6-3C). These currents are activated by 
currents negative to -50 mV (Figure 6-3B). This suggests that the Hypo PP mutation R222W 
and the PMC mutation R222Q both cause an aberrant ionic current through the voltage 
sensing domain. 
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Figure 6-2 Gating pore currents of R222Q & R222W channels without Guanidinium 
Currents were recorded in the presence of 1µM TTX in response to 300 ms voltage steps ranging 
from -140 mV to +50 mV from a holding potential of -100 mV. External bath solution contained 
120 mM NaMes, 1.8 mM CaSO4 & 10 mM HEPES, pH7.4 with NaOH. A) Representative voltage 
dependence of R222Q, R222W and WT currents before leak subtraction. B) Representative voltage 
dependence of R222Q (red circles), R222W (Blue triangles) and WT (black squares) currents after 
leak subtraction between +5mV and -20 mV. 
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Figure 6-3 Gating pore currents produced in the presence of Guanidinium 
Currents were recorded in the presence of 1µM TTX in response to 300 ms voltage steps ranging from -140 mV to +50 mV from a holding potential of -100 mV in the 
presence of two difference concentrations of guanidinium (30 mM Gn, red circles & 90 mM Gn, blue triangles) within the external bath solution. A) Voltage dependence of 
R222Q currents following leak subtracted currents, B) Voltage dependence of R222W currents following leak subtracted currents, C) Comparison of R222Q (red circles) and 
R222W (blue triangles) currents at the highest concentration of guanidinium (90 mM). Error bars represent SEM. 
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Figure 6-4  Location of R222 residue within channel 
Figures are based on homology model of rat NaV1.4 constructed by D Kuzmin, UCL (unpublished). A) Shows VSD of Domain 1 from side: R222 is highlighted 
in red with the Intercellular Negative charge Cluster (INC) S3 aspartate in blue sphere. Red and blue sticks denote the other S4 arginines and INC negative 
charges. B) Show the VSD  in relation to the pore domain.  
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6.5 Discussion 
6.5.1 Is R222Q a pathogenic mutation? 
The R222Q mutation was identified during a genetic screen of myotonia patients (See 
Chapter 4 for further details). The patient is a young male from a consanguineous family 
who present with severe muscle stiffness and pain with onset at age 14. His symptoms 
worsen with cold. The patient has reported one possible episode of weakness lasting for 35 
minutes, but has not had episodes of paralysis. Myotonia was clearly present on EMG. No 
family members were available for testing. In addition, the patient was found to have a 
heterozygous synonymous mutation in CLCN-1 (c.1650G>A). The mutation is predicted to 
create a novel splice site in exon 15 and has been previously associated with myotonia 
congenita. However, no muscle sample was available from the patient to confirm correct 
splicing of the CLCN-1 gene in the muscle.  
R222Q mutant channel expressed in HEK-293 cells showed a large hyperpolarising shift in 
the voltage dependence of activation. A smaller hyperpolarizing shift was found in the 
voltage dependence of fast inactivation. In addition, R222Q mutant channels were found to 
conduct a gating pore current when expressed in Xenopus oocytes which showed similar 
voltage dependence to gating pore currents conducted by Hypo PP mutant channels. The 
gating pore currents measured were smaller than the gating pore currents which have been 
detected in other mutations studied in the work of this thesis. 
A negative shift in the voltage dependence of activation, as observed for R222Q, is 
consistent with a PMC phenotype. The Nav1.4 mutations I693L and T704M, associated with 
episodic myotonia with paralysis, have been shown to cause a similar defect in the voltage 
dependence of activation (Brancati et al., 2003; Cannon, 2002; Yoshinaga et al., 2012). Such 
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mutation cause increased electrical excitability of the muscle and repetitive firing of action 
potentials present as myotonia in the patient. 
A PMC phenotype has not been previously associated with gating pore currents. Gating 
pore currents have been thought to solely cause Hypo PP. In fact, Hypo PP is defined as 
attacks of paralysis without myotonia and no previously mechanistic link between Hypo PP 
and myotonia has been established. Studies of the PMC DIV S4 arginine mutation, R1448C, 
showed that R1448C causes a defect in fast inactivation without causing a gating pore 
current, leading to the notion that only Hypo PP mutations conduct a gating pore current. 
In addition, gating pore currents are not necessary to cause a PMC phenotype since other 
PMC mutation affect the central pore domain and disrupt channel gating. Therefore, it is 
unlikely that the gating pore currents observed in the R222Q mutant channel contribute 
towards the myotonic symptoms present in the patient.  
Interestingly, the patient has normal potassium levels and does not experience attacks of 
paralysis despite R222Q conducting a depolarising gating pore current. In addition to the 
sodium channel mutation, the patient is also heterozygous for a synonymous CLCN-1 
mutation, which is predicted to disrupt normal gene splicing. This mutation has been 
previously described in association with recessive myotonia congenita case, where the 
proband was a homozygous carrier of the mutation. This suggests the mutation maybe 
pathogenic loss-of-function mutation. However, no functional studies have been conducted 
to confirm this mutation reduces chloride currents. It is possible that the loss of function 
mutation of the chloride channel may provide protection against episodic attacks of 
paralysis which are normally associated with hyperpolarisation activated gating pore 
currents. This hypothesis is further supported by studies of the Hypo PP mouse model 
which showed that reduction of chloride conductance using bumetanide prevented attacks 
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of muscle weakness and paradoxical depolarisation of muscle fibres in the presence of low 
potassium.  
6.5.2 Is R222W a pathogenic mutation? 
The R222W was previously reported by Matthews et al. 2009 in two unrelated Hypo PP 
kindreds but has not been functionally studied. R222W mutant channels displayed robust 
gating pore currents at negative membrane potentials. The gating pore currents observed 
from R222W mutant channels are consistent with those seen in other Hypo PP mutations 
such as R669H, R672G and R1132H (Sokolov, Scheuer, & Catterall, 2007; Struyk & Cannon, 
2007a). These findings are consistent with the notion that the depolarising currents 
contribute towards the Hypo PP phenotype. In addition, R222W mutant channels were 
found to have a reduced Na+ current amplitude with little effect on the gating of central 
pore Na+ currents when expressed inHEK-293 cells. It is not known if the R222W mutation 
leads to reduced functional expression of the channel in the muscle of the patient. Previous 
studies of Hypo PP mutations have shown that such loss of function mutations are not 
sufficient to cause the Hypo PP phenotype (Matthews et al., 2009, 2010; Struyk & Cannon, 
2007). Thus, the gating pore currents conducted by R222W channels are the likely 
pathomechanism resulting in attacks of paralysis in the patients.  
6.5.3 R222Q vs R222W 
The effects of the R222 mutations on channel functioning were found to differ with the 
nature of the substituting residue. Both mutant channels conducted gating pore currents 
with similar voltage dependence. However, gating pore currents conducted by 
R222Qchannels were much smaller gating pore currents than seen for R222W. 
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One explanation for the difference is that the different substituting residues cause different 
size conduction pathways through the gating pore. Substitution of the conserved R222 with 
the bulky tryptophan residue resulted in large gating pore currents indicating that the 
tryptophan residue is unable to prevent aberrant ionic leak through the voltage sensing 
domain. In contrast, substitution with glutamate resulted in smaller gating pore currents. It 
is possible that R222Q forms a smaller conductance pathway within the gating pore due to 
the smaller amino acid side chain.  
An alternative explanation is that the hyperpolarized shift in the voltage dependence of 
R222Q channel activation may result in the destabilisation of resting state which conducts 
the gating pore current. This would cause the voltage sensor in R222Q channels to favour 
the activated 'up' conformation. Thus, the R222Q voltage sensor is less likely to be found in 
the resting conformation which conducts the gating pore current, leading to a reduction in 
the size of the currents. This is further supported by studies of  homologous Kv10.2 
mutation, R327H, associated with epileptic encephalopathy, which showed the R2 residue 
is important for stabilising the closed state of the channel (Yang et al.,2013). It is possible 
that R222Q may destabilise the closed resting state, resulting earlier activation of the 
voltage sensor compared to wild type channels causing a hyperpolarizing shift in the 
activation curve. 
The differences observed between the mutations are sufficient to explain the difference in 
phenotypes seen. Previous studies looking at the structure-function relationship of the 
voltage sensor of the Shaker and Kv1.1 potassium channels have shown that different 
mutations of the S4 R2 residue result in differential effects on channel gating. For example, 
R2Q of Shaker and Kv1.1 causes a hyperpolarising shift in the voltage dependence of 
activation whilst R2C of Shaker causes a depolarising shift in the voltage dependence of 
activation (Larsson et al.,1996; Liman et al.,1991; Logothetis et al.,1992; Papazian et 
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al.,1991; Stühmer et al.,1989). This data shows the importance of interactions of the 
arginine residues with the surrounding environment of the voltage sensor domain. 
6.6 Conclusion 
R222Q is the first myotonia mutation to be associated with a gating pore current. However, 
the patient studied did not present with episodic attacks of weakness and the gating pore 
currents are unlikely to cause the myotonic phenotype presented by the patient. R222W 
was found to cause a gating pore currents similar to those already observed in Hypo PP 
mutations. These findings support the notion that gating pore currents are solely associated 
with attacks of paralysis. Additionally, it is thought that the different phenotypes associated 
with the two mutations studied due to the different substituting  residues which result in 
different effects on channel functioning. 
6.7 Further Work 
 To confirm the protective role of the synonymous CLCN-1 mutation a muscle biopsy 
sample is needed from the patient in order to determine whether the chloride channel 
is erroneously spliced. In addition, functional studies are needed to confirm that the 
mutation results in reduced chloride currents as is currently expected.  
 To further characterise the gating pore currents conducted by R222Q and R222W, ion 
selectivity studies are needed. Using TEVC the gating pore currents were only fully 
measured in the presence of guanidinium. Therefore, it would be preferable that these 
experiences were conducted using the cut open voltage clamp set up which is more 
sensitive.  
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Appendix 
Table of primers used for Sanger sequencing. 
Gene Exon/Name Forward Primer Reverse Primer 
M13 TAG - TGTAAAACGACGGCCAGT CAGGAAACAGCTATGACC 
SCN4A 1 GCACATCTCCCAGTCCTGAT TGGATGGCAGACAGACAGAG 
 2/3 CTCTGTCTGTCTGCCATCCA CCACACAGAGGTGCAAACAC 
 4 GCCACCTGAGTGGCATATTT GGGCTGCCTCATGTGATTAT 
 5 AGGAGCTTTGGGGGTGTCT ATCTGCCCTCTGGTCACG 
 6 CAAGCCTTGAAGATGGAGTAGG GAGGCTACCCTAGGGACTGG 
 7/8 GTGTCCATGTGGGTGACTTG CCAGCTGGAAGAGGTTCTCC 
 9 ATGTATGGAAAGGGGCACTG ACCCTGGGTCCTCTATCTCC 
 10 CTTTGGTCCCTACCCTGTCA AGGCTCCACCCCTACCTAAG 
 11 GCTTGGAAGGTGGAACAAAA CATACAGCCAGACAGCTCCA 
 12 CTCTGTGACAGGGCCTCATG TCCTCACCCCACCCCCATCC 
 13 CTGCCTTGGGTGGTGGTC TTGGGGAGATAGAAAACAGTCA 
 14a TGCCCAACATGTGGTAGTTT GCGGCTCCTTCTTCTCATC 
 14b CCCAAGGACATCATGCTCA GCTCCAGGTCACAGGAGAAT 
 15 AGGGCTGGATGAATGAATGA GCTCCAAGCTAGGTCTGCAC 
 16 TGTTGGATCCAGCTGTGAAG CCCTTCCTGTGTGTGGAGAC 
 17 ATGGCAATTTGCTGTTGTTG TGACAGCCTCTGGATGTAGC 
 18 CGGGTACCATCCCTCCTACT CTCTGGTGGTGGTTGGAGTA 
 19 AGGAAGCCCTCCCTAATTGA AGTGACACTGGGGTTGGGTA 
 20 GTTGTACCCAACCCCAGTGT CTGAGGGCAGGACCCATC 
 21 CGTTCTGTCCCCGAGACTT GGGTTTGTGCAATGGAGAGT 
 22 GCTGCCTTAAAGGTGAGGT GGGTGGAAGGCAGGAAAC 
 23 CTGCCTGTCCATGTCCTGT GTCTTCCCGAGTGCCTCA 
 24a CTCTGAGACTTGAGCAGAGCAC TCTCGAACAGGCAGATGATG 
 24b TTGCCTACGTCAAGAAGGAGTC AAGTCTGAGAGGCGGCTGTA 
 24c TCTCCTTCCTCATCGTGGTC ACCTCCTCGTGCTTCCTCTT 
 24d AAGCAGACCATGGAGGAGAA AGGCACAGTCCCAGATTCAA 
    
CACNA1S 1 GGCTGGGTGGAATGACAG TGTGATCACCCCGAATCC 
 2 GGCATCAGAGTCACAGTCCA GACCAATGAGTGCGTGCTTA 
 3 TTCCATCAGCAAGTGCAAAC TGATCCACTCTCCACCAACA 
 4 TATTTGCCGTCTCTCCCCTA TAGGAAGGGGACCCAGAACT 
 5 AGTTCTGGGTCCCCTTCCTA CCAGGAGAAACCCATTCTCA 
 6 TTCACTGTCACCGTCTGCTC GTGGTCACGCAAGTCAGAGA 
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 7 CAGGGTTGGGTGGAGTCTTA AATTGAAGGGCTCCTGTGTG 
 8 GGTGAGCAGGAAGTGAGAGG ACCATTTTGAGCCATTTTGC 
 9 TGGGCTCTTTAGCTCTTGGA GTCCCTCAGAGCAGGAACTG 
 10 GCCTGGAGTTTGTCTGAAGG GGGTATGTTGCTTTGCCACT 
 11 GGGAGTCAGGAGAAGGGAAG AACCTGCACAGATCCCAGAC 
 12 CCCTCCCTCTGTGTCACATC CCCACCTTGATCTTGAAGGA 
 13 AGTAACAGGCGTGAGCCACT GGGCCTGGCTACCTAGAAAC 
 14 TGAGGGCCTTCCACTATGTC CCAGAAGGCCAACTTGTCTC 
 15 GCCCTCTCACCACAGAGAAG AGGAGTCCCTGGAGATGGAT 
 16 CCAAGCAGTGGGTATGTGAA ATGGAGGGGTACAGGTAGGG 
 17 CAACATGCAGCCACAAAGTT AGATGAGAGCCGCATCAATC 
 18 GGAGCAGGAGGTGTATTCCA CAGCATAAAGCAGGCAGTCA 
 19 CTTCACCCTCTCTGCCACTC TGCCAGTCTCCACCTCTTTT 
 20 TGTTCTCCAAGCTCCTCCAT CTGTGGGTGGCTAGAAGCTC 
 21 GGAAGGTGGGAGTGTTTTCA AGACTTGCTGCCTCCTGATG 
 22 AGGAATGGGAGGGGTTACAG GGCTCCTTGTGCTTGAGAGT 
 23 GAGCTGTGGGAATGAACGAT AGCCTAAAGGCTGAGCTTCC 
 24 AGGAGGGACACTCACAGAGG AGGAGGGACACTCACAGAGG 
 25 CTTCCCAGCCTGACTCTCTG CACCCTTAGGCCTCTCTTCC 
 26 TTCACAGTCCTCAGCCACAG TCCATGTAGCACCTCAGCAC 
 27 CCCCTCCCCTTCTGTGTTAT GAGCAAGTTGGGAGCAGAAG 
 28 AAGAGCAAAGGGGAGAGGAG AGTTACCTCTCTGCCCAGCA 
 29 CCCACAGAGCTTCAGTCCTC AAGCCGCTATATCCATGCAC 
 30 AGTTCCTCCATGCCACAAAC GAGCGCCAGTCAGTGTCTTA 
 31 GACCCTGGAAACTGCACGTA ATCTGACACTCCAGCCATCC 
 32 CCCCCACACATTGACTTACC CAGGTCACACACCCATGAAG 
 33 AGGCAGGAGCAGATAGGTGA TGGCAGCCTCTCTGGAGTAT 
 34 GTGTGATGTGGGTGGTTCAG AAATGAAGGGGGAAGGAGAA 
 35 TCCCATATCTGAGGGAATGC CCATCAGGTCCTCACCAGTT 
 36 TCAGCAATGTCACCCAACTC TGGGGTCCTCCCTCTACTTC 
 37 GCCTGTGGGGAGAAAGTACA CTGGTCCGTTCTCAGATTCC 
 38 CGGACCAGATCCTCCATAAA CTTCTGGGCTTCCTTTTTCC 
 39 TCTCCTGGGCTGGAGAGATA TGGTAGGGAAATGTGGGAAA 
 40 CCATCCTCCTTTGGCCTTAT GCTGACATTGTCCTCCCAGT 
 41 TGAGGGAAAAGGATGTTTGG TTAGCATGAATGGGCTTTCC 
 42 AAGCGAGCCTCTGTTGACTC CCACCAATGAGCAAAATTCC 
 43 CCTGGCCTGATACTTGGAGT CTGTTGGCCCTACCCTCTCT 
 44 AGAGGGTAGGGCCAACAGAG TTTTGAGGTGGTTCCTGACC 
    
KCNJ18 Outer ATGCTGTCCTCTCTGTTC GTTCTTTTTGCCCCCTA 
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 Nest 1 TCTCCATCGAGACGCAGAC CACTCCTCCGTCACACAGC 
 Nest 2 CATCTTGCATGAAATTGACGA TTCCAGGATGACCACGATCT 
 Nest 3 CCAGGCATGACTTTGACAGA ATCTCTGACCCCCGTCTGTA 
 
Table of primers used for SCN4A mutagenesis  
Gene Mutation Forward Primer Reverse Primer 
Rat 
SCN4A 
Y168D CACCTTCACGGGGATCGATACCTTTGAGTCC
CT 
AGGGACTCAAAGGTATCGATCCCCGTGAAGGTG 
 D197G   
 R222Q CTGAGGACCTTCCAGGTGCTGCGGGCCC GGGCCCGCAGCACCTGGAAGGTCCTCAG 
 R222W CCTGAGGACCTTCTGGGTGCTGCGGGCCC GGGCCCGCAGCACCCAGAAGGTCCTCAGG 
 D640G   
 D1094G   
 E1072G   
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